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Abstract 
This thesis examines the consequences of disrupting the gene that codes for Ga2 , which 
results in the absence of signalling through the heterotrimeric G protein G2 in mice. It 
follows on from my molecular biological work in 1993 on cloning of the mouse Ga2 
gene, the work of Professor Ian Hendry, Dr. Klaus Matthaei and Albert Mellick in 
generating the mutant mouse and the work of Dr. Kim Powell (nee Kelleher) on 
characterization of the mouse phenotype. I have confirmed Dr Kim Powell's earlier 
finding that the absence of Ga2 results in the development of hypertolerance to 
morphine, by showing the existence of a relationship between the quantity of Ga2 
present, and the amount of tolerance that the mutant mouse subsequently develops. I 
have further extended the work to show that this gene dose relationship exists not only 
when morphine analgesia on the hotplate test was measured, but also when the lethality 
effects of morphine was considered. I have also demonstrated that the phenomenon 
occurs in the absence of changes in morphine metabolism in the Ga2 knockout mouse. 
The morphine analgesic tolerance that develops was shown to be non-associative and 
not due to behavioural learning differences. When physical dependence on morphine 
was examined in mutant mice, a gene dose dependent reduction in naloxone precipitated 
jumping was observed without significant differences in the other withdrawal signs. 
This suggests a dissociation of not only between morphine tolerance and physical 
dependence in the Ga2 knockout mouse, but also between the different symptoms of 
physical dependence. I have also shown that the absence of Ga2 results in a complex 
alteration of morphine stimulated locomotor responses, suggesting the possible 
alteration in function of more than one receptor in this intricate behavioural response. I 
have also examined the loco1notor responses of the Ga2 knockout mouse to 
amphetamine, where the mice show an increase in locomotor activity. This, 1n 
combination with the published observation by Yang et al. (2000), of an augmented 
locomotor response of these mice to cocaine, led me to investigate the function of 
dopamine D2-like receptors in these mice in greater detail. I demonstrated for the first 
time that dopainine D2-like receptors in the brain can couple to Gz, and a subtle 
impairment of function of one of the dopamine D2-like receptors (possibly the 
dopamine D2-short or D4 receptor) may potentially explain the altered locomotor 
response profiles of the Ga2 knockout mouse to psychostimulants and morphine as 
described above. I have also found that morphine induced hypothermia was 
.. 
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significantly attenuated in the Ga2 knockout mouse, and there were strain and species 
differences in the mechanism of morphine hypothermia. Finally, I have provided a 
co1nprehensive review of the literature on what is currently known about the 
biochemical properties and functions of Ga2 and drawn on all my data to suggest some 
insights into the organization of cellular signalling in an intact cell. These insights lay 
the theoretical foundation for future discoveries about the functions of Ga2 and other 
signalling molecules in vivo. 
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Chapter 1 
Introduction 
1.1 Introduction to heterotrimeric G proteins 
1.1.1 G proteins as signal transducers 
All living systems need to communicate with their environments, and make appropriate 
responses to environmental changes in order to survive. The surface of a living cell is 
constantly bombarded by a myriad of chemical and physical signals. Trans-membrane 
signalling, the process by which information arriving at the cell surface becomes 
transmitted to the cell interior, is vital to the proper functioning of all cells. However, 
the mechanism by which this occurs was not well understood until the pioneering 
discoveries performed in the laboratories of Martin Rodbell and Alfred Gilman, for 
which they were jointly awarded the Nobel Prize in Physiology or Medicine in 1994 
(http://www.nobel.se/ medicine/laureates/1994/press.html). From their work, we now 
know that many of the signals impacting on a cell (including light, odorants, and many 
hormones, che1nokines, neurotransmitters and drugs) act on cell surface receptors to 
cause stimulation of a unique family of membrane-associated proteins called G proteins. 
G proteins serve as signal transducers. Their role is to relay information arriving at the 
cell surface to molecular effectors (ion channels, enzymes) within the cell, which will 
ultimately allow the cell to respond appropriately to changes in the external milieu. 
The importance of G proteins 1n trans-membrane signalling is highlighted by the 
disastrous consequences that often happen when normal signalling is disrupted. Two 
well-known examples are whooping cough and diarrhea. Whooping cough occurs when 
a toxin from the bacterium, Bordetella pertussis obstructs the transduction of certain G 
protein signals, leading to aberrantly high levels of plasma insulin and an acute 
sensitivity to histamine (Bimbaumer, 1990). Diarrhea is caused by constitutive 
activation of a G protein signalling cascade in intestinal cells by cholera toxin (produced 
from the bacterium Vibrio cholerae). This results in massive amounts of water and salt 
to become constantly secreted from affected cells into the lumen of the gut (Spangler, 
1992). Besides these toxin-induced diseases, alterations in G protein pathways as a 
consequence of G protein mutations have produced many other serious illnesses. These 
1 
include tumors of the pituitary, adrenal, ovary and thyroid glands (Lyons et al., 1990), 
cardiac failure, dilative cardiomyopathy (Zalk et al., 2000), ulcerative colitis (Homquist 
et al., 1997), night blindness, essential hypertension, McCune-Albright syndrome, 
pseudohypoparathyroidism (see Farfel et al (1999) and Lania et al (2001) for a review) 
and insulin resistance, which is characteristic of non-insulin dependent diabetes mellitus 
(Chen et al., 1997; Moxham and Malbon, 1996). Additionally, alterations in G protein 
levels have also been observed in bipolar affective disorder (Young et al., 1991; Young 
et al., 1993) and in drug addiction (McLeman et al., 2000). Given the involvement of G 
proteins in the etiology of many clinical and psychiatric conditions, it is not surprising 
that understanding G protein functions is an important goal of modem medical research. 
1.1.2 Members of the guanine-nucleotide binding protein superfamily 
G proteins derive their names from their ability to bind the guanine nucleotides: 
guanosine diphosphate (GDP) and guanosine triphosphate (GTP). In this respect, they 
belong to an expanding superfamily of intracellular proteins whose activities are also 
regulated by the binding of guanine nucleotides. These other guanine-nucleotide 
interacting proteins include small GTPases from the Ras, Rho, Rab, Arf and Ran 
families, which are involved in gene expression regulation, cytoskeletal re-organization, 
vesicle trafficking and nucleocytoplasmic transport (Matozaki et al., 2000); members of 
the tubulin protein family, which regulate microtubule assembly and disassembly 
(Nogales, 2001), GTPases from the initiation and elongation factor families, which are 
essential for ribosomal protein synthesis (Kaziro et al., 1991) and the dynamin famili of 
large GTPases, which perform vital roles in endocytosis, vesicle trafficking, viral 
resistance, maintenance of mitochondrial morphology, and cell plate formation in plants 
(van der Bliek, 1999). 
Despite their wide ranging functions, almost all guanine-nucleotide binding proteins 
share a si1nilar working mechanism (Kaziro et al., 1991 ). In the inactive form, the 
protein is bound by GDP. On interaction with a guanine-nucleotide exchange factor 
(GEF), GDP is released and is replaced by GTP. Binding of GTP causes the protein to 
assume an active conformation (Sprang, 1997b ), which allows it to carry out its 
prescribed function. This is followed by hydrolysis of GTP to GDP, which returns the 
protein to its inactive form (Kaziro et al., 1991). Besides GEFs, there are a number of 
other classes of proteins that can also modulate the activity of guanine-nucleotide 
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binding proteins. For instance, guanine-nucleotide dissociation inhibitors (GDis) act to 
inhibit the guanine-nucleotide exchange reaction and therefore, prevent protein 
activation. GTPase activating proteins (GAPs), on the other hand, enhance the rate of 
GTP hydrolysis to GDP, and therefore, accelerate the return of the protein to its inactive 
configuration (Geyer and Wittinghofer, 1997). 
1.1.3 Structure of G proteins 
All G proteins comprise three subunits, which has been designated using the Greek 
letters, a , ~ and y. This unique heterotrimeric structure differentiates G proteins from 
all other guanine-nucleotide binding proteins. Among the three subunits, the a subunits 
are the largest (39 to 78 kDa) and contain the binding site for guanine nucleotides. The 
~ (35 to 44 kDa) and y (7 to 9 kDa) subunits form a stable dimer that cannot be 
dissociated unless the protein is denatured (Clapham and Neer, 1997; Neer, 1995). 
The crystallographic structures of the G protein heterotrimer (Lambright et al., 1996; 
Wall et al., 1995), the inactive and activated forms of the a subunit (Coleman et al., 
1994; Coleman and Sprang, 1998; Mixon et al., 1995; Sondek et al., 1994; Sunahara et 
al., 1997), the ~y dimer (Sondek et al., 1996) and the activated a subunit in complex 
with its effector (Slep et al., 2001; Tesmer et al., 1997) have already been solved. The 
wealth of data from these structural studies, together with the results obtained from 
biochemical and mutagenesis experiments, have provided tremendous insights into the 
mechanism of the guanine nucleotide exchange reaction on the a subunit and the way 
the a, ~ and y subunits interact with one another (Neer and Smith, 1996). 
Each a subunit is found to have three inter-connected components: a GTPase domain, 
an alpha-helical domain and an amino terminal helix (Lambright et al., 1996). The 
GTPase domain comprises a six stranded ~ sheet surrounded by a helices. These are 
organized to form five polypeptide loops (G 1 to GS), which together constitute the 
guanine nucleotide binding pocket of the G protein. The domain is evolutionarily 
conserved among all guanine nucleotide binding proteins and contains distinct sequence 
motifs responsible for binding the guanine ring, GTP and Mg2+ (Hamm and Gilchrist, 
1996; Sprang, 1997a). The alpha helical domain consists of five helices arranged to 
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produce a semi-cylindrical cup su1Tounding a long central helix. This domain forms a 
"lid" over the guanine nucleotide binding pocket, and influences the rate of GDP 
dissociation from the G protein (Hamm and Gilchrist, 1996). The amino terminal helix 
projects away from the core of the a subunit, and is involved in interaction of the a 
subunit with the 0Y subunit (Conklin and Bourne, 1993). 
The 0 subunit contains an a helix connected to a 0 propeller that is made up of seven 0 
sheets. These 0 sheets of the propeller coincide roughly with seven WD40 repeat 
sequences (Smith et al., 1999) found in the polypeptide chain (Wall et al., 1998). They 
subunit has no tertiary structure, comprising only two major a helices (Wall et al., 
1998). The absence of a tertiary structure means that the y subunit makes very little 
contact with itself, and almost all its contacts with the 0 subunit is over an extended 
hydrophobic groove along the 0 propeller, and in their amino terminal a helices. The 
extensive association between the 0 and y subunits helps to provide stability to the 0Y 
dimer (Clapham and Neer, 1997). 
The three din1ensional structures of the various G protein subunits can be visualized on 
the protein data bank website (http: //www.rcsb.org/ pdb) (Berman et al., 2000). The 
pdb entries are 1 TAD and 1 TAG for the a subunit, 1 TBG for the 0y dimer and 1 GOT 
for the heterotrimeric G protein complex. 
1.1.4 The G protein cycle 
As with other members of the guanine-nucleotide binding protein superfamily (Section 
1.1.2), G proteins function by switching alternately between an inactive GDP bound 
form and an active GTP bound state. 
In the inactive configuration, the a subunit binds GDP and associates with the 0Y 
subunit to form a heterotrimer. The G protein 0Y dimer is a guanine nucleotide 
dissociation inhibitor (GDI) (Higashijima et al., 1987; Sprang, 1997b), and its 
association with the a subunit helps to stabilize the GDP bound a subunit (Wall et al. , 
1998), to minimize spontaneous activation of the G protein. In order to activate the G 
protein, contact of the G protein with a GEF is required. In trans-membrane signalling, 
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an activated G protein coupled receptor (GPCR) serves as a GEF. G protein coupled 
receptors are cell surface receptors with seven hydrophobic trans-membrane helices 
(Morris and Malbon, 1999). The binding of an agonist (e.g. neurotransmitter, hormone) 
to the receptor produces a conformational change in the receptor (Bourne, 1997) that 
allows it to interact effectively with its cognate G protein and serve as its GEF 
(Gudermann et al., 1996). The mechanism by which the stimulated receptor catalyses 
the exchange of GDP for GTP on the G protein a subunit is still not understood (Hamm, 
2001; Marin et al., 2002). Based on the crystallographic structure of the G protein 
heterotrimer (Lambright et al., 1996; Wall et al., 1995; Wall et al., 1998) and the 
proposed contact sites between the receptor and G protein (Hamm, 1998), one 
hypothesis is that the receptor uses the ~y dimer as a lever to pry open the guanine 
nucleotide binding pocket of the a subunit, causing GDP to be released (Rondard et al., 
2001). This dissociation of GDP from the a subunit is the rate limiting step in G 
protein activation (Ferguson et al., 1986). After the dissociation of GDP, GTP, which is 
present at a much higher cellular concentration than GDP (Neer, 1995), attaches to the 
guanine nucleotide binding pocket of the a subunit. The binding of GTP switches the a 
subunit to its active conformation (Lambright et al., 1996; Sunahara et al., 1997), and in 
this conformation, the affinity of the a subunit for the ~y dimer (Wall et al., 1998) and 
for the receptor is assumed to decrease, leading to sequential dissociation of the a 
subunit and the ~y dimer from the receptor (Neer, 1995). Following this, the GTP-
bound a subunit and ~y dimer interact with their respective downstream effectors, and 
transduce the signal of receptor activation (Bimbaumer, 1990). 
Similar to other 1nembers of the guanine-nucleotide binding protein superfamily, the G 
protein a subunit is a GTPase (Kaziro et al., 1991). The a subunit becomes inactivated 
when its intrinsic GTPase activity hydrolyses the bound GTP to GDP. This most likely 
occurs via a nucleophilic substitution 2 (SN2) mechanism, where the y phosphate of 
GTP is transfen·ed to water (Sprang, 1997b ). The intrinsic GTPase activity of G protein 
a subunits can be enhanced by interaction with certain effectors (such as phospholipase 
C-~, type V adenylate cycalse, pl l 5RhoGEF) and a family of proteins known as 
regulators of G protein signalling (RGS), which function as GAPs (Ross and Wilkie, 
2000; Scholich et al., 1999). Since G protein a subunits show wide variations in their 
intrinsic GTP hydrolysis rates (Fields and Casey, 1997), GAPs can play an important 
role in detem1ining the time length of signal onset. After GTP hydrolysis, the GDP 
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bound a subunit re-associates with the ~y dimer, allowing the G protein cycle to 
continue. 
Although the G protein cycle presented above is widely accepted, there is still 
controversy whether dissociation of G protein into its component a and ~y subunits 
actually occurs after its activation in vivo (Rebois et al., 1997). The original supporting 
evidences for the subunit dissociation hypothesis have been questioned as they were 
obtained in solutions containing detergent and high magnesium concentrations (Rebois 
et al., 1997). When G protein activation is examined under physiological conditions, 
both a and ~y subunits co-purify in a 1: 1 ratio stoichiometrically with one another and 
with the effector, suggesting dissociation of the ~y subunit from the a subunit might not 
have occurred (Marbach et al., 1990). Furthermore, a mutant G protein that cannot 
undergo subunit dissociation, has been found to transduce receptor activation signals, as 
well as normal G proteins (Klein et al., 2000). On the other hand, many of the amino 
acid residues on the ~ subunit that are in contact with the a subunit have been 
demonstrated to be essential for effector stimulation by the ~y dimer (Ford et al., 1998). 
Based on this evidence, it is concluded that upon G protein activation, subunit 
dissociation has to occur to expose these residues concealed by the a subunit to ~y 
effectors (Ford et al., 1998). This would account for the huge body of empirical data 
showing both the a and ~y subunits are independently capable of modulating the 
activities of a vast number of downstream effectors (Clapham and Neer, 1997; 
Offermanns, 2001). 
1.1.5 Diversity of G proteins 
The human genome has been estimated to contain twenty-seven a, five ~ and thirteen 
y subunits (Venter et al., 2001). Although the ~y dimer has now been recognized to 
play an important role in effector activation (Carozzi et al., 1993; Clapham and Neer, 
1997; Koch et al., 1994; Logothetis et al., 1987; Tang and Gilman, 1991) and in 
determining signalling specificity (Dippel et al., 1996; Hou et al., 2000; Johansen et al., 
2001; Kleuss et al., 1993; Robillard et al., 2000), G proteins have conventionally been 
named according to the unique structures of their a subunits. Classification of G 
proteins based on the amino acid sequence homology among the a subunits has 
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produced four large G protein families. These are the Gs family, the Gi family, the Gq 
family and the G12 family (Table 1.1 ). 
1.1.5.1 The a subunits 
The Gas family consists of Gas and the odorant receptor G protein, Ga0 1r. Gas has a 
large number of possible alternative isoforms (Monteith et al., 1995; Novotny and 
Svoboda, 1998; Pasolli et al., 2000; Ye et al., 1999) and demonstrates complicated 
tissue specific imprinting (Li et al., 2000). The protein was originally named based on 
its ability to stimulate the intracellular enzyme, adenylate cyclase, which catalyses the 
conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate 
(cAMP) (Kahn and Gilman, 1984). To date, ten different isoforms of adenylate cyclase 
have been identified in mammals, and Gas has been found to be capable of stimulating 
nine of them (Adenylate cyclase types I to IX) (Hanoune and Defer, 2001). The only 
adenylate cyclase it fails to stimulate is a novel cyclase named soluble adenylate 
cyclase, which incidentally, is localized to both the soluble and particulate fractions of 
cells (Zippin et al., 2001) and appears to be resistant to regulation by all G proteins 
(Buck et al., 1999). Similar to Gas, Ga01r also exerts a stimulatory effect on adenylate 
cyclase activity in a mammalian cell line (Jones et al., 1990; Jones and Reed, 1989) and 
in neural tissue where Ga01r is expressed (Corvol et al., 2001). Another distinguishing 
feature of all members in this family is that they possess an arginine residue in their 
GTPase domains that represents the target of adenosine diphosphate (ADP) ribosylation 
by cholera toxin. Modification of the GTPase domain by the toxin leads to a 
suppression of the a subunit's intrinsic GTPase activity, resulting in constitutive 
activation of the G protein (Bourne et al., 1989). 
The Gai family is the largest of the G protein families. All family members, with the 
exception of Gaz (Casey et al., 1990) and an alternatively spliced variant of Gai2 
(Montmayeur and Borrelli, 1994), contain a carboxyl terminal cysteine residue, which 
serves as the substrate for ADP-ribosylation by pertussis toxin (Kaziro et al., 1991). 
Since the carboxyl terminal of the a subunit is involved in G protein-receptor 
interaction (Conklin and Bourne, 1993), the structural alteration induced by the toxin 
disrupts coupling of the G protein to the receptor (Maus et al., 1990), resulting in an 
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impairment of receptor mediated signalling. The prototypical member of the Gi family 
is Gai, and it was originally named based on its ability to inhibit adenylate cyclase, and 
therefore opposed the stimulatory effects of Gas (Bokoch et al., 1984). However, it was 
subsequently discovered that only certain isoforms of adenylate cyclases are inhibited 
by Gai. These are the types I (weak to moderate inhibition), III, V, VI, VIII and IX 
isoforms of adenylate cyclase (Dessauer et al., 1996; Hanoune and Defer, 2001; Taussig 
et al., 1994). However, it should be emphasized that not all members of the Gi family 
cause adenylate cyclase inhibition. Besides the three Gai isoforms, only Ga2 and Ga0 
have been shown to be capable of inhibiting adenylate cyclase. Specifically, Ga2 can 
inhibit the types I, V and VI isoforms of adenylate cyclase (Ho et al., 2000; Kozasa and 
Gilman, 1995) while Ga0 appear to exert an inhibitory effect only on type I adenylate 
cyclase (Taussig et al., 1994). 
The Gaq family consists of five members. All of them share the capacity to stimulate 
isozymes belonging to the phospholipase C-beta (PLC-~) family (Lee et al., 1992; 
Offermanns and Simon, 1995; Wu et al., 1992). Activation of PLC-~ cleaves the 
phospholipid, phosphatidylinositol-4,5-biphosphate into the intracellular messengers, 
inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Neves et al., 2002). IP3, in 
tum triggers the release of calcium from intracellular stores, and the consequent rise in 
cytosolic calcium, recruits protein kinase C to the plasma membrane. At the membrane, 
DAG in combination with calcium, causes the activation of protein kinase C (Alberts et 
al., 1994; Asaoka et al., 1992), a serine-threonine kinase with diverse functions in the 
cell (Liu and Anand, 2001; Ventura and Maioli, 2001). Besides activating the protein 
kinase C cascade, members of the Gq family may also trigger other signalling cascades 
through the stimulation of protein tyrosine kinase 2 (Della Rocca et al., 1997; Shi and 
Kehrl, 2001). 
The Ga 12 family contains only 2 1nembers, Ga12 and Ga13. Although Ga12 and Ga13 
appear to be expressed ubiquitously (Hepler and Gilman, 1992), the signal transduction 
pathways mediated by Ga12113 in vivo remain poorly understood as most experiments 
investigating Ga1211 3 have been performed using transfected cell lines (Neves et al., 
2002). However, mice deficient in Ga12 and Ga13 have been produced and analyses of 
these mice have provided some insights into the functions of these G proteins 
(Offermanns, 2001). The loss of Ga13 in mice causes embryonic lethality, probably 
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resulting from a failure of angiogenesis 1n the yolk sac and abnormal vascular 
organization in the head mesenchyme. Additionally, thrombin induced cell migratory 
responses was absent in Ga13 deficient fibroblasts (Offermanns et al., 1997). 
Subsequent studies establish that Ga13 directly stimulates pl 15RhoGEF (Hart et al., 
1998), the GEF for the small G protein, Rho. Rho plays an important role in the 
regulation of the actin cytoskeleton and in cell motility (Sah et al., 2000), and it is 
hypothesized that altered Rho signalling is likely to have contributed to the cell 
migration defects observed in the Ga13 knockout animals (Offermanns, 2001). A 
deficiency of Ga 12 in mice produces no obvious phenotype, although intriguingly, Ga 12 
knockout mice that are simultaneously deficient in Gaq or heterozygous for Ga 13 die in 
utero (Gu et al., 2002). This suggests that Ga12 is involved in mouse embryonic 
development, although its deficiency can be compensated for by activation of either 
Gaq or Ga13. 
1.1.5.2 The 0y subunits 
In addition to the a subunits, the 0 and y subunits are increasingly recognized to 
contribute to the diversity of G protein functions. For instance, the activities of various 
G protein gated inwardly retifying potassium channels (Dascal, 1997) and voltage 
dependent calcium channels (Zamponi and Snutch, 1998) have been found to be 
principally regulated by the 0Y subunits. At present, five 0 and thirteen y subunits, each 
with a distinctive tissue distribution, are known to exist (Table 1.2). Compared to the y 
subunits, the 0 subunits are less heterogeneous. For instance, G01 to G04 share more 
than 80% amino acid sequence similarity (Gautam et al., 1998) and they have a 
ubiquitous expression, which suggests many are probably co-expressed in the same 
cells. This has led to the suggestion that 0 subunits are likely to have a limited ability to 
generate diversity or to account for signalling specificity (Vanderbeld and Kelly, 2000). 
On the other hand, it may be that the different co-expressed 0 subunits are non-
redundant and each of them may preferentially interact with distinct a and y subunits, as 
well as receptors and effectors. In congruence with this, differences between the four 0 
subunits in transducing the effects of various hormones on downstream effectors have 
been observed (Johansen et al., 2001). Moreover, the discovery of GPs and its 
alternatively spliced variant GPs(long), which share only 53% amino acid sequence 
homology with the other G0 isoforms (Maier et al., 2000), and which are uniquely 
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expressed in nervous tissues and in the retina respectively (Watson et al., 1994; Watson 
et al., 1996; Zhang et al., 2000), will add to the contribution made by the 0 subunit to G 
protein diversity. Consistent with this idea, the G05 subunit has been found to 
discriminate between different receptor and effector subtypes (Maier et al., 2000; 
Robillard et al., 2000). 
The y subunit is the smallest of the three G protein subunits. Despite its small size, the 
thirteen currently known y subunits demonstrate considerable diversity in their amino 
acid sequence (Vanderbeld and Kelly, 2000), and can be classified based on amino acid 
homology into four subfamilies (Table 1.2). All y subunits are post-translationally 
modified by the attachment of an isoprenoid group to a cysteine residue four amino 
acids from the carboxyl terminal, followed by proteolytic cleavage of the three terminal 
residues and finally, methylation of the exposed prenylcysteine (Higgins and Casey, 
1996). The isoprenoid group attached is either a fifteen carbon famesyl group or a 
twenty carbon geranylgeranyl group depending on the nature of the last amino acid at 
the carboxyl terminal. If the terminal amino acid is a leucine residue, 
geranylgeranylation occurs (Moores et al., 1991). However, if it is serine, glycine, 
alanine, cysteine, threonine, histidine, asparagine or glutamine, famesylation occurs 
(Moores et al., 1991). Members of the yl subfamily have a serine residue at their 
carboxyl termini and are therefore famesylated, while all other known y subunits have a 
terminal leucine residue and are geranylgeranylated (Gautam et al., 1998). Prenylation 
of the y subunit is essential for association of the 0Y dimer with the a subunit (Higgins 
and Casey, 1994; Matsuda et al., 1994; Matsuda et al., 1998) and the nature of the 
prenylation (~1hether famesylation or geranylgeranylation) can influence the strength of 
the interaction between the 0y dimer with the plasma membrane, as well as with G 
protein receptors and effectors (Balcueva et al., 2000; Fogg et al., 2001; Gautam et al., 
1998; Matsuda et al., 1998). Accordingly, G proteins that contain y subunits belonging 
to the yl subfamily may interact with receptors (Butkerait et al., 1995; Kisselev et al. , 
1995) and effectors (Iniguez-Lluhi et al., 1992) differently from G proteins that contain 
y subunits from other y subfamilies. Besides the carboxyl terminal, other regions of the 
y subunit may also be involved in determining the specificity of G protein interaction 
with receptors and effectors (Lim et al., 2001; Myung et al., 1999). For instance, the yl 
and yl 1 subunits are both famesylated and share very similar carboxyl terminal amino 
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acid sequences, yet the a2a adrenergic receptor prefers G proteins containing the yl 1 
subunit over those containing the yl subunit (Richardson and Robishaw, 1999). 
Taken together, although G proteins are often referred to base on the identity of their a 
subunits, it is clear from the above review that all three subunits in the heterotrimer 
contribute to the interaction of the G protein with receptors and effectors. Accordingly, 
the functional consequences of G protein activation depend on the combination of a, ~ 
and y subunits making up the G protein that associates with a particular receptor. If 
each of the twenty-seven currently known a subunits is able to combine with any of the 
other distinct ~ and y subunits to form a heterotrimer, this would result in (27 x 5 x 13) 
1755 possible G proteins. However, random associations between the subunits do not 
occur in nature (Exner et al., 1999; Kontani et al., 1992; Lee et al., 1995; Pronin and 
Gautam, 1992; Vanderbeld and Kelly, 2000). Due to selectivity between certain a and 
y subunits for one another (Rahmatullah et al., 1995) and structural compatibility 
between the ~ and y subunits (Wall et al., 1998), as well as their differential tissue 
distribution (Tables 1.1 and 1.2), specific combinations of subunits have been observed 
to interact preferentially with one other (Asano et al., 1999; Exner et al., 1999), 
resulting in a more limited pool of G proteins. Nonetheless, this 'limited' pool of G 
proteins is still large, and identifying the specific a~y composition of a G protein will be 
important for defining the function of a particular G protein. 
1.1.6 Regulators of G protein Signalling 
Besides contacting receptors and effectors, G proteins also interact with members from 
the Regulator of G protein Signalling (RGS) family. RGS proteins represent a large 
family of proteins coded in humans by twenty seven different genes (Venter et al., 
2001). They share a characteristic RGS domain that is about 130 amino acids in length, 
which can interact with Ga subunits (Zheng et al., 1999). Based on sequence homology 
within their RGS domains, the currently known RGS proteins have been grouped into 
five subfamilies (Table 1.3). With the exception of axin and conductin from the RA 
subfamily, all RGS proteins are capable of stimulating the intrinsic GTP hydrolysis rate 
of Ga subunits, and hence, function as GAPs (Ross and Wilkie, 2000). On top of this, 
there are a number of other molecules containing domains homologous to RGS domains 
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Table 1.1: The mammalian heterotrimeic G protein families 
Family a subunit Mass Toxin a Tissue Distribution 
(kDa) 
Gs as (short) 44.2 CTX Ubiquitous 
as (long) b 45.7 CTX Ubiquitous 
as (XL) c, 4 785 CTX5 N euroendocrine tissues (pituitary, adrenal 
medulla, pancreas)4'6, cerebellar purkinje cells4 
aolf 44.7 CTX Olfactory epithelium, Neuronal7 (striatum, 
dentate gyrus, medial habenula), heart8 
Gi au 40 CTX, PTX Retinal rods, taste buds 
at2 40.1 CTX, PTX Retinal cones, kidney 1°, pancreas 11 , pituitary 11 , 
adrenal 11 
agust 40.5 PTXd Taste buds 
ail 40.3 PTX Widely expressed 
ai2 
e 40.5 PTXe Ubiquitous 
ai3 40.5 PTX Widely expressed 
aol 
f 40 PTX Brain and others 
ao2 
f 40.1 PTX Brain and others 
a z 40.9 Brain and others 11 
Gq aq 42 Ubiquitous 
a11 42 Widely expressed 
a14 41.5 Kidney, lung, spleen, testis, liver, pancreas 11 
a1s 43 Hematopoietic cells 
a16 43.5 Hematopoietic cells 17 
G12 a12 44 Ubiquitous 
a13 44 Ubiquitous 
a Sensitivity of the G protein a subunits to modification by cholera toxin (CTX) or pertussis toxin (PTX). 
b Both the long and short isoforms of as possess a number of alternately spliced variants 1,2,3. 
c The extra large isoform of as, as (XL) consists of at least 3 alternately spliced isoforms6. 
d agust (gustducin) is a substrate for pertussis toxin 12 . Its sensitivity to cholera toxin has not been investigated 
although the arginine residue (Rl 78) that serves as the site of ribosylation by the toxin is present in the protein 13. 
e ai2 has two alternatively spliced froms 14. The spliced variant of ai2 that is localized to the golgi apparatus is likely 
to be resistant to pertussis toxin as it lacks the cysteine residue, which is the substrate of adenosine diphosphate 
(ADP) ribosylation by the toxin 14. 
f Two alternate forms of a 01 and a 02 have been found in the brain 15' 16. 
This table is compiled using the information from Hepler and Gilman (1992) (Pg. 384, table 1) and Offermanns (2001) (pg. 1636, table 1), with the following additional references: (Monteith et al., 1995) 1, (Ye et al., 1999)2, (Novotny and Svoboda, 1998)3, (Kehlenbach et al. , 1994)4, (Klemke et al., 2000)5, (Pasolli et al., 2000)6, (Herve et 
al., 2001)7, (Ferrand et al. , 1999)8, (Ruiz-Avila et al. , 1995)9, (Yamaguchi et al., 1997) 10, (Zigman et al., 1994) 11 , (Hoon et al., 1995) 12, (McLaughlin et al., 1992) 13, (Montrnayeur and Borrelli, 1994) 14, (McIntire et al., 1998b) 15, 
(McIntire et al., 1998a) 16, (Amatruda, III et al., 1991) 17. 
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Table 1.2: Diversity of G protein py subunits 
Subfamily 
Yi 
Y2 
Ys 
YB 
Subunit 
f3i 
f32 
f33 a 
f34 
f3s a 
Yi 
Yscone 
Y11 
Yi4 
Y2 
Y3 
Y4 
Y7 
Ysolf 
Y12 
Ys 
Yio 
YB 
Mass 
(kDa) 
37.3 
37.3 
37.2 
37.2 
39 I 44 10 
8.4 
7.7 
8.5 
7.7 
7.9 
8.5 
8.4 
7.5 6 
7.8 
7 _911 
7.3 
7.2 
7.9 
Tissue Distribution 
Ubiquitous 
Widely expressed 
Widely expressed 
Widely expressed 
Brain and spinal cord (f35) Retina (f3s-Iong) 1 
Retinal rods 
Retinal cones 
Heart, lung, spleen, placenta, pancreas, skeletal muscle 2 
Heart, liver, skeletal muscle2 
Brain, adrenal gland, testis, white blood cells, lung 
Brain ( neurons 4) and testis 
Brain, lung, skeletal muscle, kidney, pancreas5 
Brain, heart, lung, , kidney, spleen6 
Olfactory and vemeronasal neurons 
Ubiquitous (Glial cells in the brain4) 
Liver, heart, kidney, lung, brain , neuronal precursor cells 
Ubiquitous5 
Thalamus, retina and taste buds 
a The P3 subunit has an alternately spliced shorter variant, P3-short 9,while the Ps subunit 
has an alternately spliced longer variant, p5-long10. 
This table is prepared using the information from Hepler and Gilman (1992) (Pg. 384, table 2) and Vanderbeld and 
Kelly (2000) (Pg. 539, Table 1) with the following additional references : (Zhang et al. , 2000) 1, (Balcueva et al. , 
2000)2, (Modarressi et al., 2000)3, (Morishita et al., 1997)4, (Ray et al., 1995)5, (Cali et al. , 1992)6, (Asano et al. , 
2001)7, (Blake et al., 2001)8, (Virchow et al., 1999)9, (Watson et al., 1996) 10, (Morishita et al., 1995) 11 . 
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Table 1.3: The ma1nmalian RGS protein family 
Subfamily 
RZ 
R4 
R7 
R12 
RA 
Protein 
RGSZl 
RET-RGSl 
RGSZ2 
GAIP 
RGSl 
RGS2 
RGS3 
RGS4 
RGS5 
RGS8 
RGS13 
RGS16 
RGS6 
RGS7 
RGS9 
RGSll 
RGSlO 
RGS12 
RGS14 
Ax.in 
Conductin 
Tissue Distribution 
Brain 
Retina 
Not determined 
Ubiquitous, low in brain 
B-lymphocytes, lung 
Ubiquitous 
Ubiquitous 
Brain, heart 
Ubiquitous 
Brain 
Lung 
Ubiquitous 
Brain 
Brain, B-cells 
Retina, neurons 
Brain 
Brain 
Brain, spleen, lung, testis 
Brain, spleen, lung 
Ubiquitous 
Lung, thymus 
Protein Interaction domains 
RGS 
RGS 
RGS 
RGS, PDZ 
RGS 
RGS 
RGS 
RGS 
RGS 
RGS 
RGS 
RGS 
RGS, GGL, DEP 
RGS, GGL, DEP 
RGS, GGL, DEP 
RGS, GGL, DEP 
RGS 
RGS, RBD, PDZ, PTB, GPR 
RGS, RBD, GPR 
RGS, APC, GSK, PP2A, Cat, DIX 
RGS, APC, GSK, PP2A, Cat, DIX 
This table is compiled based on information provided in Ross & Wilkie (2000) and De Vries, L. et al. 
(2000). The abbreviations for protein interaction domains referred to in the table are: RGS (Regulator of 
G protein Signalling domain), PDZ (PSD95/Dlg/Z0-1 homology domain), GGL (Gy-like domain), DEP 
(Dishevelled/EGL-I 0/pleckstrin homology domain), RBD (Ras/Rap binding domain), GPR (G protein 
regulatory motif or GoLoco binding motif), PTB (Phosphotyrosine binding domain), APC (Adenomatous 
Polyposis Coli protein binding motif), GSK (Glycogen Synthase Kinase 30 binding domain) PP2A 
(Protein Phosphatase 2A binding domain), Cat (0 Catenin binding domain) and DIX (Dishevelled and 
Axin homology domain). 
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that also allow them to interact with Ga subunits. These include the Rho selective 
guanine nucleotide exchange factor, p 115RhoGEF, which function as GAPs for both 
Gcx12 and Gcx 13 (Kozasa et al., 1998) and G protein coupled receptor kinase 2 (GRK2), 
which inhibits Gcxq mediated phospholipase C -~ activity through sequestration of 
activated Gcxq (Kozasa, 2001 ). 
Several larger RGS proteins contain protein interaction domains outside their RGS 
domains (Table 1.3). These protein interaction domains may help to link G protein 
signalling to other signalling cascades within the cell (De Vries et al., 2000). For 
instance, the presence of a Ras/Rap binding motif in RGS 12 and RGS 14 might allow 
these two RGS proteins to become the center of two signalling networks that involve G 
proteins and Ras/Rap GTPases (Ponting, 1999). Additionally, these other protein 
interaction domains may also play a direct role in regulating G protein function. The G 
protein regulatory domain ( also known as the GoLoco binding domain) is found in 
RGS 12 and RGS 14, and the domain has been shown to bind specifically to the ex 
subunits of some Gcxi family members to inhibit GDP release (Hollinger et al., 2001; 
Kimple et al., 2002). Therefore, RGS 12 and RGS 14 can serve as guanine nucleotide 
dissociation inhibitors (GDis) (Hollinger et al., 2001; Kimple et al., 2001) in addition to 
their role as GAPs, and this would be expected to severely dampen the signalling of 
those G protein ex subunits they interact with. On the other hand, RGS proteins from the 
R 7 subfamily contain a 64 amino acid region, called a G-gamma-like domain. This G-
gamma-like domain, originally identified based on its sequence similarity to G protein y 
subunits, has been found to bind G~5 subunits specifically (Snow et al., 1998). In 
phospholipid vesicles, RGS9 (a member of the R7 subfamily) is capable of associating 
with G~s and Gcx0 to form a heterotrimer and support receptor stimulated guanine 
nucleotide exchange on the Gcx0 subunit (Sondek and Siderovski, 2001). In Xenopus 
oocytes, co-expression of G~5 with RGS7 (another member from the R7 subfamily) or 
RGS9 lead to acceleration of the kinetics of coupling between m2 muscarinic 
acetylcholine receptor and G protein coupled inward rectifying potassium channels 
(Kovoor et al., 2000). Since G~5 and RGS proteins from the R 7 subfamily are 
predominantly expressed in nervous tissues (De Vries et al., 2000; Watson et al., 1994), 
their association with one another and with Ga subunits could produce a heterotrimer 
with rapid inactivation kinetics ( due to GAP activity on the RGS protein), and 
contribute to the rapidity and specificity of neuronal signalling. 
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1.1.7 Covalent modifications of G proteins 
G protein subunits are subjected to a number of co-translational and post-translational 
modifications (Chen and Manning, 2001; Dunphy and Linder, 1998). These 
modifications play an important role in determining the properties of the G protein, 
which could sometimes lead to alteration of their functions. Two examples already 
mentioned are ADP-ribosylation of a subunits from the Gas family by cholera toxin 
causing prolonged G protein activation, and ribosylation of a subunits from the Gai 
family by pertussis toxin, leading to disruption of receptor-G protein coupling. 
On the other hand, most covalent modifications appear to be essential for the G protein 
to function normally. Prenylation refers to the attachment of one or more isoprenyl 
groups ( either a fifteen carbon famesyl group or a twenty carbon geranylgeranyl group) 
to cysteine residues near the carboxyl terminal of a protein (Bhatnagar and Gordon, 
1997). The attachment takes place via a stable thioether bond, and occurs in all G 
protein y subunits (Gautam et al., 1998). This lipid modification is a pre-requisite for 
the ~y subunits to associate with the a subunit to form the G protein heterotrimer 
(Higgins and Casey, 1994), and plays a key role in targeting both the ~y dimer (Simonds 
et al., 1991) and the a subunit (Fishburn et al., 2000) to the membrane. 
The a subunits are also dependent on lipid modifications to assist them in their 
localization to the membrane. Myristoylation refers to the attachment of a fourteen 
carbon myristate group to a glycine residue on a protein via an amide bond (Bhatnagar 
and Gordon, 1997). This reaction happens co-translationally and is catalysed by the 
enzyme myristoyl CoA: protein N-myristoyltransferase, which specifically recognizes 
an amino terminal MGXXXS motif unique to a subunits from the Gai family (Chen 
and Manning, 2001). Therefore, only Gai family members are myristoylated and 
myristoylation results in anchorage of the a subunit to the membrane, so that they can 
interact with their cognate receptors (Morales et al., 1998; Mumby et al., 1990). For a 
subunits from other G protein families, lipid modification takes place via 
pahnitoylation. Palmitoylation refers to the post-translational attachment of palmitic 
acid ( a sixteen carbon saturated fatty acid) to cysteine residues near the amino terminals 
of proteins (Bhatnagar and Gordon, 1997). The majority of G protein a subunits are 
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palmitoylated, and the process occurs via a reversible thioester bond (Dunphy and 
Linder, 1998). Palmitoylation increases the hydrophobicity of the a subunits and helps 
in stabilizing their association with the plasma membrane (Fishburn et al., 2000). This 
may be particularly important for a subunits that are not myristoylated since attachment 
of G proteins to the membrane is thought to require at least two hydrophobic signals, 
one from the isoprenyl group on the y subunit and the other from the a subunit (Dunphy 
and Linder, 1998; Fishburn et al., 1999; Morales et al., 1998). Additionally, 
palmitoylation of the a subunit has been found to increase the affinity of the a subunit 
for the ~y subunit (Iiri et al., 1996) and block the GAP activity of RGS proteins (Tu et 
al., 1997). Reversible palmitoylation may therefore play a key role in regulating the 
interaction of the a subunit with the ~y subunits and with RGS proteins. 
Protein phosphorylation and dephosphorylation represent another covalent modification 
whereby the functions of a G protein can be regulated. Phosphorylation has been 
observed to occur on the serine residues of Ga2 , Ga 12 and Gy12 by protein kinase C, on 
the tyrosine residues of Gai, Gas and Gaq by tyrosine kinases and on a histidine residue 
of G~ possibly via a nucleoside diphosphate kinase (Chen and Manning, 2001). Protein 
phosphorylation could alter the strength of the association between a and ~y subunits 
(Fields and Casey, 1995; Kozasa and Gilman, 1996; Morishita et al., 1995), and 
influence the interaction of the phosphorylated G protein subunit with downstream 
effectors (Yasuda et al., 1998) and RGS proteins (Wang et al., 1999). 
1.2 Gaz: a G protein a subunit with unique biochemical properties 
1.2.1 Ga2 : a member of the Gai family 
Ga2 was discovered in 1988 by reduced stringency hybridization of a bovine Gan and a 
rat Gai2 probe to cDNA libraries from human retina and rat brain respectively (Fong et 
al., 1988; Matsuoka et al., 1988). Based on sequences that are conserved between the 
human an~ rat Ga2 cDNAs and at the same time, differ maximally from the sequences 
of other Gas, we designed a pair of polymerase chain reaction (PCR) primers, which 
allowed the amplification and subsequent cloning of the corresponding partial mouse 
Ga2 cDNA from cerebellum (Leck, 1993). The full mouse Ga2 cDNA (Genebank 
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accession number: XM_109580) has recently become available and its sequence 
matches exactly with that of our partial mouse Ga2 cDNA (Genebank accession 
number: AF059672). Comparison of the translated mouse Ga2 protein sequence with 
that from human and rat shows the three polypeptides share greater than 98% sequence 
identity, confirming that they are the same protein. 
The amino acid sequence of Gaz is most similar to that of the Gais, leading to the 
classification of Ga2 as a member of the Gai family (Simon et al., 1991 ). Ga2 shares 
66-67% identity with Gai1, Gai2 and Gai3, 59-60% identity with Ga0 and 55-57% 
identity with Gat (Matsuoka et al., 1988). 
1.2.2 Unique features in the Gaz protein sequence 
Although Ga2 is a member of the Gai family, the rather low sequence identity between 
Gaz and other Gai family members suggest Ga2 may possess characteristics that differ 
from other family members. Analysis of the polypeptide sequence of Ga2 reveals a 
distinctive GTSNS sequence in its GTPase domain that replaces a consensus GAGES 
motif found in other members of the Gai family (Figure 1.1, Panel A). When an 
analogous GTSNS mutation is made in Gas, the mutant exhibits a fifty fold reduction in 
GTPase activity compared to wildtype Gas (Casey et al., 1990). One may therefore 
expect Ga2 to show a sluggish rate of GTP hydrolysis, which will make its active GTP-
bound conformation relatively stable when the protein becomes activated. Another 
unique feature in the Ga2 polypeptide sequence is the substitution by isoleucine of a 
cysteine residue located four amino acids from the carboxyl terminal ends of other Gai/o 
proteins (Figure 1.1, Panel B). This cysteine residue is the target of ADP ribosylation 
by pertussis toxin, which disrupts receptor-G protein coupling by causing structural 
changes to the carboxyl terminals of Gai/0 subunits (Dratz et al., 1993). The absence of 
the cysteine residue is expected to make Ga2 resistant to modification by the toxin. 
1.2.3: Gaz has a sluggish GTPase activity 
Predictions about the biochemical properties of Ga2 based on information available in 
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Panel A: 
Gaz 39-46: 
Gai1 39-46: 
Gai2 39-46: 
Gai3 39-46: 
Gaol 39-46: 
Gao2 39-46: 
Gat1 35-42: 
Gat2 39-46: 
Gagust 39-46: 
Gas 46-53: 
Gaq 45-52 
Ga12 63-70: 
Panel B: 
Gaz 348-355: 
Gai1 347-354: 
Gai2 348-355: 
Gai3 347-354: 
Gaol 347-354: 
Gao2 347-354: 
Gat1 343-350: 
Gat2 347-354: 
Gagust 347-354: 
sGai2 359-366: 
Gas 387-394: 
Gaq 352-359: 
Ga12 374-381: 
L G T s N s G K 
L G A G E s G K 
L G A G E s G K 
L G A G E s G K 
L G A G E s G K 
L G A G E s G K 
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L G A G E s G K 
L G A G E s G K 
L G A G E s G K 
L G T G E s G K 
L G A G E s G K 
N L K y I G L C 
N L K D C G L F 
N L K D C G L F 
N L K E C G L y 
N L R G C G L y 
N L R G C G L y 
N L K D C G L F 
N L K D C G L F 
N L K D C G L F 
p L s s D s V p 
H L R Q Y E L L 
N L K E Y N L V 
N L K D I M L Q 
s 
s 
s 
s 
s 
s 
s 
s 
s 
s 
s 
s 
Figure 1.1: Comparison of the amino acid sequence of Ga2 with other Gai family 
members, and with representative members of the Gas, Gaq and Ga12 families, in the 
G 1 loop of the GTPase domain (Panel A) and in the carboxyl terminal region (Panel B). 
sGai2 is an alternative carboxyl terminal spliced variant of Gai2 and its predicted amino 
acid sequence can be found in Montmayeur & Borrelli (1994). The gene bank 
accession numbers of the other depicted sequences are: for Ga2 (XP _109580) , Gai1 
(NP _002060), Gai2 (P08752), Gai3 (XP _010738), Ga0 1 (AAM12608), Gao2 
(AAM12609), Gat1 (XP _017793), Gat2 (NP _005263), Gagust (S24352), Gas (P04894), 
Gaq (XP _123396), Ga12 (Q03113). 
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its unique amino acid sequence have been confirmed. When the intrinsic rate of GTP 
hydrolysis of recombinant Ga2 is measured, the obtained kcat of 0.05 min-1 (at 30°C) is 
two hundred times slower than the corresponding kcat of Gas, Ga0 and the Gais, which 
have kcat values in the range of 10 min-1 at 30°C (Casey et al., 1990; Fields, 1998). 
Hence, it would take 10-12 minutes for half of all the bound GTP on Ga2 to hydrolyse 
compared to just several seconds for these other Ga subunits (Casey et al., 1990). 
Coincidentally, Ga9 , which has the same threonine substitution as Ga2 at position 4 7 of 
the protein (Figure 1. 1, panel A) also demonstrates a slow kcat of 0.8 min-1 (Berstein et 
al., 1992). Other studies suggest that the substitution with serine at position 42 for the 
conserved glycine may also contribute to the weak hydrolytic activity of Ga2 (Sprang, 
1997a). On the other hand, Ga12, in spite of sharing the same GAGES motif as most 
other Ga subunits (Figure 1.1, Panel A), also exhibits a very slow GTP hydrolysis rate 
(kcat of 0.1-0.2 min-1) (Kozasa and Gilman, 1995). Therefore, the intrinsic GTPase 
activities of G protein a subunits are not determined solely by the GAGES sequence 
(Fields and Casey, 1997). There are other regions of the protein that contribute as well 
(Sprang, 1997a). 
The sluggish GTPase activity of Ga2 means that once Ga2 becomes activated, it can 
remain in that state for a relatively long time. This unusual property of Gaz makes it a 
possible candidate for mediating signal transduction over long distances. Intriguingly, 
Ga2 has been observed to be transported along the axons of sensory neurons, which led 
to the hypothesis that Ga2 may function as a stable retrograde messenger, carrying 
infonnation from the axon terminal back to the cell body (Hendry et al., 1995b). 
The slow GTP hydrolysis rate of Ga2 has also inspired a search for molecules that can 
stimulate its sluggish GTPase activity (Fields, 1998; Wang et al., 1997). This effort 
resulted in the identification of a Ga2 selective RGS protein, RGSZ 1. Like other RGS 
proteins which can serve as GAPs for Ga subunits, RGSZl is a GAP for Gaz (Glick et 
al., 1998; Wang et al., 1998). According to one estimate, RGSZl increases the rate of 
GTP hydrolysis of GTP bound Ga2 more than four hundred fold, bringing its 
deactivation t112 to just one second at 30°C (Wang et al., 1998). Besides RGSZl, 
another relatively selective GAP for Ga2 is RET-RGS 1, which has also been shown to 
increase the GTPase activity of Ga2 by more than four hundred times (Wang et al., 
1998). RGSZl and RET-RGSl are two of several splice variants from the gene RGS20 
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(Barker et al., 2001). Since Ga2 is also expressed in tissues where RGSZl and RET-
RGS 1 are not expressed (Faurobert et al., 1999; Glick et al., 1998; Wang et al., 1998), 
the different splice variants of RGS20 may together account for multiple Ga2 selective 
GAP activity in various tissues. 
A number of other RGS proteins (including RGSZ2, GAIP, RGS4, RGS 10) can also 
stimulate the slow GTP hydrolysis rate of Ga2 in vitro (Barker et al., 2001; Popov et al., 
1997; Tu et al., 1997; Wang et al., 1999). However, these RGS proteins appear to be 
relatively broad spectrum GAPs for members of the Gai family (Berman et al., 1996; 
Popov et al., 1997) (Barker et al., 2001). RGS4 and GAIP are GAPs for Gaq as well 
(Hepler et al., 1997; Huang et al., 1997b). 
1.2.4 Resistance to cholera toxin, pertussis toxin and N-ethylmaleimide 
Consistent with expectations from its amino acid sequence, Ga2 has been found to be 
insensitive to treatment with pertussis toxin (Casey et al., 1990) and the sulfhydrl-
alkylating agent, N-ethylmaleimide (Sidhu et al., 1998). Both pertussis toxin and N-
ethylmaleimide target the unique carboxyl terminal cysteine residue found in most Gai 
family members to disrupt receptor-G protein coupling (Shinoda et al., 1990). Besides 
Ga2 , there is only one other Gai family member that lacks this cysteine residue (Figure 
1. 1, Panel B). This is an alternative carboxyl terminal spliced form of Gai2 , which has 
also been predicted to be insensitive to pertussis toxin treatment (Montmayeur and 
Borrelli, 1994). However, unlike Ga2 , which localizes to the plasma membrane 
(Morales et al., 1998), this spliced Gai2 variant resides in the Golgi apparatus, where it 
has been suggested to be involved in transporting proteins to the endoplasmic reticulum 
(Picetti and Borrelli, 2000). Therefore, Ga2 is currently the only member within the 
Gai family, which can 1nediate pertussis toxin/ N-ethylmaleimide resistant signalling 
across the plasma membrane. 
Like most Gai family members, Ga2 is also insensitive to cholera toxin (Casey et al., 
1990). Cholera toxin catalyses the ADP-ribosylation of an arginine residue in the 
GTPase domain of transducin (Van Dop et al., 1984) and Gas (Bourne et al., 1989), 
leading to an inhibition of their GTPase activities (Kaziro et al., 1991). Although this 
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arginine residue is present in all cuiTently known Ga subunits, only members of the Gas 
family and transducin are substrates of the toxin (Hepler and Gilman, 1992; Klemke et 
al., 2000). This suggests amino acid residues that are not directly modified by the toxin 
also contribute to determining substrate suitability. 
1.2.5 Sensitivity of the spontaneous guanine nucleotide exchange rate of 
Gaz to Magnesium 
Another unique biochemical property of Ga2 is the way its spontaneous guanine 
nucleotide exchange rate is affected by magnesium. All G protein a subunits possess a 
magnesium binding site that is tightly coupled to the guanine nucleotide binding site 
(Sprang, 1997a), and the bound magnesium can influence the affinity of Ga for 
GDP/GTP, and thereby change the spontaneous guanine nucleotide exchange rate on the 
a subunit (Higashijima et al., 1987). The basal guanine nucleotide exchange rate of 
Ga2 has been determined and found to be optimal at low micromolar concentrations of 
free magnesium (k= 0.02min-1 at 30°C, 0.5µM Mg2+) (Casey et al., 1990). This result 
stands in contrast to other Gas where the optimum rate of guanine nucleotide exchange 
occurs at significantly higher millimolar concentrations of magnesium (Higashijima et 
al., 1987; Kozasa and Gilman, 1995; Linder et al., 1990; Singer et al., 1994). In the 
case of Ga2 , magnesium concentrations exceeding 50µM cause its rate of guanine 
nucleotide exchange to decline rapidly, reaching a value close to zero as magnesium 
levels rise to millimolar concentrations (Casey et al., 1990). This phenomenon is 
explained by stabilization of the GDP-bound form of Ga2 by magnesium (Casey et al. , 
1990). In contrast, magnesium has virtually no effect on the affinities of other Gas for 
GDP, but helps to stabilize their GTP (or GTPyS) bound conformation instead (Gilman, 
1987; Graziano et al., 1989; Higashijima et al., 1987). 
The intracellular free magnesium concentration is typically in the range of 0.5-1 mM in 
neurons and probably most other cells (Li et al., 2001; McCarthy and Kumar, 1999; 
Rajdev and Reynolds, 1995). At these magnesium concentrations, there would 
practically be no dissociation of GDP from Ga2 , and activation of Gaz would be 
expected to show high fidelity, whereby only a receptor capable of coupling to Gaz 
could proinote the exchange of GDP for GTP (Barr et al., 1997). 
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1.2.6 Sensitivity of Gaz selective GAPs to Magnesium 
In contrast to the effects of magnesium on the spontaneous guanine nucleotide exchange 
reaction of Gaz, the slothful GTP hydrolysis rate of activated Ga2 is relatively 
unaffected by the divalent cation (Casey et al., 1990). Due to the sluggishness of Gaz' s 
intrinsic GTPase activity, hydrolysis of the bound GTP on Ga2 is expected to be 
facilitated by a RGS protein in vivo. Interestingly, while the GAP activities of non-
selective RGS proteins (RGS4 and RGS 10) show a slight decline as the magnesium 
concentration rises from lµM to lmM, the GAP activities of both Ga2 specific GAPs, 
RGSZl and RET-RGSl, increase four fold over this magnesium concentration range 
(Wang et al., 1998). Therefore, the association of these Ga2 specific GAPs with Ga2 
would lead to further dampening of Ga2 signalling by ensuring rapid signal termination 
under normal physiological conditions. 
1.2. 7 Inactivation of Gaz by arachidonic acid 
Besides magnesium, arachidonic acid and other cis-unsaturated fatty acids have also 
been shown to inhibit the guanine nucleotide exchange reaction of Ga2 (Glick et al., 
1996). The inhibition occurs after GDP has dissociated from Ga2 , through a direct 
interaction of the lipid micelle with the nucleotide free form of the protein. This 
prevents Ga2 from binding GTP, leading to inactivation of the protein (Glick et al., 
1996). The effect of arachidonic acid appears specific for Ga2 , as guanine nucleotide 
binding to Gail, Ga0 and Gas are not affected, and Gai3 is inhibited to a significantly 
smaller degree (Glick et al., 1996). In the cell, arachidonic and other fatty acids are 
synthesized from membrane lipids through activation of the phospholipase A2 enzyme 
(Alberts et al., 1994; Farooqui et al., 2000). Stimulation of a number of receptor 
systems, including serotonin (Felder et al., 1990), glutamate (Pellerin and Wolfe, 1991), 
acetylcholine (Tence et al., 1994) and dopamine (Vial and Piomelli, 1995), can elicit 
arachidonic acid release. However, whether the ensuing transient increase in 
arachidonic acid concentration near the plasma membrane has an effect on Gaz, and the 
physiological relevance of Ga2 inactivation by such a mechanism (if it occurs in vivo) is 
currently unknown. 
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1.2.8 Lipid modification of Gaz 
At a lower concentration, arachidonic acid may have other effects on Ga2 • In blood 
platelets, arachidonic acid has been reported to bind Ga2 via a reversible thioester bond 
(Hallak et al., 1994b ). The function of the arachidonoylation is currently unknown but 
such lipid modification is expected to increase the hydrophobicity of Ga2 , strengthening 
its association with the membrane compartment. Besides arachidonoylation, Ga2 is also 
subjected to myristoylation (Mumby et al., 1990) and palmitoylation (Morales et al., 
1998) due to the presence of a MGCXXS sequence at its amino terminal (Chen and 
Manning, 2001 ). The second glycine residue is myristoylated while the third cysteine 
residue is reversibly palmitoylated, with myristoylation as a pre-requisite for 
palmitoylation to occur (Hallak et al., 1994a). Myristoylation increases the 
hydrophobicity of Ga2 and is essential for anchoring Ga2 to membranous compartments 
(Hallak et al., 1994a). However, the targeting of Ga2 to the plasma membrane appears 
to be controlled by its association with the prenylated ~y subunits (Fishburn et al., 
2000). 
Palmitoylation of Ga2 has been found to inhibit the GAP activity of GAIP, RGS4, 
RGSl0 and brain Ga2-GAP (which consists of RGSZl and possibly other Gaz GAPs) 
towards Ga2 , and de-palmitoylation reversed this inhibition (Tu et al., 1997). Given 
Ga2 has a very slow intrinsic GTPase activity (Casey et al., 1990), the association of 
Ga2 with a GAP is almost necessary for signal termination. Reversible palmitoylation 
may therefore represent a very important mechanism for regulating Gaz signalling. 
1.2.9 Phosphorylation of Gaz 
One other important biochemical property of Ga2 is its ability to be phosphorylated. 
Ga2 is phosphorylated by both protein kinase C (Kozasa and Gilman, 1996; Lounsbury 
et al., 1991) and p21-activated kinase 1 (PAKl) (Wang et al., 1999). The 
phosphorylation by protein kinase C occurs primarily on two amino terminal serine 
residues, serine 16 and serine 27 (Lounsbury et al., 1993), with serine 27 being the 
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kinetically preferred phosphorylation site (Wang et al., 1999). PAKl, on the other 
hand, phosphorylates Ga2 specifically at serine 16 only (Wang et al., 1999). The 
phosphorylation by both kinases takes place independently of the activation state of Ga2 
and causes a decrease in affinity of the a subunit for the ~y subunit (Fields and Casey, 
1995; Wang et al., 1999). Phosphorylation of Ga2 also blocks the GAP activities of all 
Ga2 -GAPs that are studied, including RGSZ 1, GAIP, RET-RGS 1, RGS4 and brain Ga2 
GAP (Glick et al., 1998; Wang et al., 1998; Wang et al., 1999). Accordingly, if Ga2 is 
already in its dissociated activated form when it is being phosphorylated, it will likely 
remain in that state for a much longer period of time due to the significant attenuation of 
Ga2 -GAP activity. If G2 is as a heterotrimer when Ga2 is being phosphorylated, the 
consequent decrease in affinity of Ga2 for the ~y subunits ( as a result of the 
phosphorylation) may help G2 to become activated more easily since the ~y dimer (as a 
GDI) normally inhibits GDP dissociation from the a subunit (Sprang, 1997b ). 
However, one may expect the dissociated GTP-bound form of Ga2 to be the preferred 
phosphorylation substrate of both protein kinase C and P AKl as the presence of the ~y 
subunit inhibits phosphorylation of Ga2 by both kinases (Fields and Casey, 1995; 
Kozasa and Gilman, 1996; Wang et al., 1999). Therefore, signalling events that lead to 
the activation of either P AKl or protein kinase C are likely to exert a significant 
positive impact on Ga2 signalling. 
1.3 Tissue distribution of Gaz 
The tissue distribution of a protein can sometimes provide important clues about its 
function. For instance, gustducin, a G protein found almost exclusively in taste buds 
(McLaughlin et al., 1992), is involved in the signal transduction of bitterness 
(Margolskee, 2002). Ga2 also has a rather restrictive tissue distribution, suggesting it 
may have a special role in those cells that express the protein. 
Within the brain, Ga2 mRNA has been consistently detected in the cerebral cortex, 
amygdala, caudate nucleus, putamen, nucleus accumbens, substantia nigra, subthalamic 
nucleus, thalamus, cerebellum, medulla and hippocampus (Friberg et al., 1998; Glick et 
al., 1998; Wang et al., 1998). Ga2 mRNA is either present at very low levels or is 
absent in the globus pallidus (Friberg et al., 1998), and is found variably in the corpus 
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callosum (Friberg et al., 1998; Glick et al., 1998; Wang et al., 1998). 
Immunohistochemical localization has confirmed the existence of Gcx2 in the cerebral 
cortex, hippocampus (where neurons of the dentate gyrus and Amman's horn stain 
intensely), basal ganglia, thalamus and cerebellum, and absence in glia and white matter 
tracts (Hinton et al., 1990). Gcxz has also been localized by both in situ hybridization 
and western blot techniques to the hypothalamus (Sanchez-Blazquez et al., 1995; Serres 
et al., 2000), and has been reported to be present in the mouse periaqueductal gray 
(Garzon et al., 1997b; Garzon et al., 1997a; Sanchez-Blazquez et al., 1995). Elsewhere 
in the nervous system, Gcx2 has been found in the pituitary gland (Paulssen et al., 1991), 
the retina (Fong et al., 1988; Hinton et al., 1990; Jiang et al., 1991; Zigman et al., 1994), 
the ear (Magovcevic et al., 1995) and in sensory and sympathetic ganglia (Hendry et al., 
1995b; Hinton et al., 1990; Kelleher et al., 1998) of the spinal cord (Wang et al., 1998). 
In short, Gcx2 appears to be ubiquitous within much of the nervous system. 
Among peripheral tissues, Gcx2 is expressed in the adrenal medulla (Casey et al., 1990; 
Hinton et al., 1990), in blood platelets (Carlson et al., 1989; Casey et al., 1990; Gagnon 
et al., 1991) (Kelleher et al., 2001), in megakaryocytes (Gagnon et al., 1991), in 
interleukin 2 activated natural killer cells (Al Aoukaty et al., 1997; Maghazachi et al., 
1996), in the islets of the pancreas (Zigman et al., 1994), in sperm cells (Glassner et al., 
1991) and at very low levels in erythrocytes (Premont et al., 1989). Using northern or 
western blot techniques, Gcx2 has also been detected in tissues such as the heart (Garibay 
et al., 1991), the liver (Spicher et al., 1988), the kidney (Spicher et al., 1988; Zigman et 
al., 1994), the lung (Zigman et al., 1994), the spleen (Zigman et al., 1994) and the 
placenta ( el Mabrouk et al., 1996). However, the findings in these areas have not been 
consistently replicated by others (Casey et al., 1990; Garibay et al., 1991; Zigman et al., 
1994 ), suggesting Gcx2 is either present at low levels in these tissues or the detection is 
due to contamination from blood platelets, which appear to be a relatively abundant 
source of the protein (Casey et al., 1990; Gagnon et al., 1991; Woulfe et al., 2002). 
Consistent with the predominant localization of Gcx2 in neuronal, adrenal, pituitary and 
blood tissues, Gcx2 has also been found in a number of cell lines derived from these 
sources. These include the neuroblastoma cell lines SH-SY5Y (Ammer and Schulz, 
1994), SK-N-SH and SH-EP (Garibay et al., 1991), the pheochromocytoma cell line 
PC12 (Garibay et al., 1991), the mouse anterior pituitary cell line AtT-20 (Hallak et al., 
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1994a), the rat pituitary tumor cell lines GH3, GH4C1 and GH12C1 (Paulssen et al., 
1991), the megakaryoblastic leukemia cell line MEG-01 (Nagata et al., 1995) and the 
basophilic leukemia cell line RBL-2H3 (Hallak et al., 1994a; Hide et al., 1991). 
Additionally, Gaz has been reported to be present in the hepatoma cell line, HepG2 
(Garibay et al., 1991) and in the African green monkey kidney cell line, COS-7 
(Belcheva et al., 2000), suggesting that Ga2 may normally also be expressed in liver 
(Spicher et al., 1988) and kidney tissues (Spicher et al., 1988; Zigman et al., 1994), or 
the expression occurs as a result of cell transformation. 
At the ultrastructural level, Ga2 immunoreactivity is associated with the outermost 
aspect of the nuclear membrane, the endoplasmic reticulum, the inner surface of the 
plasma membrane, and with small granules on the microtubules of proximal dendrites 
(Hinton et al., 1990). Ga2 also accumulates on both sides of a nerve ligature and this 
accumulation is sensitive to colchicine, an inhibitor of microtubule function (Crouch et 
al., 1994). These observations are consistent with Ga2 being transported in neurons, 
although its physiological significance is unclear. 
1.4 Guanine nucleotide exchange factors for Gaz 
Ga2 has a slow basal guanine nucleotide exchange rate (k= 0.02min-1 at 30°C and 
0.5µM Mg2+) and this rate further declines to near zero at physiological concentrations 
of magnesium (0.5-lmM) (Casey et al., 1990). This property of Gaz appears to be 
unique among Ga subunits and is similar to that seen with the small GTPase Ras, a 
protein with oncogenic potential (Hall and Self, 1986). This may suggest that 
spontaneous activation of Ga2 , if not carefully regulated, can lead to disastrous 
consequences. Therefore, G2 activation is expected to show high fidelity, requiring a 
GEF to catalyse the exchange of GDP for GTP on the a subunit. 
1.4.1 G protein coupled receptors 
GPCRs are the de facto GEFs for G proteins. They comprise one of the largest and 
most diverse superfamily of proteins in our body (Bockaert et al., 2002). Based on 
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hydropathy analysis of their amino acid sequences, all GPCRs are predicted to share a 
common three dimensional architecture, characterized by seven hydrophobic trans-
membrane helices (TM-I to TM-VII) connected by six alternating extracellular (E-1 to 
E-3) and intracellular loops (I-1 to I-3) (Bockaert and Pin, 1999)) (Harmar, 2001). 
Additionally, a fourth intracellular loop (I-4) linking the seventh transmembrane helix to 
palmitoylated cysteine residues at the carboxyl terminal is found in some members of 
the superfamily (Marin et al., 2000). The extracellular surface, containing the amino-
terminal and extracellular loops, is responsible for ligand discrimination and binding 
(Schwartz, 1994). The cytoplasmic face, which contains the intracellular loops and the 
carboxyl terminal tail, is involved in the recognition and activation of G proteins 
(Conklin and Bourne, 1993). The molecular mechanism by which ligand binding 
causes activation of a G protein is still unknown (Hamm, 2001 ). Precise mechanistic 
details may vary between members of this diverse superfamily and may depend on the 
particular G protein a receptor is coupled to (Bae et al., 1997; Cabrera-Vera et al., 
2002). However, it is generally possible to subdivide the superfamily of GPCRs based 
on their preference for members of a particular G protein a subunit family (Hur and 
Kim, 2002). For instance, opioid receptors couple preferentially to members of the Gi/o 
family (Standifer and Pasternak, 1997) while vasopressin Vl receptors predominantly 
couple to members of the Gq111 family (Birnbaumer, 2000). This observation highlights 
the existence of interaction sites on both receptors and G protein a subunits for 
directing specificity of coupling (Moller et al., 2001), and suggests homologous G 
protein a subunits from the same G protein family may share certain common structural 
features that allow them to interact with a particular receptor. 
Accordingly, G2 , a member of the Gi/o family, has been found to be capable of coupling 
to all Gu0 coupled receptors in transfection and reconstitution studies (Ho and Wong, 
1998). These receptors include the serotonin lA receptor (Barr et al., 1997; Butkerait et 
al., 1995), theµ (Chan et al., 1995), 8 (Tsu et al., 1995a) and K (Lai et al., 1995) opioid 
receptors, the nociceptin ( orphanin FQ) receptor (Chan et al., 1998), the neurokinin 1 
receptor (Barr et al., 1997), the thrombin receptor (Barr et al., 1997), the adenosine Al 
receptor (Wong et al., 1992), the a 2 adrenergic receptor (Wong et al., 1992), the 
muscarinic M2 receptor (Parker et al., 1991), the melatonin la, lb and le receptors (Ho 
and Wong, 1998), the lysophosphatidic acid receptor (Wong et al., 1992), the 
complement C5a receptor (Shum et al., 1995), the formyl peptide receptor (Tsu et al., 
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1995b), the dopamine D5 receptor (Sidhu et al., 1998) and all members of the dopamine 
D2-like receptor family (Obadiah et al., 1999). 
These in vitro studies indicate Gz possess the necessary structural elements required for 
recognition by these receptors. However, it does not tell us whether these receptor-G2 
interactions occur in vivo, and if it does, in which specific tissues there is actual receptor 
coupling with Gz. The functional coupling to G2 in vivo is determined by a variety of 
factors including the level of expression of G2 at various points in time, the relative 
abundance of Gz compared to other Gi/o family members in regions of the cell where 
receptors are found ( e.g. axon terminal versus cell body), as well as the specific 
combinations of 0 and y subunits available for associating with Ga2 to couple to the 
receptor. Given that Gail, Gai2 and Gai3 are widely expressed (Hepler and Gilman, 
1992) and are present at high levels in brain cells (Stemweis and Robishaw, 1984) and 
in blood platelets (Woulfe et al., 2002) (the principal tissues where Ga2 have been 
found) and Ga0 , another Ga1 family member, is the major G protein a subunit in 
neurons, accounting for 0.5% of all brain membrane proteins (Asano et al., 1988), the 
capacity of G2 to compete with these other abundant Gi/o family members for 
preferential coupling to a receptor, will depend on its relative affinity for the receptor, 
the comparative G2 concentration in the local region of the cell where the receptor is 
found and whether special scaffolding proteins exist that interact preferentially with Gz 
for organization of the receptor G protein signalling complex (Albert and Robillard, 
2002; Huang et al., 1997a; Milligan and White, 2001). Additionally, the composition of 
the 0 and y subunits that Ga2 binds to in vivo is also likely to influence the interaction of 
G2 with a receptor. It has been found that the receptor interacting domains of G proteins 
are not only on the a subunit (Cabrera-Vera et al., 2002), but also incorporate the 
carboxyl terminal of the y subunit (Azpiazu and Gautam, 2001; Wess, 1998), and 
possibly the 0 propeller region of the 0 subunit (Taylor et al., 1996). Consistent with 
the involvement of the 0Y dimer in receptor interaction, the identity of the 0 subunit 
(McIntire et al., 2001) and they subunit (Hou et al., 2000) have been found to directly 
influence the efficiency of G protein coupling. The composition of the 0Y dimers that 
partner with Ga2 has never been investigated, and it is also not known whether different 
me1nbers of the Gai family vary in their preference for particular 0Y subunits. This is an 
important area of research that will further our understanding of the basis of receptor-G 
protein coupling. 
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To date, a number of in vivo studies have investigated the receptors that couple to G2 in 
different body tissues. In mouse periaqueductal gray, an area of the brain involved in 
the analgesic effects of opioids and the processing of nociceptive information (Smith et 
al., 1988; Sohn et al., 2000), theµ opioid receptors were found to couple to both Gi2 and 
G2 (Garzon et al., 1997b; Garzon et al., 1997a). This was shown by the ability of 
antibodies against Gai2 and Gaz to block morphine and [D-Ala2,N-MePhe4,Gly-ol5] 
enkephalin (DAMGO) stimulated low Km GTPase activities of the two G proteins 
(Garzon et al., 1997b ). Chronic treatment with antisense oligonucleotides to Ga2 
produced the same effect as Ga2 antibodies. Although morphine and DAMGO were 
preferential agonists at the µ recepto_r, they can also bind 8 and K opioid receptors with 
significantly lower affinities (Goldstein and Naidu, 1989). The authors demonstrated 
that the effects of morphine and DAM GO in their experiments were due almost entirely 
to the µ receptor as the 8 receptor antagonist ICI-174,864 had negligible effects on 
morphine and DAM GO stimulated low Km GTPase activities (Garzon et al., 1997b ). In 
contrast, antibodies and oligonucleotides against Ga2 had no effect on the low Km 
GTPase activity stimulated by the 8 receptor agonist [D-Pen2'5]enkephalin (DPDPE), 
while antibodies against Ga12 produced significant effects (Garzon et al., 1997b ). The 
results of this experiment suggest that µ opioid receptors in the mouse periaqueductal 
gray are coupled to both Gi2 and G2 , while 8 opioid receptors are coupled to Gi2- In 
another study using immunoelectrophoresis to examine the activation of Ga subunits 
from mouse periaqueductal gray membranes as a result of receptor stimulation, 
morphine and DAMGO were found to cause a dose dependent increase in Gai2 and Gaz 
associated immunoreactivities (Garzon et al., 1997a). This morphine and DAMGO 
induced activation of Gai2 and Ga2 was not significantly affected by the 8 receptor 
antagonist ICI-174,864 (Garzon et al., 1997a), again indicating that stimulation of theµ 
receptor by both agonists is responsible for the effects. In this experiment, the 8 
receptor agonist DPDPE also caused activation of Gai2, but not Gaz. In comparison, a 
second 8 receptor agonist, [D-Ala2]deltorphin II, stimulated both Gai2 and Gaz, 
although the stimulation was significantly greater for Gai2 than for Gaz (Garzon et al., 
1997a). Another interesting finding from this experiment is that of the two µ receptor 
agonists, morphine is more effective than DAMGO in the stimulation of Gaz (EDso for 
morphine = 0.17± 0.01 pM, ED50 for DAM GO = 0.36± 0.05nM), while the reverse is 
true for the stimulation of Gai2 (ED50 for morphine= 0.80± 0.06nM, EDso for DAMGO 
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= 16.0± 1.4pM) (Garzon et al., 1997a). One possible explanation for this intriguing 
phenomenon is that the binding of morphine and DAM GO to the µ receptor may result 
in the selective stabilization of different receptor conformational states, which vary in 
their preference for coupling to different G proteins (Kenakin, 1997). Consistent with 
coupling of the µ opioid receptors to G2 and Gi2, the same group of researchers have 
gone on to demonstrate that intracerebroventricular (i.c.v.) administration of antibodies 
or antisense oligonucleotides against either Gai2 or Ga2 , led to an impairment of both 
morphine and DAMGO analgesia (Sanchez-Blazquez et al., 1993; Sanchez-Blazquez et 
al., 1995). To verify their technique, they also demonstrated that their antisense 
treatment reduced Gaz protein expression in the periaqueductal gray, striatum, thalamus 
and hypothalamus by between 16% to 54% (Sanchez-Blazquez et al., 1995). As for 
analgesia mediated by the 8 receptor agonists, DPDPE and [D-Ala2]deltorphin II, 
antisense oligonucleotides and antibodies against Ga2 have no effect while those against 
Gai2 and Gai3, caused a reduction in analgesia (Sanchez-Blazquez et al., 1993; 
Sanchez-Blazquez et al., 1995). This behavioural finding is consistent with preferential 
coupling of 8 opioid receptors to Gi2 and Gi3 . A similar study conducted by a different 
group of researchers, however, showed that while i.c.v. administration of Gai2 antisense 
oligonucleotides significantly reduced morphine analgesia, antisense oligonucleotides 
against Ga2 have very little effect (Standifer et al., 1996). The later researchers, 
nonetheless, did not validate whether their Ga2 antisense, which was made against the 
human Ga2 gene sequence, was effective in decreasing Ga2 protein expression in mice. 
A blast search (Altschul et al., 1997) based on the human Ga2 sequence that was 
employed, fail to recognize the mouse Ga2 mRNA sequence. This would explain the 
western blot data obtained by a second group of investigators, who employed an 
identical human Ga2 antisense, and found very little attenuation of mouse Gaz protein 
expression even after a large quantity (20µg) of oligonucleotides had been injected 
(Karim and Roerig, 2000). 
In blood platelets, the a 2a adrenergic receptor has been shown to couple preferentially to 
Gz, despite Gi2 being more highly expressed (Woulfe et al., 2002; Yang et al., 2000). 
Epinephrine, the natural ligand of adrenergic receptors, inhibits cAMP formation and 
activates the small GTPase Rap 1 in platelets, both of which may contribute to platelet 
activation (Woulfe et al., 2002; Yang et al., 2000). In platelets that lack Gaz, this 
epinephrine induced inhibition of cAMP production and Rap 1 activation is diminished 
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significantly (Woulfe et al., 2002; Yang et al., 2000). Furthermore, epinephrine lost its 
ability to potentiate platelet aggregation elicited by a number of platelet activators 
including ADP, serotonin, collagen, GYPGQV (a P AR4 thrombin receptor agonist) and 
U46619 (a thromboxane A2 receptor agonist) in Ga2 deficient platelets (Yang et al., 
2000). In congruence with this, Ga2 deficient mice also showed a reduction in 
thromboembolic mortality caused by epinephrine and collagen, although the mortality 
rate following ADP (which activates a Ga12 coupled receptor) (Jantzen et al., 2001) and 
collagen administration were the same (Yang et al., 2000). These results clearly 
de1nonstrate that in the absence of Ga2 , epinephrine responses are impaired and suggest 
a 2a adrenergic receptors in platelets couple preferentially to G2 • 
In the nervous system, a2a adrenergic receptors are involved in the modulation of many 
physiological and behavioural processes including pain, mood, anesthesia, vigilance and 
body temperature (Kable et al., 2000; Lakhlani et al., 1997; Schramm et al., 2001). The 
effects of mood elevating drugs in Ga2 deficient mice have been investigated. 
Compared to wildtype controls, mice deficient in Ga2 failed to respond to the anti-
depressant effects of desipramine and reboxetene, two compounds that block 
neurotransmitter reuptake at norepinephrine transporters (Yang et al., 2000). This 
phenotype of Ga2 deficient mice bears superficial resemblance to that of the 
a2a adrenergic receptor knockout mice, which are insensitive to the antidepressant 
effects of imipramine, a norepinephrine and serotonin reuptake inhibitor (Schramm et 
al., 2001). These preliminary findings are consistent with a possible coupling of Gz to 
CX2a adrenergic receptors in the nervous system. 
The Ga2 deficient mouse demonstrates another interesting phenotype: an enhanced 
locomotor response to cocaine. This increase in cocaine induced locomotor activity 
exhibited by Ga2 knockout mice is sustained over the entire period of cocaine treatment 
(Yang et al., 2000). Although cocaine inhibits reuptake by the norepinephrine 
transporter, it also blocks serotonin and dopamine transporters (Uhl et al., 2002). 
Studies on mice that lack either the norepinephrine, serotonin or dopamine transporters 
have shown the dopaminergic system to be responsible for the locomotor stimulation 
produced by cocaine (Uhl et al., 2002). The locomotor response to cocaine is abolished 
in mice that lack the dopamine transporter (Sora et al., 1998; Sora et al., 2001b), while 
still present in mice that are deficient in either the serotonin or norepinephrine 
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transporters (Sora et al., 2001 b; Xu et al., 2000a). The locomotor hyperactivity 
observed in Gaz deficient mice following cocaine treatment might therefore suggest an 
alteration in dopaminergic neurotransmission in the mutant mice and G2 could be 
coupled to a dopamine receptor. Experiments in vitro have established G2 to be capable 
of transducing the signal produced by activation of dopamine D2, D3 and D4 receptors 
(Obadiah et al., 1999). There is also evidence that the dopamine D5 receptor can couple 
to G2 (Sidhu et al., 1998). Dopamine receptors are localized pre and post-synaptically 
(Missale et al., 1998; Picetti et al., 1997; Rivera et al., 2002; Svingos et al., 2000). 
Presynaptic receptors consist of two types: autoreceptors, which are found on 
dopaminergic neurons and function to regulate dopamine release; and heteroreceptors, 
which control the release of other neurotransmitters. Studies of dopamine D2 and D3 
receptor knockout mice have established autoreceptors to be primarily of the D2 type 
(Benoit-Marand et al., 2001; L'hirondel et al., 1998; Rouge-Pont et al., 2002; Schmitz et 
al., 2001), with the D3 receptor making only a minor contribution (Joseph et al., 2002). 
Presynaptic D4 and D5 receptors, on the other hand, appear to be heteroreceptors, where 
there is evidence that they regulate glutamate and acetylcholine release respectively 
(Hersi et al., 2000; Price and Pittman, 2001; Rubinstein et al., 2001). The absence of 
dopamine D2 receptors in mice has been found to produce an augmented cocaine 
induced increase in extracellular dopamine concentration, which has been attributed to 
an impairment of D2 autoreceptor function (Rouge-Pont et al., 2002). Cocaine elicited 
dopamine release is an important contributor to cocaine induced hyperlocomotor 
activity since the response can be blocked by dopamine receptor antagonists (Delfs et 
al., 1990) (Neisewander et al., 1995). Therefore, it is possible that cocaine's increased 
locomotor activation in Ga2 knockout mice may be explained by the coupling of Gz to a 
dopamine autoreceptor, whose function is impaired as a result of the loss of Gaz. 
In the hypothalamus, cells in the paraventricular nucleus (PVN) have been shown to 
contain Ga2 (Serres et al., 2000). These PVN neurons also express serotonin (5HT) lA 
receptors (Li et al., 1997), and stimulation of these receptors results in the secretion of 
oxytocin and corticotropin releasing hormone (CRH) (Bagdy, 1996) from magnocellular 
and parvocellular cells respectively (Li et al., 1997). From the hypothalamus, the CRH 
secreted is released into the pituitary portal blood, which in tum stimulate corticotropes 
in the anterior pituitary gland to release adrenocorticotropic hormone (ACTH) (Aguilera 
et al., 2001). The reduction of Ga2 levels in the PVN through the infusion of Gaz 
antisense into the ventricles, has been shown to attenuate the rise in plasma oxytocin 
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and ACTH caused by activation of 5HT-1A receptors (Serres et al., 2000). It was 
further demonstrated that this 5HT-1A receptor stimulated oxytocin secretion was 
resistant to pertussis toxin, while the ACTH secretion was partially toxin sensitive, 
consistent with the involvement of a pertussis toxin resistant G protein in the 
transduction pathway (Serres et al., 2000). Based on these results, 5HT-1A receptors in 
the PVN have been proposed to be preferentially coupled to Gz (Serres et al., 2000). 
While this may be the case, it is also possible that the administration of Gaz antisense 
into the ventricles, has disrupted Gz coupling to other receptors, which are in the 
circuitry that produced the 5HT-1A receptor mediated responses. This is particularly 
relevant to the SHT-1 A receptor stimulated ACTH secretion, which is dependent on the 
integrity of CRH type I receptors on corticotropes (Aguilera et al., 2001 ). 
There are two major CRH receptors in the brain, the type I and type II receptors, each 
with their own alternate spliced variants (Perrin and Vale, 1999). CRH type I receptors 
are localized predominantly in the pituitary where they mediate ACTH secretion 
(Aguilera et al., 2001), as well as in the olfactory bulb, cerebral cortex, cerebellum, 
thalamus, hypothalamus and brain stem (Radulovic et al., 1998). The type II receptors, 
on the other hand, are found mainly in frontal and occipital cortices, amygdala, lateral 
septum, entorhinal cortex and hypothalamic regions (Primus et al., 1997). CRH binds 
with higher affinity to the type I receptor (Primus et al., 1997), while urocortin is the 
predominant ligand at the type II receptor based on its anatomical localization (Kozicz 
et al., 1998). Both CRH type I and II receptors are believed to preferentially couple to 
Gs to activate adenylate cyclase activity (Chen et al., 1993; Lovenberg et al., 1995). 
However, in cerebral cortical membrane preparations, CRH and urocortin were found to 
stimulate the incorporation of [ a-32P]-GTP-y-azidoanlide, a photoreactive form of GTP 
into Gas, Gai, Gaq111 , Ga0 and Gaz, suggesting that CRH receptors can couple to all of 
these G proteins (Grammatopoulos et al., 2001). The G protein stimulation profiles of 
the two peptide agonists were similar, with the exception of Gaq11 1, which was 
stimulated to a greater extent by urocortin (Grammatopoulos et al., 2001). One 
common criticism of the [ a-32P]-GTP-y-azidoanlide labeling technique is that the 
labeling of a large number of G protein a subunits by receptor stimulation could be an 
experimental artifact in broken cell preparations, where membrane disruptions allow the 
formation of unnatural receptor G protein complexes (Albert and Robillard, 2002). To 
address this and other possible concerns, the authors demonstrated that under their 
experimental conditions, stimulation of the a 1 adrenergic receptor labeled only Gag, 
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stimulation of the a2 receptor labeled only Gai/o and stimulation of the ~ adrenergic 
receptor labeled only Gas, which are consistent with the preferred G protein coupling of 
these receptors discovered using other techniques (Grammatopoulos et al., 2001). From 
these results, it is possible that Gz may be coupled to a receptor stimulated by CRH and 
urocortin in the cerebral cortex. Interestingly, CRH receptors in rat Leydig cells has 
been reported to couple to a pertussis toxin resistant G protein to inhibit adenylate 
cyclase activity (Ulisse et al., 1989; Ulisse et al., 1990). To date, Ga2 has not been 
reported to be present in Leydig cells, although it has been found in sperm cells 
(Glassner et al., 1991). 
Chemokine receptors are classified into four subfamilies and named according to the 
type of chemokines they bind to. These are (i) the CC receptor subfamily (with eleven 
members from CCRl to CCRl 1), which binds ligands CCLl to CCL27, (ii) the CXC 
receptor subfamily (with five members from CXCRl to CXCR5), which binds CXCLl 
to CXCL14, (iii) the CX3C receptor subfamily (with a single member CX3CR1) that 
binds CX3CL1 and (iv) the XC receptor subfamily (with a single member XC-Rl) that 
binds XCLl and XCL2 (Bajetto et al., 2001). The majority of ligands in the CC and 
CXC receptor families are promiscuous and can bind more than one receptor (Bajetto et 
al., 2001). Interleukin-2 activated natural killer (IANK) cells express Ga2 (Al Aoukaty 
et al., 1997; Maghazachi et al., 1996) and the chemotaxis of these cells in response to 
CCL2 (monocyte chemoattractant protein 1; MCP-1 ), CCL3 (macrophage inflammatory 
protein la, MIP-la) and CCL5 (regulated on activation nonnal T cell-expressed and 
secreted; RANTES) were blocked by antibodies against Gas, Ga0 and Gaz (Al Aoukaty 
et al., 1996). The antibodies also prevented agonist stimulated binding of the non-
hydrolysable GTP analogue, GTPyS, as well as GTPase activities elicited by these 
agonists (Al Aoukaty et al., 1996). Being promiscuous, the three ligands can potentially 
bind to a number of CC receptors, including CCRl, CCR2, CCR3 CCR4, CCR5 and 
CCRl 1 (Bajetto et al., 2001). CCR5 is not expressed by IANK cells (Inngjerdingen et 
al., 2001), leaving the five remaining CC receptors as possible candidates for coupling 
to G2 • Additionally, G2 can also couple to the CCR6 and the CX3CR1 receptors found 
in IANK cells (Al Aoukaty et al., 1998; Inngjerdingen et al., 2001). This is 
demonstrated by the capacity of the CCR6 receptor specific agonist, CCL20 
(macrophage inflammatory protein 3a; MIP-3a) and CX3CR1 receptor specific agonist 
CX3CL1 (fractalkine) to stimulate GTPyS binding to Ga2 (Al Aoukaty et al. , 1998). 
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However, in the same experiment, CCL20 also activated G0 and Gq, and CX3CL1 
stimulated Gi as well (Al Aoukaty et al., 1998), suggesting that the CCR6 and CX3CR1 
receptors are capable of coupling to multiple G proteins (inclusive of G2 ) or there are as 
yet undiscovered receptors that the ligands can bind to (that may couple to G2). 
Chemokine receptors (e.g. CX3CR1) have also been found in neurons (Bajetto et al., 
2001; Meucci et al., 1998), and it is possible that G2 may mediate the functions of some 
of these receptors in the nervous system. 
1.4.2 G protein coupled receptor dimers and oligomers 
GPCRs can also associate with one another to form dimers and/or oligomers (Bouvier, 
2001; Rios et al., 2001). This is supported by data from radiation inactivation, Western 
Blot, co-immunoprecipitation and cross-linking experiments, as well as results from 
bioluminescence and fluorescence resonance energy transfer studies in living cells (Rios 
et al., 2001; Salahpour et al., 2000). When two GPCRs labeled with different 
fluorescent molecules are co-expressed in the same cells, they can effect resonance 
energy transfer from one to the other, indicating that the GPCRs lie very close to one 
another on the plasma membrane (Angers et al., 2000; McVey et al., 2001; Ramsay et 
al., 2002). Furthermore, structural data from crystallography of the rhodopsin receptor 
suggested the cytoplasmic surface of a GPCR monomer is just barely broad enough for 
interaction with both the a and ~y subunits of a G protein (Bourne and Meng, 2000). 
This may imply that one GPCR can only couple to one G protein; or higher order GPCR 
complexes exist, which may allow simultaneous interactions with more than one G 
protein, as well as leaving sufficient room for interaction with accessory proteins such 
as arrestins, G protein coupled receptor kinases and scaffolding proteins. Taken 
together, the current available evidences suggest that GPCR complexes are likely to 
exist in vivo. 
There are two types of GPCR complexes: homomers which are formed from identical 
GPCR units and heteromers which arise from the association between distinct protein 
units (Rios et al., 2001). Not all GPCRs can heteromerize with one another. For 
instance, among the opioid receptors, the 8 and K receptors (Jordan and Devi, 1999), as 
well as the µ and 8 receptors (George et al. , 2000; Gomes et al., 2000) can heteromerize 
with each other, but theµ and K receptors are not able to (Jordan and Devi, 1999). 
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The list of GPCRs capable of forming homomers with themselves or heteromers with 
another GPCR is rapidly expanding, and includes a number of GPCRs previously 
identified to be capable of coupling to Gz. As current technology does not allow easy 
determination of receptor structure, whether the receptors that interacted with G2 in the 
experiments are monomers, dimers or oligomers, and whether they are homomers or 
heteromers is presently unknown. Receptor heteromerization has been observed to 
result in the creation of receptor complexes with novel signalling properties, where 
ligand binding affinities, signalling efficacies, G protein coupling preferences, as well as 
receptor desensitization and trafficking characteristics can change (George et al., 2000; 
Rios et al., 2001). For instance, when theµ and 8 opioid receptors are expressed alone, 
the agonist detected high affinity receptor binding states, together with agonist induced 
inhibition of adenylate cyclase, are sensitive to pertussis toxin, indicating that the 
receptors are coupled to Gu0 proteins. However, co-expression of the two receptors 
caused both the high affinity receptor binding state and adenylate cyclase inhibition to 
become pertussis toxin resistant, suggesting that the receptors are now coupled to 
another G protein (George et al., 2000). Based on present knowledge, this G protein 
preferred by the µ-8 heteromer is likely to be G2 since G2 is the only currently known 
pertussis toxin insensitive G protein that is capable of coupling to plasma membrane 
bound receptors to produce inhibition of adenylate cyclase. 
1.4.3 Other types of receptors 
Conventional activators of G protein signalling are receptor proteins with seven 
transmembrane segments (Bockaert et al., 2002). Evidence accumulated over the past 
decade, however, has expanded the list to include receptors with a single 
transmembrane spanning domain. Examples include the insulin receptor, which 
stimulates Gq11 1 (Imamura et al., 1999), the insulin-like growth factor 1 receptor, which 
activates Gi (Dalle et al., 2001) and the NKR-Pl receptor, which has been found to 
couple to Gi3, Gs, Gq111 , and G2 (Al Aoukaty et al., 1997). The demonstration that the 
NKR-Pl receptor can couple to four G proteins was based on evidences obtained using 
IANK cell membranes. Stimulation of the NKR-Pl receptor in IANK cells significantly 
enhanced GTPyS binding to Gai3, Gas, Gaq/1 l and Ga2 , but not to Gao, Gail, Gai2, 
Ga12 and Ga13 (Al Aoukaty et al., 1997). Immunoprecipitation of the receptor protein 
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with antibodies against various G protein a subunits also demonstrated that Gai3, Gas, 
Gaq111 and Gaz can associate with the NKR-Pl receptor (Al Aoukaty et al., 1997). 
However, as all of the above evidence was based on data using broken membrane 
preparations, it is not known whether the coupling between the NKR-Pl receptor and 
the four G proteins that has been observed would also occur in intact cells. The 
presence of protein scaffolds and/or cytoskeletal elements in intact cells may limit the 
range of G proteins that a receptor can gain access to, and thus increase signalling 
specificity (Dumont et al., 2002; Oh and Schnitzer, 2001). 
IANK cells are involved in the lysis of allogeneic and tumor target cells (Maghazachi et 
al., 1996). To lyse cells, IANK cells need to identify their targets and such target 
identification is critically dependent on cell surface receptors. The NKR-Pl receptor is 
an example of such a receptor, and if G2 is really a signal transducer for the receptor, 
one may expect target cell recognition and lysis to be affected when G2 is prevented 
from performing its normal function. When antibodies against Ga2 were incorporated 
into permeabilized natural killer cells, there was a significant reduction in the lysis of 
allogeneic and tumor target cells (Maghazachi et al., 1996), consistent with G2 playing a 
role. In contrast, incorporation of antibodies against Gas and Gaq did not affect target 
cell lysis (Maghazachi et al., 1996), suggesting that they either do not couple to the 
NKR-Pl receptor in vivo or they may mediate other functions of the NKR-Pl receptor. 
1.4.4 Receptor independent G protein activators 
In addition to receptors, there are many other accessory proteins and molecules that can 
influence the guanine nucleotide exchange reaction on the G protein a subunit. These 
include volatile anesthetics ( e.g. halothane ), which suppress GTP binding to Gai 
(Pentyala et al., 1999); type V adenylate cyclase, which facilitate receptor mediated 
activation of Gs and Gi (Scholich et al. , 1999; Wittpoth et al., 2000); tubulin, which 
enhances the exchange of GTP for GDP on Gas and Gai l (Popova et al., 1994); the 
neuronal growth associated protein (GAP-43) and ~ amyloid precursor protein, which 
can activate G0 independent of the receptor (Okamoto et al., 1995; Strittmatter et al., 
1991); a family of proteins known as Activators of G protein Signalling (AGS), which 
are capable of activating G proteins based on various receptor independent mechanisms 
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(Cismowski et al., 2001); and the free radical OH; which directly activates Gi and G0 
(Nishida et al., 2000; Nishida et al., 2002). 
The capacity of many of these agents to modify the guanine nucleotide exchange 
activity of Gaz has not been examined. However, in the case of the OH free radical, the 
activation mechanism is known to consist of two steps. In the first step, OH modifies a 
cysteine residue at position 287 of Gai/o, leading to dissociation of Ga from G~y- The 
second step entails modification of another cysteine at position 326 of Gai/o· This 
causes dissociation of GDP and binding of GTP to the a subunit (Nishida et al., 2002). 
Both of these cysteine residues are conserved in Ga2 • This may therefore represent an 
additional mechanism through which activation of G2 can occur. 
1.5 Effectors of Gaz 
1.5.1 Adenylate cyclase 
Since Ga2 is a member of the Gai family, it may be expected to share some of the same 
molecular effectors as Gai. Gai was originally discovered and named based on its 
ability to inhibit the enzyme adenylate cyclase (Bokoch et al., 1984; Wong et al., 1991; 
Wong et al., 1992). Therefore, it was not surprising that adenylate cyclase became the 
first downstream effector identified for Ga2 • The expression of Ga2 in human 
embryonic kidney 293 cells (which do not contain Ga2 ) was found to cause agonist 
induced inhibition of adenylate cyclase activity, which was normally pertussis toxin 
sensitive, to become resistant to the toxin (Wong et al., 1992). To verify that these 
results were due to the a subunit of G2 , and not to the ~y subunits, both of which would 
be activated by the agonist, a mutationally activated form of Gaz (Gaz Q205L), where a 
conserved glutamine residue in the GTPase domain was replaced with leucine, was 
employed. Expression of this Ga2 mutant was found to produce dose dependent 
inhibition of adenylate cyclase activity, confirming Gaz' s role in the suppression of 
cAMP accumulation (Wong et al., 1992). To date, there are ten distinct isoforms of 
adenylate cyclase identified in mammals ( adenylate cyclase types I to IX and soluble 
adenylate cyclase) (Hanoune and Defer, 2001). Ga2 has been found to be capable of 
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only inhibiting adenylate cyclases types I, V and VI (Ho et al., 2000; Kozasa and 
Gilman, 1995), all of which are also inhibited by the Gais (Hanoune and Defer, 2001). 
1.5.2 RaplGAP 
The GAP of the small monomeric G protein, Rap 1, has been shown to be another 
downstream effector of Gaz. Rap 1 GAP binds Gaz only in its active GTP bound form, 
and not in the inactive GDP bound form (Meng et al., 1999). The binding of Rap 1 GAP 
to activated Gaz has no effect on the sluggish GTP hydrolysis rate of Gaz, but instead, 
attenuates the Gz GAP activity of RGSZ 1 and RGS 10 (Meng et al., 1999). The result is 
therefore a potential lengthening of the Gz signal. However, Rap 1 GAP also reduce the 
capacity of activated Gaz to inhibit type V adenylate cyclase (Meng et al., 1999). 
Currently, it is not known whether the ability of Gaz to inhibit the type I and VI 
isoforms of adenylate cyclase will be similarly attenuated. If the attenuation applies to 
all forms of adenylate cyclases that Gaz interacts with, it may cancel out the effect of 
prolonged Gaz signalling on adenylate cyclase activity brought about by the inhibition 
of Gz GAP by Rap 1 GAP. However, signalling to other Gaz effectors and G~y effectors 
may still be prolonged. 
The binding of Gaz to RaplGAP does not interfere with RaplGAP's interaction with 
Rap 1, as Rap 1 GAP binds the two proteins on different parts of the molecule (Meng et 
al., 1999). The precise amino acid residues that interact with Gaz has not been mapped, 
but it has been found to occur within the first seventy four amino acids of Rap 1 GAP 
(Meng et al., 1999). This amino terminal region of Rap 1 GAP has recently been found 
to contain a G protein regulatory ( or Goloco) motif, which binds selectively to members 
from the Gai family (Natochin et al., 2001; Siderovski et al. , 1999). It is therefore 
likely that Gaz interacts with Rap 1 GAP through this binding motif. 
Although Rap 1 has a ubiquitous tissue distribution, it is found in particularly high 
abundance in blood platelets, neutrophils and brain (Bos, 1998). Nervous tissues and 
blood platelets are the two principal sources of Gaz (Casey et al., 1990), and it is 
possible that the interaction between Gaz and Rap 1 in these tissues may be functionally 
significant. In blood platelets, stimulation of Gaz has been found to cause increased 
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activation of Rap 1, which n1ay play a role in platelet activation (Woulfe et al., 2002). 
The mechanism by which stimulation of Ga2 leads to Rap 1 activation in platelets is still 
unknown. Since activated Gaz can bind to Rap 1 GAP, it has been suggested that the 
increased activation of Rap 1 may be due to an inhibition of Rap 1 GAP activity by 
activated Gaz (Woulfe et al., 2002). Preliminary data, however, suggests that the 
binding of Gaz to Rap 1 GAP does not modify the GAP activity of Rap 1 GAP towards 
Rapl (Meng et al., 1999). An alternative mechanism is the recruitment of RaplGAP by 
Ga2 causes Rap 1 GAP to be relocated to particular subcellular compartments, which 
decreases its opportunity of interacting with activated Rapl (Meng et al., 1999). These 
and other possibilities will need to be explored in future research. 
In nervous tissues, activation of Rap 1 results in the stimulation of extracellular signal 
regulated kinase (ERK) (also known as mitogen activated protein kinase or MAP 
kinase), which is involved in the regulation of synaptic plasticity and neuronal survival 
(Grewal et al., 1999). The interaction between Ga2 and Rapl in nervous tissues has not 
been examined. However, the lack of Ga2 in sympathetic neurons attenuated nerve 
growth factor (NGF) dependent neuronal survival in the presence of pertussis toxin 
(Powell et al., 2002). NGF has been shown to activate Rap 1 (Yao et al., 1998), and this 
results in sustained activation of ERK (York et al., 1998), which likely contribute to the 
survival of sympathetic neurons (Xue et al., 2000). As in blood platelets, stimulation of 
Ga2 may result in greater Rapl activation (Woulfe et al., 2002), which in tum 
contributes to improved sympathetic neuron survival in the presence of pertussis toxin 
(Powell et al., 2002). When pertussis toxin is absent, stimulation of Gai, which is also 
capable of activating Rapl (Woulfe et al., 2002) and cause stimulation of the ERK 
signalling cascade (Mochizuki et al., 1999), may compensate for the loss of Gaz. 
Interestingly, NGF has been found to cause persistent activation of Rap 1 in endosomes, 
which is prevented by disruption of Golgi and endosomal compartments with brefeldin 
A (Wu et al., 2001). These NGF containing endosomes have been proposed to serve as 
signalling organelles for transportation of the NGF survival signal back to the cell body 
of neurons with long axons (Grimes et al., 1997; Sandow et al., 2000). Both Gai and 
Gaz have been found to be retrogradely transported by neurons (Hendry et al., 1995a). 
However, their co-localization with Rap 1 and NGF has never been investigated. It is 
possible that they may bind to Rap 1 GAP and Rap 1 in the same signalling organelle, to 
modulate the activation state of Rap 1. 
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1.5.3 G protein Regulated Inducer of Neurite outgrowth (GRIN) 
G protein Regulated Inducer of Neurite outgrowth 1 (GRINl) and GRIN2 are two 
downstream effectors of G protein a subunits based on their preferential interaction 
with the activated forms of Ga2 and Ga0 (Chen et al., 1999). Besides Ga2 and Ga0 , 
GRINl has also been found to bind to Gail and Ga12, but not Gas or Gag (Chen et al., 
1999). When GRINl or GRIN2, together with a mutationally activated form of Ga0 
(Ga0 Q205L) were co-transfected into embryonic kidney MA104 and neuroblastoma 
Neuro2a cells, both proteins were found to be capable of inducing the formation of 
neurite-like processes in these cells (Chen et al., 1999). However, whether the 
interaction of GRINl or GRIN2 with activated Ga2 would also trigger neurite 
extension, has not been investigated. Based on subcellular distribution analysis of 
membranes from embryonic mouse brains, GRINl and Ga0 were found to co-localize 
and were particularly enriched in growth cone membranes while Ga2 was distributed 
throughout all membrane fractions (Chen et al., 1999). A possible role of activated Ga2 
may therefore be to sequester GRINl, preventing its interaction with activated Ga0 and 
accordingly, regulate neurite growth and the morphology of the cell. 
1.5.4 Eyes Absent transcription cofactor Eya2 
Eya2, the mammalian homologue of the drosophila eyes absent (Eya) protein, is another 
downstream effector of Ga2 • Eya2 was found to interact specifically with the activated 
forms of Ga2 and Gai2, but not with activated Gas or the GDP bound forms of the a 
subunits, suggesting it could potentially serve as another effector for members of the 
Gai family (Fan et al., 2000). The binding of Ga2 or Gai2 to Eya2 prevents Eya2 from 
interacting with its other partner, a member from the Six protein family (Fan et al., 
2000). Normally, the docking of Eya2 to a Six protein would result in the complex 
being translocated from the cytosol into the nucleus, where it induces gene transcription 
(Ohto et al., 1999). The presence of activated Ga2 and Gai2, however, suppresses this 
translocation and causes Eya2 to remain in the cytoplasm (Fan et al., 2000). 
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In drosophila, Eya is essential for development of the compound eye. A deficiency in 
Eya causes progenitor cells in the eye disc anterior to the morphogenetic furrow, to 
undergo apotosis, instead of differentiation (Bonini et al., 1993). Since eye 
development is evolutionarily conserved between flies and humans, it is likely that the 
mammalian homologues of Eya will also have some role in vertebrate eye development 
(Fee et al., 2002). Consistent with this, Eya2 has been found to be extensively 
expressed in the mouse central nervous system, including all crancial placodes, which 
give rise to the eyes, the nose and various sensory ganglia during organogenesis (Xu et 
al., 1997). The level of Eya2 expression is also maintained in the placode derived 
structures until at least E16.5 (Xu et al., 1997). The interactions of Gai2 and Ga2 with 
Eya2 during development have not been examined. However, it is interesting to note 
that the expression level of Ga2 is very low in the brain and various sensory ganglia at 
E 15, and the level increases from then on, to peak at around two to three weeks after 
birth (Kelleher et al., 1998). The very low expression level of Ga2 in the central 
nervous system early in mouse development may be important to prevent suppression of 
Eya2 mediated gene transcription, so that organogenesis can proceed. Later in 
development, it is possible that receptor mediated activation of Ga2 (and Gai2) induced 
by molecules secreted by other cells into the extracellular matrix may play a role in 
regulating the transcription activity of Eya2. 
1.6 Examination of Gz signalling through the Gaz knockout mouse 
The review of the literature presented above suggests that Ga2 is a protein with unique 
biochemical properties. Therefore, the signalling pathways activated by Gz may serve a 
special role in those tissues in which Ga2 is expressed. However, most of the research 
on G2 has been performed in vitro. The investigation of its functions in vivo has been 
hampered by the lack of pharmacological tools, and its intracellular localization (which 
means cells may need to be destroyed to allow antibodies to gain access to the protein). 
Gene targeting is a very powerful molecular biological tool that has gradually been 
developed over the last twenty-five years (Capecchi, 2001 ). The technique allows a 
very 'clean' and precise ablation of a protein, which is otherwise difficult to achieve by 
the use of other methods (antibodies, antisense oligonucleotides). It also allows the 
impact of mutagenizing a gene on a whole organism to be studied, and therefore, 
enables the functions of the protein to be examined in vivo. 
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In an attempt to discover the physiological importance of signal transduction pathways 
mediated by Gz, my laboratory has adopted this technique to 'knockout' Ga2 in mice. 
The inactivation of Gaz through disruption of its coding sequence, would result in a null 
protein, and prevent the assembly of G2 in cells. This work was started during my 
honours year in 1993, when I successfully cloned the mouse Ga2 cDNA (Leck, 1993). 
When I returned in 1999, the Ga2 knockout mouse had already been generated. Dr. 
Kim Powell (nee Kelleher), for her Ph.D. studies, was examing the phenomenon of 
opioid tolerance in these mice. At that time, she has already successfully demonstrated 
that the Ga2 knockout mouse develop greater morphine tolerance in the hotplate test, 
but not in the tail flick test. I suggested that we examine the responses of these mice to 
cold pain since there is evidence that morphine may affect spinal nociceptive neurons 
sensitive to 'intense cold' differently from other nociceptive stimuli (Casey, 1996; Craig 
and Hunsley, 1991). We did not find any difference in the responses of the Ga2 
knockout mouse to 'hot' or 'cold' pain, strengthening our hypothesis that the greater 
tolerance to morphine that developed in the Ga2 knockout mouse is mediated 
supraspinally. This work has subsequently been published (Hendry et al., 2000). In 
this thesis, I present work, which I have performed from then on, whereby I examine the 
mechanisms underlying the increased morphine tolerance in the Ga2 knockout mouse. 
The results from biochemical assays using broken membrane preparations to study G 
protein activation by morphine and other opioid agonists have largely been 
unsuccessful, as I could not find any consistent difference between tolerant wildtype 
and Ga2 knockout brain membranes. This is despite performing the assay under a 
variety of different ionic concentrations of magnesium and sodium, which may affect 
the activation kinetics of different G proteins (Casey et al., 1990). Nonetheless, I have 
ruled out pharmacokinetic and behavioural mechanims as explanation for the greater 
morphine tolerance in Ga2 knockout mice (Chapter 3). I have also extended the 
research to examine other effects of morphine in these mice: including physical 
dependence (Chapter 3), locomotor activation (Chapter 4) and thermoregulation 
(Chapter 6). Furthermore, since the Ga2 knockout mouse showed increased locomotor 
activity in response to cocaine (Yang et al., 2000) and there is evidence that Gz can 
couple to dopamine D2-like receptors in vitro (Obadiah et al., 1999; Wong et al., 
1992), I have also examined the functions of dopamine D2-like receptors in these mice 
(Chapter 5). 
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Chapter 2 
Materials and Methods 
2.1 Animals 
Mutant Ga2 knockout mice were derived from heterozygous founders generated 
originally by gene targeting in the C57BL/6 mouse strain as described (Hendry et al., 
2000). Briefly, a 1.8kb Hind III- Eco RI fragment containing the PGKneor cassette was 
blunt-end cloned into a Bsa B 1 site located 160bp downstream of the translation start 
site in a 3.8kb genomic fragment of the Ga2 gene. A 2.84 kb Hind III-EcoRI fragment 
of the PGK. TK cassette was added to the 3' end of the targeting vector. The linearised 
vector was electroporated into C57BL/6 embryonic stem cells and homologous 
recombinants were identified by positive-negative selection (Mansour et al., 1988) and a 
polymerase chain reaction (PCR) based strategy using nested primers, (Nitschke et al., 
1993). Verification of the targeting was made by Southern blot analysis of genomic 
DNA from selected ES cells restricted with KpnI or Hind III-Eco Rl and the targeted 
clones shown to have only one site of integration of the near gene. Chim~ras were 
obtained by blastocyst injection and shown to transmit the targeted gene through the 
germline. Heterozygous mice were inter-crossed to obtain mice homozygous for the 
targeted Ga2 gene. 
Mice used for the experiments, although of pure C57BL/6 origin, were crossed for 8 
generations into the C57BL/6 background to remove any random mutations that might 
have occurred in the parental C57BL/6 stem cells used for electroporation. The animals 
were housed 4-6 to a cage in a temperature-controlled room maintained at 23±2°C, with 
food and water available ad libitum . All experiments were performed on age and 
gender matched C57BL/6 mice, using protocols approved by the Animal 
Experimentation Ethics Committee of the Australian National University or the 
Macquarie University. Adult mice were between 3 and 8 months of age, while pre-
adolescent mice were between 24 and 27 days old. Male mice were used in all 
experiinents, except in Chapter 3, where gender differences in the analgesic response to 
morphine was examined, and in Chapter 5 for the experiment on measurement of ACTH 
released by various drugs, where equal numbers of wildtype and Gaz knockout females 
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were included to make up for insufficient mouse numbers. Where possible, mice of 
different genotypes, but comparable age were evaluated in parallel in the experiments. 
When this was not possible due to shortage of resources, wildtype and Gaz knockout 
mice were evaluated alternately. 
2.2 Drugs 
Nor-binaltorphimine (Nor-BNI), U-50,488 hydrochloride (trans-(dl)-3,4-dichloro-N-
methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzeneacetamide) and 75mg morphine base 
pellets were generous gifts from Kevin Gormley at the Research Triangle Park, NIDA, 
Bethesda, Maryland, USA Other drugs were purchased: d-amphetamine sulfate (May 
and Baker, UK), quinpirole (Sigma, St. Louis, MO, USA), 8-hydroxy-dipropylamino-
tetralin (8OH-DPAT) (Sigma, St. Louis, MO, USA), SKF 38393 (Tocris Cookson, 
Bristol, UK), corticotropin releasing hormone (CRH) (Sigma, St. Louis, MO, USA), 
morphine tartrate (David Bull Laboratories, Australia), morphine hydrochloride 
(Macfarlan Smith, U.K.), naloxone hydrochloride (ICN Biomedicals, Aurora, OH, 
USA) and haloperidol (Sigma, St. Louis, MO, USA). 
All drugs were dissolved in physiological saline and administered in a volume of 10 
µ1/ gram mouse weight subcutaneously unless otherwise stated. Morphine tartrate 
(David Bull Laboratories, Australia) was administered in all antinociceptive assays and 
morphine hydrochloride (Macfarlan Smith, U.K.) was used to induce tolerance during 
chronic morphine treatment. All morphine concentrations reported were the 
concentrations of the respective morphine salts. Haloperidol was dissolved in a drop of 
acetic acid and diluted with saline. 
2.3 Chemicals 
All chemicals were obtained from Sigma (St. Louis, MO, USA) or ICN Biomedicals 
(Aurora, OH, USA) unless otherwise stated. 
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2.4 Antibodies 
The antibodies against Ga2 were made by Professor Ian Hendry and Dr. Michael 
Crouch at the John Curtin School of Medical Research (Australian National University, 
Canberra, Australia). Antibodies against Gail, Gai2, Gai3, Ga0 , Gas, Gaq, Gai (common), 
and G~(comrnon) were generous gifts from Dr Michael Crouch. The G~(common) antibody 
recognized a common peptide sequence found in G~ 1, G~2 and G~3. 
2.5 Western Blotting 
Mouse brain homogenates were prepared at a concentration of 20% (w/v) in SDS 
(sodium dodecyl sulphate) sample buffer (10% glycerol, 2.5% dithiothreitol, 3% SDS, 
bromophenol blue, 0.5M Tris-HCl, pH 6.8) and spun in a refrigerated centrifuge at 
10,000g for 20 minutes. Forty µl of supernatant containing 0.5 mg protein were loaded 
onto a 9% SDS-polyacrylamide gel. After gel electrophoresis, the resolved proteins 
were electro-transferred onto a nitrocellulose support. The nitrocellulose was blocked 
with 5% skim milk at room temperature for 1 hour, and then incubated with the 
appropriate primary antibody at 5°C overnight. The blot was rinsed four times with 
phosphate buffered saline containing 0.1 % (v/v) Tween20 (PBST) for 15 minutes each, 
then incubated with horseradish peroxidase conjugated secondary antibody (Amersham 
Pharmacia, United Ivngdom) at room temperature for 1 hour. This was followed by 
extensive washing with PBST for four hours, with 4 changes. The bands were detected 
using the Enhanced Chemiluminescence kit (Amersham Pharmacia, United Kingdom) 
and visualized on a Phosphoimager (Fuji, Japan). Analysis of the amount of protein in 
each band was performed using the ScienceLab Image Gauge Software (Fuji, Japan). 
2.6 The Hotplate Assay 
The hotplate apparatus comprised a cylinder (13.2 cm high and 15.2 cm in diameter) 
with a metallic floor plate maintained at a temperature of 52 ± 0.5°C. Animals were 
picked up by their tails and placed gently onto the cylinder floor. An observer blind to 
the genotype of the mouse recorded the time taken for each mouse to respond by either 
licking of its hindpaw or jumping from the hotplate. To minimize tissue damage, a 
maximum response latency of 150 seconds was recorded and the mouse removed from 
the hotplate if it failed to respond within this time period. The antinociceptive response 
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was expressed as a percentage of the maximum possible effect (¾MPE), calculated for 
each mouse based on the following formula: [(post-drug latency - baseline latency)/ 
(cutoff latency- baseline latency) * 100]. 
2.7 Morphine Treatment and Testing 
Mice were tested on the hotplate during the mornings of the first, fourth and seventh day 
of morphine treatment. Three pre-drug trials were conducted immediately before 
morphine administration. The first reading was discarded, while the later two (where 
the animals were injected with physiological saline) were averaged to obtain the 
baseline response latency. Following this, mice were injected intra-peritoneally with 
successive doses of morphine tartrate and tested every twenty minutes to generate a 
cumulative dose response curve (Sora et al., 1997). The highest cumulative dose of 
morphine tartrate administered were 56mg/kg on Day 1, 220mg/kg on Day 4 and 
370mg/kg on Day 7. To induce tolerance, these doses were supplemented with 
subcutaneous morphine hydrochloride injections on the evenings of day 1 (50mg/kg), 
day 4 (200mg/kg) and day 7 (300mg/kg), as well as on the mornings and evenings of 
day 2 (l00mg/kg), day 3 (150mg/kg), day 5 (250mg/kg) and day 6 (300mg/kg). In 
summary, the following total cumulative dose of morphine were administered to mice 
over a seven day period (in mg/kg: Day 1: 106, Day 2:200, Day 3: 300, Day 4: 420, Day 
5: 500, Day 6: 600, Day 7: 370 (morning only)). 
For the induction of morphine tolerance in mice that were not used for the hotplate 
assay, a similar protocol as that described above was followed, except that the 
cu1nulative morphine dosing the mice were supposed to receive on the mornings of days 
1, 4 and 7 was substituted with a large bolus dose of morphine hydrochloride ( day 1: 
50mg/kg, day 4: 200mg/kg, day 7: 300mg/kg). Mice used for the naloxone precipitated 
withdrawal experiments were administered a further 300mg/kg of morphine 
hydrochloride on the evening of day 7 before being assessed for physical dependence on 
day 8. 
The pellet implant method was used to induce morphine tolerance in some mice. With 
this protocol, each mouse was implanted subcutaneously with one 75mg morphine base 
pellet under light ether (APS Ltd, NSW, Australia) anaesthesia. They were then left to 
recover under a hot lamp for 30 minutes. 
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2.8 Morphine lethality 
Tolerant wildtype and Gcx2 knockout mice chronically treated with morphine for 7 days 
were administered subcutaneously with a high dose of morphine hydrochloride (700 to 
900mg/kg) and the percentage of mice that died within 6 hours from the injection was 
recorded. 
2.9 N aloxone precipitated withdrawal 
Mice chronically treated with morphine or saline for 7 days were administered 50mg/kg 
morphine HCl or saline on the morning of day 8. Two hours later, the mice was 
injected intraperitoneally with 4mg/kg naloxone HCl. Immediately following the 
injection, each mouse was placed in a large transparent plexiglas cage ( 48cm x 24cm) 
divided by 3 lines lengthwise and one line breadthwise into 8 squares. Two observers 
blind to the genotype and drug treatment condition of the mice counted the number of 
bouts of jumping, wet dog shakes and line crossings over a 15-minute time period. 
Body weights were determined before the administration of naloxone and 60 minutes 
later. 
2.10 Measurement of cyclic AMP levels in brain tissues 
Male wildtype and Gcx2 knockout mice were chronically treated with morphine or saline 
for 7 days. On day 8, they were given another dose of 50mg/kg morphine HCl or saline. 
Two hours later, 4mg/kg naloxone HCl was administered. The mice were sacrificed 
after 20 minutes by rapid decapitation and the head was immediately irradiated in a 
lkW microwave for 3 seconds to inactivate phosphodiesterases (Lenox et al., 1977). 
The striatu1n and periaqueductal gray (P AG) were dissected on ice, and cyclic AMP was 
extracted with ethanol. Tissue cyclic AMP levels were measured using a 
radioimmunoassay kit (Amersham Pharmacia, United Kingdom). Tissue protein was 
estimated using a protein assay kit (Bio-rad, Hercules, CA, USA). 
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2.11 Morphine pharmacokinetic studies 
Tolerant mice treated with morphine for 6 days following the protocol described above 
were administered 50mg/kg of morphine on the morning of day 7. About two hours 
after the last morphine injection, mice were killed by an over-dose of ether and blood 
was drawn from the jugular veins. The blood was allowed to clot at 3 7°C for 1 hour, 
then kept in a refrigerator for 3 hours for the clot to contract. Subsequently, the 
supernatant was transferred to a new polypropylene tube, centrifuged at 246g at 4 °C for 
4 minutes, and the clear serum carefully pippetted into a new tube. Serum from saline 
injected animals was processed in parallel to serve as controls. All sera were stored at -
20°C until ~ent by overnight courier on dry ice to Professor Maree Smith's laboratory at 
the School of Pharmacy, University of Queensland for further analysis. 
2.12 Quantification of morphine and M3G in mouse serum 
Serum concentrations of morphine and morphine-3-glucuronide (M3G) were quantified 
using high-performance-liquid-chromatography with mass spectrometric detection 
(HPLC-MS/MS) at Professor Maree Smith's laboratory (Wright et al., 2000). Aliquots 
of serum (50 µl) were added to 10ml polypropylene tubes, followed by 100µ1 of internal 
standard (hydromorphone, 2 ng/µl). Samples were deproteinated by the addition of 150 
µl of acidified (1 % formic acid) acetonitrile, which was followed by vortex mixing for 
10 seconds. After centrifugation, the supernatant was decanted into clean EppendorfTM 
tubes and the fluid was removed using a Savant centrifugal vacuum dryer. The dried 
residues were then re-constituted with 50µ1 aliquots of deionised water (18.2 MO), 
followed by vortex mixing for 30 seconds. Sample aliquots (20µ1) were then injected 
onto the HPLC-MS/MS and the compounds of interest were separated from endogenous 
components of plasma using a Zorbax SB-C18, 5 µm 2.1 x 50 mm stainless steel column 
and an isocratic mobile phase comprising methanol: 0.1 % formic acid (9:91) at a flow 
rate of 0.15 ml/min. The HPLC-MS/MS system comprised a Shimadzu VP HPLC 
system, and a Perkin-Elmer API 300 mass spectrometer. This assay was highly specific 
as each drug of interest was identified and quantified using selected ion monitoring 
according to the mass ratio of the parent ion to the daughter ion as follows, viz. 
morphine 286.2/201.1, M3G 462.5/286.2, hydromorphone 286.4/184.6. The recoveries 
for morphine and M3G from serum were 74% and 58% respectively (Wright et al. , 
50 
2000) and the lower limits of quantification for morphine and M3G were 156 and 313pg 
injected on-column respectively. 
Standard curves comprising six to seven concentrations of morphine and M3 G were 
processed in random order with each batch of mouse serum samples. Regression 
analysis was used to produce standard curves, which were accepted if the correlation 
coefficients were> 0.995. Intra-day and inter-day coefficients of variation (¾CVs) for 
control serum samples containing added morphine (3.9 ng/ml) and M3G (7.8 ng/ml) in 
concentrations that were identical to those used for the lower limit of quantification 
were <15% (Wright et al., 2000). 
2.13 Measurement of body temperature 
Mice were housed individually in separate cages for about one hour prior to the start of 
each experiment, which took place between 1330 and 1530hrs in the afternoon. Body 
temperature was measured with a rectal thermister probe (Physitemp Instruments, 
Clifton, New Jersey, USA). The probe was inserted into the rectum to a depth of about 
3cm, which provided a reliable measure of the animal's core body temperature. To 
habituate the mice to the testing procedure, the body temperature of the mouse was 
measured every 15 minutes for one hour prior to drug administration. 
2.14 Measurement of plasma corticosterone levels 
Mice were housed individually overnight in separate cages. The collection of blood 
samples via retro-orbital bleeding always occurred between 0900hrs and 1 000hrs the 
next morning, and was performed within forty seconds from initial disturbance of the 
cage. Mice were bled either without any injection (basal measurement), 15 minutes 
after subcutaneous injection with saline vehicle or at the indicated time intervals after 
50mg/kg of subcutaneous morphine hydrochloride. About 100µ1 of blood was collected 
into ice-cold tubes containing 50 Kallikrein inhibitor unit of aprotinin and 2.5 µI of 6% 
ethylenediaminetetraacetic acid. The blood was centrifuged at 246g for 20 minutes at 
4 °C, and the plasma stored in a -70°C freezer until ready for hormonal analysis. The 
level of corticosterone in blood plasma was determined using a radioimmunoassay kit 
obtained from ICN Biomedicals (Aurora, OH). In some experiments, the corticosterone 
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synthesis inhibitor, metyrapone was administered subcutaneously two hours prior to 
morphine treatment. 
2.15 Measurement of ACTH release induced by different drugs 
Mice were housed individually overnight in separate cages. The collection of blood 
samples via retro-orbital bleeding took place between 0900hrs and 1 000hrs, and was 
performed within forty seconds from initial disturbance of the cage. Mice were bled 
either without any injection (basal measurement), or 15 minutes after subcutaneous 
injection with saline vehicle, 0.5mg/kg 8-hydroxy-dipropylamino-tetralin (8OH-DPAT), 
lmg/kg quinpirole or 30 minutes after intraperitoneal injection with saline vehicle or 
1 0µg/kg CRH. About 100µ1 of blood was collected into ice-cold tubes containing 50 
Kallikrein inhibitor units of aprotinin and 2.5 µl of 6% ethylenediaminetetraacetic acid. 
The blood was centrifuged at 246g for 20 minutes at 4 °C, and the plasma stored in a -
70°C freezer until ready for hormonal analysis. The level of ACTH in blood plasma 
was determined using a radioimmunoassay kit obtained from ICN Biomedicals (Aurora, 
OH, USA). As the level of ACTH did not differ when blood samples were collected 
either 15 or 30 minutes after saline injection, the data were combined during data 
analysis to obtain a single mean control value for mice of each genotype. 
2.16 Automated measurement of locomotor activity 
Mice were accustomed to the testing room for two hours prior to the start of each 
experiment. Locomotor activity measurement always commenced between 1330 and 
1530hrs in the afternoon. After the injection of a drug or saline vehicle, each mouse 
was placed immediately into a cage (29cm x 18cm) fitted with 2 pairs of infra-red 
photocells positioned 1.5 cm above the floor and spaced 10cm apart. The cage was 
made to look identical to the home cage, with sawdust, food and water. The set up 
allows the locomotor activity of eight mice (four wildtype and four Gaz knockouts) to 
be evaluated simultaneously in eight cages separated visually from one another. 
2.17 Analysis of locomotor activity profile 
In Chapter 4, the morphine stimulated locomotor activity profile of each mouse was 
analysed by measuring three parameters: (i) the total number of beam breaks during the 
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first hour after morphine administration, (ii) peak activity and (iii) duration of response. 
Peak activity is operationally defined as the maximum number of beam breaks in any 
15-minute time bin. The duration of the morphine response was measured by the time it 
took for the locomotor activity of a morphine treated mouse to return to within two 
standard errors from the activity average of saline treated mice. 
2.18 Constant Potential Amperometry 
Each mouse was anaesthetized with an intraperitoneal injection of 1.5g/kg urethane. 
The mouse's head was shaved and carefully placed in a stereotaxic frame (David Kopf 
Instruments, Tujunga, CA, USA) containing a mouse head-holder adaptor (Stoelting, 
Kiel, WI, USA). The body temperature of the mouse was maintained at 40 ± 0.5°C with 
a temperature-regulated heating pad (TC-831; CWE Inc., New York, NY). Three holes 
were drilled through the animal's skull: one for the reference/auxiliary electrode, 
another for the stimulating electrode and a third relatively larger hole for both the 
recording electrode and an adjacent 31 g stainless-steel guide cannula. The tip of a 
concentric bipolar stimulating electrode (SNE-100; Rhodes Medical Co., Woodland 
Hills, CA, USA) was positioned in the medial forebrain bundle (MFB) 2.1mm posterior 
to the bregma and 1mm lateral to the medial line (Franklin and Paxinos, 1997). The 
depth of the electrode was about 4.3mm from the dura, and was adjusted for every 
experiment so that the release of dopamine was close to maximum. The recording 
electrode, which utilized a carbon fibre (l0µm thick and 250µm long, Thome! Type P, 
Union Carbide, USA) as the active recording surface, was implanted into the core 
region of the ipsilateral nucleus accumbens. The coordinates were 1.5mm anterior to 
the bregma and 1mm lateral to the medial line. Again, the depth, which was between 
3.3 to 3.5mm from the dura, was adjusted for each experiment to maximize dopamine 
release. For drug infusion, a guide cannula was implanted as close to the recording 
electrode as possible (0.2 to 0.3 mm), with its end positioned 1mm above the tip of the 
recording electrode, so that when the infusion cannula (1 00µm o.d., Polymicro Tech. 
Inc., AZ, USA) was inserted, its tip was approximately in line with the middle of the 
recording electrode's carbon fiber. The tip of the reference/auxiliary electrode 
combination was positioned through one of the contralateral skull holes and placed in 
contact with cortical tissue. 
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The recording electrode was left to equilibrate in the tissue for approximately one hour. 
After the recording electrode showed stable stimulation-evoked dopamine responses, a 
baseline response profile for each mouse was acquired by applying a train of 
monophasic 0.5msec duration pulses (15 pulses at 50Hz, 500~tA) once every thirty 
seconds for 2.5 minutes. Six stimulation-evoked responses were recorded auto1natically 
by a Macintosh computer n1nning the 'Chart' program (ADinstruments, Castle Hill, 
NSW, Australia) and were subsequently averaged to obtain a mean baseline response. 
Thereafter, 1 00ng of quinpirole in a volume of 1 µl was infused slowly into the nucleus 
accumbens through the injection cannula via a 1 0~tl microsyringe over a time period of 
4 minutes. At 15 minute time intervals from the start of infusion, a mean dopamine 
release profile was obtained by averaging the responses from six stimulating pulse 
trains, following exactly the same protocol as was used for obtaining the baseline 
response. Recordings continued for at least 90 minutes after the start of quinpirole 
infusion. 
Upon the completion of each experiment, an 1ron deposit was made in the MFB 
stimulation site by passing direct current (1 00~tA for 10sec) through the stimulating 
electrode. The mouse was then euthanized with an overdose of urethane (3g/kg). The 
brain was removed, immersed overnight in 10% buffered formalin containing 0 .1 % 
potassium ferricyanide (Lancaster Inc., Eastgate, UK), and then stored in a solution 
containing 30% sucrose and 10% formalin until sectioning. After fixation, 40~nn 
coronal sections were cut on a freezing microtome. A Prussian blue spot, which is 
produced from a redox reaction of ferricyanide, marks the stimulation site. The 
placements of the electrochemical recording electrode, stimulating electrode and 
microinfusion cannulae were determined under a light microscope and recorded on 
representative coronal diagra1ns (Franklin and Paxinos, 1997). 
2.19 Data Analysis. 
All data analysis were performed with the Statistical Package for the Social Sciences 
(SPSS) software (SPSS Inc., Chicago, USA). For parametric data containing one factor 
with only two levels, data analysis was performed using the student's t test. For all 
other parametric data, the Analysis of Variance (ANOV A) procedure was used. To 
analyse gender differences in morphine analgesia and tolerance between mice of 
different genotypes (Chapter 3), repeated measures ANOV A was performed e1nploying 
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morphine dose as a within subject factor and genotype as a between subject factor. In 
analysing the data of mice implanted with morphine pellets (Figure 3.4), time after 
morphine pellet implant was a within subject factor and genotype was a between subject 
factor. ANOV A of the data presented in Chapters 4, 5 and 6 was accomplished using 
time as a within-subject factor, drug dose and genotype as between-subject factors. All 
possible interactions between the factors were examined. However, in most cases, only 
interactions that were significant at p<.05 or better were reported. During the 
performance of repeated measures ANOV A, the Huynh-Feldt correction was applied 
when the sphericity assumption was violated. All post-hoc multiple comparisons were 
performed with Fisher's least significant difference procedure (Winer, 1970). For the 
non-para1netric morphine withdrawal data presented in Chapter 3, the Kruskal-Wallis 
one-way ANOV A test was used. The plotted values in all figures are the means ± SEM. 
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Chapter 3 
Morphine tolerance and physical dependence in the Gaz knockout 
mouse 
3.1 Introduction 
Morphine is a potent pain reliever. It is commonly used for alleviating post-surgical 
pain and is recommended by the World Health Organization for treating moderate to 
severe pain associated with advanced cancer (Collett, 1998; Zech et al. , 1995). 
However, prolonged use of morphine often necessitates dose escalation even in the 
absence of disease progression, to achieve the same degree of analgesia, resulting in 
increased cost as well as risk of drug dependence. This rightward shift in the dose 
response curve is due to the development of drug tolerance, a complex clinical 
phenomenon that remains poorly understood. 
Prolonged use of a drug can produce tolerance in a number of ways: Firstly, this can 
induce changes in its distribution and metabolism. This form of tolerance, also known 
as pharmacokinetic tolerance, is commonly caused by an increase in the rate of drug 
metabolism after repeated administrations. The consequent faster decline of its 
concentration in the blood and at its sites of action result in a smaller drug response. 
Additionally, if the metabolism of the drug produces metabolites with antagonistic 
properties, accumulation of these metabolites could lead to tolerance by counteracting 
the actions of the drug. In the case of morphine, one of its major metabolites, 
morphine-3-glucuronide (M3G), as well as a less abundant metabolite, normorphine-3-
glucuronide (nor-M3G), have both been shown to attenuate morphine induced 
antinociception (Smith and Smith, 1998; Smith et al., 1990). The accumulation of both 
of these metabolites in the body could therefore oppose the pain relieving properties of 
morphine and potentially play a role in the development of tolerance (Smith and Smith, 
1995). 
A second form of tolerance is called pharmacodynamic tolerance. Morphine binds to 
opioid receptors, which in tum causes the activation of receptor bound G proteins, to 
inhibit adenylate cyclase, open potassium channels and produce other effects within the 
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cell (Standifer and Pasternak, 1997; Williams et al. , 2001). Continuous exposure to 
morphine can promote adaptive changes in the receptors and cellular systems affected 
by the drug. These changes include short and long term receptor desensitisation, 
compensatory upregulation of adenylate cyclase activity, as well as adaptations in the 
neuronal circuitry involved with morphine effects (Williams et al., 2001). The 
contribution of one of these cellular mechanisms to morphine tolerance in a whole 
animal has been demonstrated in a mouse that lacks 0-arrestin 2, a protein putatively 
involved in receptor desensitization. Compared to chronically morphine treated 
wildtype mice, mice deficient in 0-arrestin 2 did not develop morphine tolerance and 
this was paralleled by an intact coupling of opioid receptors to G proteins, suggesting an 
absence of opioid receptor desensitization (Bohn et al., 2000). 
Thirdly, in addition to pharmacological parameters, learning can also play a 
contributory role to the development of morphine tolerance (Ramsay and Woods, 1997). 
Associative tolerance develops through the repeated pairings of morphine 
administration with specific environmental cues (such as weighing before drug 
injection, testing for analgesia). Gradually, these cues acquire the properties of a 
conditioned stimulus and elicit a conditioned response that opposes the pharmacological 
effects of morphine. This diminution in morphine's effects appears as tolerance 
(Mitchell et al., 2000). Associative tolerance to the analgesic effects of morphine has 
been shown to require the stimulation of cholecystokinin B receptors in the amygdala, 
suggesting that the amygdala forms part of the circuitry that is responsible for 
developing this type of tolerance (Mitchell et al., 2000). 
Besides causing tolerance, chronic morphine treatment also produces abstinence 
symptoms when the drug is abruptly withdrawn (physical dependence). These 
withdrawal symptoms include reduced locomotor activity, teeth chattering, diarrhea, 
wet dog shakes, body weight loss and jumping behaviour in rodents (Schulteis et al., 
1994). The observation that the extent of morphine tolerance is related to the degree of 
physical dependence, has led to the hypothesis that opioid tolerance and physical 
dependence may share a common underlying mechanism (Way et al. , 1969). Indeed, 
the frequent co-occurrence of drug tolerance and dependence is highlighted in a recent 
edition of the Diagnostic and Statistical Manual of Mental Disorders (American 
Psychiatric Association, 1994), where tolerance is listed as one of two main diagnostic 
criteria of physiological substance dependence. Currently, there is no good model to 
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explain physical dependence at the level of the whole organism. However, at the cellular 
level, the compensatory upregulation of adenylate cyclase activity in opioid sensitive 
neurons, as a result of prolonged morphine exposure, has been applied to explain both 
morphine tolerance and dependence (Collier, 1980; Finn and Whistler, 2001; Williams et 
al., 2001). According to this hypothesis, the decreased potency of morphine in the 
tolerant state, results from its lower efficacy to produce inhibition of cyclic AMP levels, 
due to a compensatory superactivation of adenylate cyclase activity within the cell. 
Withdrawal of morphine unmasks this latent upregulation of cyclic AMP levels, leading 
to a supra-basal rebound that reverses morphine's effects (Finn and Whistler, 2001). 
Superficially, some of the symptoms of morphine withdrawal, such as hyperalgesia 
(Laulin et al., 1999), reduced locomotor activity and diarrhea (Schulteis et al. , 1994), 
appear opposed to the acute analgesic, locomotor activating (Sora et al., 2001a) and 
gastrointestinal anti-transit effects of morphine (Pol et al., 2001). Morphine dependence 
at the cellular level n1ay play a role in the development of these symptoms. 
Three types of opioid receptors have been cloned, and they have been designated using 
the Greek letters, µ, 8 and K (Kieffer, 1999) (Alexander et al. 2000). Although morphine 
can bind to all three receptors, it has the highest affinity for theµ receptor (Goldstein and 
Naidu, 1989; Raynor et al., 1994). Morphine analgesia and physical dependence are 
mediated through the µ receptor as these effects are abolished in the µ receptor knockout 
mouse (Matthes et al., 1996). The 8 receptor, on the other hand, has been implicated in 
the development of n1orphine tolerance, as mice that lack the 8 receptor did not develop 
tolerance to the analgesic effects of morphine to a significant degree (Zhu et al. , 1999b ). 
All opioid receptors are G protein coupled receptors. In vitro, the acute activation of all 
three receptors has been shown to inhibit adenylate cyclase through the stimulation of G2 
or pertussis toxin sensitive Gu0 (Ozawa et al., 1999; Tso et al. , 2000; Tso and Wong, 
2000b ). Following chronic opioid treatment, there was a compensatory increase in 
adenylate cyclase activity that was sensitive to the effects of pertussis toxin (Ozawa et al. , 
1999; Tso et al., 2000; Tso and Wong, 2000a; Tso and Wong, 2000b; Tso and Wong, 
2001). However, either Gi1, Gi2, Gi3 or Gz alone was found to be insufficient to mediate 
the chronic opioid induced superactivation of adenylate cyclase activity. This suggests 
that the adenylate cyclase superactivation is either mediated by Go or requires the 
si1nultaneous sti1nulation of more than one Gi/o/z protein (Tso and Wong, 2000a; Tso and 
Wong, 2000b; Tso and Wong, 2001). Nonetheless, in experiments performed by another 
research group, G2 alone could substitute for Gi/o to mediate adenylate cyclase 
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superactivation, although only a small effect was seen (Ozawa et al., 1999). The 
discrepancy in results between the studies might be due to differences in the level of 
over-expression of Gz in the two experiments. Together, the data seem to suggest that 
the parallel stimulation of more than one Gi, G0 or G2 protein is required for the chronic 
opioid induced superactivation of adenylate cyclase activity in vitro. 
In the brain, µ opioid receptors have been reported to couple to Gi2 (Garzon et al., 
1997a), Gz (Garzon et al., 1997b; Garzon et al., 1997a; Garzon et al., 1998) and G0 
(Jiang et al., 2001 ). There is evidence that the 'µ receptor', which morphine binds to, 
prefers Gz over Gi2 (Garzon et al., 1998). High affinity binding of morphine to its 
receptor was significantly attenuated after pre-incubation of brain membranes with 
antibodies against Ga2 • In contrast, pre-treatment with Gai2 antibodies did not affect 
morphine binding to its receptor. When another preferential agonist at the µ receptor, 
[D-Ala2,N-MePhe4,Gly-ol5]-enkephalin (DAMGO) was tested, there was a significant 
reduction in receptor binding affinity after pre-treatment with both antibodies (Garzon 
et al., 1998). Since antibody pre-treatment is assumed to prevent the G protein from 
interacting with its receptor, leading to a decrease in receptor affinity for its agonists, 
these data suggest that the 'morphine' receptor couples preferentially to G2 , while the 
'DAMGO' receptor couples to both G2 and Gi2 in the brain. Both the 'morphine' and 
'DAMGO' receptors are likely to be opioid receptors of theµ subtype as the experiment 
was performed in the presence of the 8 receptor antagonist, ICI-17 4,864, and the 
experimental conditions employed favour the detection of high affinity receptor binding 
states (Garzon et al., 1998). Although there is evidence for the existence of different 
pharmacological subtypes ofµ receptors (Pasternak, 2001), only oneµ receptor has ever 
been cloned (Kieffer, 1999). Receptor heterodimerization between opioid receptor 
subtypes ( e.g µ-8, 8-K) can generate 'novel receptors' with distinct pharmacological 
profiles (Jordan and Devi, 1999) and G protein coupling preferences (George et al., 
2000). Furthermore, multiple carboxyl terminal spliced variants of the µ receptor have 
been reported to exist (Pasternak, 2001 ), greatly increasing the potential of generating µ 
receptors with different pharmacological properties. The 'morphine' and 'DAMGO' 
receptors may therefore correspond to homogeneous or heterogeneous populations of 
these µ receptors, or µ-8 heteroreceptors. 
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Consistent with Gz playing a role in transducing the effects of morphine receptor 
activation in the brain, mice lacking the a subunit of G2 , have been observed to 
demonstrate either reduced supraspinal morphine analgesia ( as measured by the 'hot 
plate' test) (Yang et al., 2000) or no difference in acute morphine analgesia but greater 
development of tolerance to the supraspinal analgesic effects of morphine after chronic 
treatment (Hendry et al., 2000). However, there were a few deficiencies in both of these 
studies. Firstly, mice of mixed genetic backgrounds were used and the hitchhiking of 
'background genes' in the strains employed have been reported to be potentially capable 
of contributing to the analgesic effects of morphine (Lariviere et al., 2001). Secondly, 
basal nociceptive thresholds were not taken into account when analysing morphine 
analgesia. For instance, the control mice in Yang et al. (2000)'s paper have a longer 
baseline response latency than Ga2 knockout mice. After taking into account this 
difference in response baseline, it appears that there may be little or no difference in 
morphine induced analgesia between mice of the two genotypes. Thirdly, gender 
differences in morphine analgesia (Cicero et al., 2002; Kepler et al., 1991; Krzanowska 
et al., 2002) have not been considered in both studies. In our earlier paper, we have 
used mice of mixed genders (same number of mice from each genotype). The gender of 
the mice was not reported in Yang et al. (2000). The mixing of mouse genders could 
mask any gender difference that might be present. 
In this chapter, I have sought to confirm the involvement of Ga2 in supraspinal 
morphine analgesia (as measured by the hot plate test) (Pastoriza et al., 1996) and 
tolerance by clarifying the issues discussed above and exploring whether the observed 
effect is dependent on the quantity of Ga2 present. The finding of a gene dose 
relationship would further strengthen the hypothesis that Ga2 plays an essential role in 
the development of morphine tolerance. I have also investigated some of the 
mechanisms that may explain the increased morphine tolerance observed in the Ga2 
knockout mouse. My results suggest that the augmented tolerance in the mutant mouse 
is not due to changes in morphine metabolism, and greater tolerance still develops in the 
absence of opportunities for associative learning. Besides showing increased analgesic 
tolerance, the Ga2 knockout animals also demonstrated greater tolerance to the toxicity 
effects of morphine after chronic treatment. This suggests that the loss of Gaz may 
have a protective effect against drug over-dose among chronic morphine users. Finally, 
I have also investigated whether physical dependence on morphine is altered in these 
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mutant mice. The absence of Gcxz is associated with a reduction in naloxone 
precipitated jumping behaviour, indicating that the signalling pathways mediated by 
Gcx2 are also involved in the expression of physical dependence. 
3.2 Results 
3.2.1 Basal nociceptive threshold and habituation to the hotplate. 
The baseline response latencies of male and female wildtype and Gcx2 knockout mice 
were examined in the drug free condition over 6 trials. Mice deficient in Gcx2 showed a 
slightly enhanced response latency on the first trial. This difference between mice of 
the two genotypes was abolished after the mice have habituated to the hotplate on 
subsequent trials (Figure 3 .1 ). Therefore, the mice employed in the following 
experiments were always habituated to the hotplate for 3 trials before being tested for 
n1orphine analgesia using a cumulative 1norphine dosing regime (Sora et al., 1997). To 
compute the baseline response latency, the responses of each mouse from the second 
and third trials were averaged. 
3.2.2 Acute morphine analgesia is altered in the Gcxz knockout mouse. 
Acute morphine analgesia was tested in drug free wildtype and Gcx2 knockout mice. 
The loss of Gcx2 produced a small gene dose dependent rightward shift in the morphine 
dose response curve in fen1ale mice (Genotype main effect: F(2,25)=15.032, p<.001), 
that was absent in male mice (F(2,22)<1, NS) (Figure 3.2a). Male Gcx2 knockout 1nice 
demonstrated a tendency of reduced morphine analgesia at low morphine doses, which 
disappeared at doses > 3 51ng/kg. 
3.2.3 Gene dose dependent alteration of morphine tolerance on the 
hotplate. 
Next, I investigated whether Gcx2 might play a greater role in mediating the analgesic 
effects of 1norphine after tolerance development. Mice that have been treated with 
morphine for 3 days were tested again on the morning of the fourth day. A distinct 
difference was apparent in both male (Genotype main effect: F(2,22)= 26.2, p<.001) 
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Figure 3.1: Basal nociceptive threshold and habituation to the hotplate in wildtype and 
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(16 +/+, 16 -/-) wildtype and Gcx2 knockout mice were determined on the 52°C hotplate 
over six trials. Means± S.E.M. are shown. * p<.05 
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Figure 3.2: Development of morphine tolerance in the Gaz deficient mouse. Cumulative morphine dose response curves (on a logarithmic scale) 
were generated in male (9 +/+, 8 +/-. 8 -/-) and female (10 +/+. 8 +/-. 10 -/-) Ga2 knockout(-/-), heterozygous(+/-) and wildtype (+/+) mice on ~ the 52°C hotplate test. (A) Drug free mice treated acutely with morphine. (B) Mice that have been chronically treated with morphine for 3 days 
were tested on day 4. (C) The same mice had been chronically treated with morphine for 6 days and were tested on day 7. The values plotted 
are the means+/- SEM. The method used is described in Chapter 2. 
and female (F(2,25)=12.5, p<.001) wildtype and Ga2 knockout mice, where mice 
lacking Ga2 appear to have stopped responding to morphine (Figure 3 .2b ). A further 3 
days of n1orphine treatment caused wildtype and heterozygous mice to become more 
tolerant, with little effect on Gaz knockout mice, which were already very tolerant 3 
days earlier. The heterozygous mice appeared to develop tolerance at a faster rate than 
wildtype mice (Figure 3 .2c ), producing an intermediate level of response that was 
significantly reduced compared to male (Genotype main effect: F(l,15)= 24.1, p<.001) 
and female (F(l,16)= 7.183, p<.02) wildtype mice. 
3.2.4 Greater analgesic tolerance to morphine in Gaz knockout mice 
occurs in the absence of opportunities for behavioural learning. 
In the behavioural protocol employed in our earlier paper (Hendry et al., 2000) and 
here, mice were habituated to the hotplate in earlier test sessions before showing a 
difference in their behavioural responses on subsequent days. Such habituation to the 
test environment during the period of morphine treatment has been reported to 
significantly decrease morphine induced analgesia compared to animals which have not 
been habituated (Gebhart and Mitchell, 1971; Gebhart and Mitchell, 1972; Milne and 
Gamble, 1989). To exclude the possibility that the observed behavioural difference 
reported above was due to a greater capacity of the Ga2 knockout mouse to learn 
coinpensatory behavioural strategies associated with hot plate testing, additional 
experiments were performed where inice were tested for the first time on the hotplate 
after 6 days of chronic morphine treatment (these mice were not tested on days 1 and 4). 
Both male and female mice were used, with an equal number of both genotypes for each 
gender. Coinpared to drug-free mice (Figure 3 .2a), the first exposure of chronically 
morphine treated mice to the hotplate reproduced the same altered morphine tolerance 
(Genotype main effect: F(l,18)= 9.08, p<.01), with Ga2 knockout animals failing to 
respond to n1orphine doses up to 300 mg/kg and wildtype animals showing much less 
tolerance (Figure 3 .3). 
Furthermore, in the cun1ulative morphine dosing protocol, mice were injected with 
n1orphine every 20 minutes prior to analgesic testing on the hotplate. It may be argued 
that the increased tolerance that developed in the Gaz knockout mouse is associative in 
nature due to mutant mice learning the association between morphine injection and 
hotplate testing faster than wildtype mice. Associative tolerance to morphine involves 
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Figure 3.3: Altered morphine tolerance in the Ga2 knockout mouse occurs in the 
absence of behavioral habituation. Ten mice of each genotype ( 6 males, 4 females) 
were chronically treated with morphine for six days (starting from a total cumulative 
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the 52°C hot plate for the first time and the response latency of each mouse to a 
cun1ulatively increasing dose of morphine was recorded. * p<.05, ** p<.01 
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the participation of neuronal circuitry in the a1nygdala (Mitchell et al. , 2000), where Ga 2 
has been found (Glick et al., 1998; Wang et al. , 1998). To investigate whether the Ga 2 
knockout mouse would still develop greater tolerance to morphine in the absence of 
opportunities for associative learning, wildtype and mutant mice were implanted with 
morphine pellets, and tested on the hotplate 2, 24, 48, 72 and 96 hours after the implant. 
Morphine lost its analgesic effects in the Ga2 knockout mouse about 48 hours after the 
implant, compared to 96 hours in wildtype mice (Figure 3.4) (Genotype main effect: 
F(l,11)= 5.44, p<.05). Taken together, these results suggest that the increased analgesic 
tolerance to morphine that developed in the Ga2 knockout 1nouse is not a result of 
behavioural learning. 
3.2.5 Gene dose dependent morphine lethality in tolerant mice 
Lethality from morphine over-dose is known to be mediated through the µ opioid receptor 
(Loh et al., 1998; Sora et al., 2001a). To investigate whether the Ga2 knockout mouse were 
indeed more tolerant to high doses of morphine, drug-free and chronically morphine treated 
wildtype and Ga2 knockout mice were administered an over-dose of morphine. Most mice 
entered a convulsive state and died within the first 4 hours of injection. However, 
1norphine treated Ga2 knockout mice were found to be capable of tolerating higher 
1norphine doses co1npared to similarly treated wildtype and heterozygous mice (Table 3.1). 
Whereas the median lethal dose (LD50) of chronically treated wildtype mice was less than 
700mg/kg, heterozygous mice showed a LD50 of about 750mg/kg, and chronically treated 
Gaz knockout mice had a LD50 greater than 800mg/kg. Drug-free wildtype and Ga2 
knockout mice had a LD50 of 400mg/kg, similar to values reported by Loh et al. (1998). 
3.2.6 Wildtype and Gaz knockout . mice show similar morphine 
pharmacokinetics. 
The liver plays an important role in morphine metabolis1n (Aasmundstad et al., 1993) and 
Ga2 has been reported to be expressed in the liver (Spicher et al. , 1988). Therefore, I 
exan1ined whether phannacokinetic differences could account for the development of 
greater morphine tolerance in the Ga2 knockout mouse. Serum levels of morphine and its 
major n1etabolites, M3G and Nor-M3G in male and female wildtype and Gaz knockout 
mice on day 7 of morphine treatment were measured. Despite the Gaz knockout animals 
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Figure 3 .4: Non-associative tolerance to the analgesic effects of morphine is enhanced 
in the Ga2 knockout mouse. Male wildtype and Ga2 knockout mice (6+/+, 7-/-) were 
implanted with 75mg morphine pellets, and tested on the hotplate 2, 24, 48, 72 and 96 
hours after the implant. The mean ¾MPE ± S.E.M. are shown. Similar data were 
obtained for two other groups of male and female mice tested for up to 48 hours after 
the i1nplant. * p<.05 
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Figure 3.5: Serum morphine, morphine-3-glucuronide (M3G) and nor-morphine-3-
glucuronide (nor-M3G) levels in tolerant Ga2 knockout(-/-) and wildtype mice(+/+). 
Six mice of each genotype were chronically treated with morphine for 6 days (starting 
from a total cumulative dose of 100 mg/kg on day 1 to 600 mg/kg on day 6). On day 7, 
mice were administered 50mg/kg of morphine and 2 hours later, mice were 
anaesthetized and trunk blood was collected from the jugular vein. Two other 
experiments ( one performed on tolerant male mice and the other on tolerant female 
mice) sacrificed at different time intervals after morphine administration produced 
similar levels of morphine and M3G between wildtype and Ga2 knockout mice. 
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Table 3 .1: Percentage of morphine tolerant mice that survive various doses of 
morphine. Figures in parentheses indicate the actual number of mice tested that 
survived the particular morphine dose. 
Morphine Dose +/+ +/- -/-
900mg/kg 0% 0% 33.3% 
(0/2) (0/2) (2/6) 
800mg/kg 13.0% 42.9% 76.5% 
(3/23) (6/14) (13/17) 
700mg/kg 33.3% 60% 100% 
(3/9) (3/5) (8/8) 
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showing greater tolerance, there was no significant difference in the levels of morphine 
or its metabolites in the sen1m (Figure 3.5). 
3.2. 7 Alteration of physical dependence on morphine in the Gaz knockout 
mouse 
Morphine tolerance and physical dependence have been suggested to share a common 
underlying mechanism (Way et al., 1969). Since the Ga2 knockout mouse show greater 
tolerance to morphine, it is possible that they 1nay also be more dependent physically. 
The degree of physical dependence is usually measured based on the severity of 
1norphine withdrawal signs, after withdrawal has been precipitated in tolerant animals 
by treating with the opioid antagonist, naloxone. One of the most prominent sign of 
morphine withdrawal in rodents is naloxone precipitated jumping behaviour, whose 
severity has previously been found to correlate with the degree of morphine tolerance 
(Way et al., 1969). Contrary to expectations, I observed a gene dose dependent 
reduction of naloxone precipitated jumping in both male (Kruskal-Wallis ANOV A by 
genotype, n= 54, x2 = 22.5, p<.001) and female (n =44, x2 = 17.4, p<.001) Ga2 
knockout mice (Figure 3 .6a). However, there was no consistent gene dose relationship 
across genders in the other withdrawal signs, wet dog shake (Figure 3.6b) and naloxone 
induced weight loss (Figure 3.6d). For naloxone elicited depression of loco1notor 
activity (Figure 3 .6c ), there appears to be a gene dose dependent trend for the Ga2 
knockout 111ouse to be more severely affected. However, the relationship was not 
statistically significant in both male (x2= 4.58, p=.10) and female (x2= 4.60, p=.10) Ga2 
knockout 1nice. 
3.2.8 Cyclic AMP levels in saline and chronically morphine treated mice 
One cellular halhnark of morphine withdrawal is the compensatory upregulation of 
cyclic AMP levels by an opioid antagonist (Finn and Whistler, 2001). Cyclic AMP 
levels were 111easured in the striatum and periaqueductal gray of chronic morphine or 
saline treated mice, 20 111inutes after the administration of naloxone. These two brain 
regions were chosen because they have previously been known to contain opioid 
sensitive neurons (Gutstein et al., 1998; Petruzzi et al., 1997) and Gaz (Garzon et al., 
1997b; Garzon et al., 1997a; Glick et al., 1998; Hinton et al., 1990; Wang et al., 1998). 
The level of cyclic AMP in the striatum of morphine tolerant Gaz knockout mice was 
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Figure 3.6: Alteration of physical dependence on morphine in the Ga2 knockout mouse. 
Morphine tolerant (male: 21 +/+, 17 +/-, 16 -/-; female: 17 +/+, 13 +/-, 14 -/-) or saline 
treated (male: 8 +/+, 13 +/-, 11 -/-; female: 8 +/+, 9 +/-, 9 -/-) mice were given a priming 
dose of either 50mg/kg morphine or saline after 7 days of treatment. Two hours later, 
the mice were weighed, and abrupt withdrawal was precipitated using 4mg/kg naloxone. 
Immediately, each mouse was placed into a large observation cage, and two observers 
who were blind to the mice's genotype and drug treatment condition counted (A) the 
number of jumps, (B) wet dog shakes and (C) line crossings (locomotor activity) made 
by each mouse within a 15 minutes time period. The correlations between the scores of 
the two observers were 0.99 for jumps, 0.81 for wet dog shakes, and 0.98 for line 
crossings. The mice were weighed again 45 minutes later, and (D) the percentage 
weight loss was computed for each mouse. Means ± S .E.M. are shown. 
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Figure 3. 7: Cyclic AMP levels in the striatum and periaqueductal gray of chronically 
morphine and saline treated mice. Male wildtype and Ga2 knockout mice were 
chronically treated with morphine (12 +/+, 12 -/-) or saline (18 +/+, 6 -/-) according to 
the protocol described in Chapter 2, followed by an intraperitoneal injection of 4mg/kg 
naloxone HCl, 2 hours after the last treatment. The mice were sacrificed 20 minutes 
later by rapid decapitation and the head was immediately irradiated in a lkW 
microwave for 3 seconds to inactivate phosphodiesterases. The striatum and 
periaqueductal gray (P AG) were dissected on ice, and cyclic AMP was extracted using 
ethanol. Tissue levels of cyclic AMP and protein were measured using kits that were 
commercially available. Means ± S.E.M. values are shown. Comparison between 
morphine treated+/+ and-/- mice: * p<.05. 
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greater than tolerant wildtype mice (t(22)= 2.81 , p<.02) (Figure 3.7). However, none of 
the levels measured in morphine treated mice was above that of saline treated animals. 
3.2.9 Gene dose dependent expression of Gaz protein in the brain of the 
mouse. 
The gene dose dependent effect on morphine tolerance and naloxone precipitated 
jumping suggest that the level of expression of the Gaz protein depends on gene dosage. 
The levels of Gaz protein in the brains of rnale wildtype, heterozygous and Gaz 
knockout mice were analysed on western blots. The result showed that the level of Gaz 
protein in the brains from heterozygous mice was about 41.6 ± 4.1 % (n=4) of that from 
wildtype mice (Figure 3.8). 
3.2.10 Lack of compensation by other G protein a subunits in drug free 
and morphine tolerant mouse brains. 
The levels of expression of other G protein a subunits were determined to assess 
whether the observed phenotypes could be due to compensation by other G proteins. In 
both nai:ve and morphine tolerant mouse brains, there was no detectable change in the 
level of expression of Gai, Ga0 , Gaq and Gas (Figure 3.9). 
3.3 Discussion 
The clinical importance of morphine as an analgesic has made understanding the 
mechanisms underlying morphine analgesia, tolerance and dependence one of the key 
goals in modem pain research. This goal has been facilitated by the advent of gene 
knockout technology, which allowed mice with defined lesions to specific molecular 
targets along the opioid signal transduction pathway to be made. Using this approach, 
the µ opioid receptor has been identified to be essential for morphine induced analgesia 
and physical dependence (Loh et al., 1998; Matthes et al., 1996; Sora et al., 1997) and 
the 8 receptor for the development of analgesic tolerance (Zhu et al., 1999b ). Both of 
these receptors have been shown to couple to Gaz in vivo (Garzon et al., 1997a) and in 
vitro (Ho and Wong, 2001 ). Previous work employing the antisense oligonucleotide 
approach to examine the role of Gaz in acute supraspinal morphine analgesia have 
yielded varying results, with one report demonstrating a significant attenuation of 
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Figure 3. 8: Gene dose dependent expression of Gaz proteins in wildtype, heterozygous, 
and knockout mouse brains. The proteins from the brains of four male mice of each 
genotype were analysed by SDS- polyacrylamide gel electrophoresis, electro-transferred 
onto nitrocellulose, and blotted with a Gaz specific antibody. The blot was 
subsequently re-probed with a G~(common) antibody as a gel loading control. 
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Figure 3.9: Levels of Ga2 , Gai, Gaq, Ga0 , Gas(1ong) and Gas(short) in the brains from 
naive and 1norphine tolerant wildtype and Ga2 knockout mice. The proteins from the 
brains of naive and morphine tolerant wildtype and Ga2 knockout mice were analysed 
by SDS- polyacrylamide gel electrophoresis, electro-transferred onto nitrocellulose, and 
blotted with antibodies specific for Ga2 , Gai, Gaq, Ga0 , and Ga5 • 
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supraspinal morphine analgesia after loss of Gaz (Sanchez-Blazquez et al., 1995), and 
another showing little effect (Standifer et al., 1996). The latter, however, has employed 
an oligonucleotide against the human Ga2 gene sequence, which may not be effective 
against mouse Gaz (see Chapter 1, section 1.4.1). I have therefore used the Ga2 
knockout mouse generated in my laboratory to investigate the involvement of Ga2 in 
morphine analgesia in greater detail. 
The earlier studies by Yang et al. (2000) and my laboratory have employed Ga2 
knockout mice of mixed genders and genetic backgrounds, and morphine analgesia was 
measured without correcting for differences in baseline response latencies. While the 
baseline response latencies of the Ga2 knockout mice used by Yang et al. (2000) were 
shorter compared to their control mice, our mutant mice demonstrate a longer latency 
relative to wildtype mice on the first trial. The reason for this difference is unclear. 
Since our mice were in a pure C57BL/6 genetic background and the mice used by Yang 
et al. (2000) were from a mixed C57BL/6: 129/Sv:SJL background (Ioffe et al., 1995), 
the difference could be due to genes from either the 129/Sv or SJL backgrounds or both. 
Alternatively, differences in experimental procedure (Yang et al. (2000) used a 58°C 
hotplate) might have also contributed to the difference. 
When acute morphine analgesia was examined, a gender difference was apparent, with 
female Ga2 knockout mice demonstrating a gene dose related decrease in morphine 
analgesia, and little difference among male mice. Gender variations in morphine 
antinociception have generally been attributed to differences in the organization of male 
and female brains (Cicero et al., 2002; Krzanowska et al., 2002). The periaqueductal 
gray, an area of the brain involved in the production of morphine antinociception 
(Behbehani et al., 1990; Smith et al., 1988), contains Ga2 (Garzon et al., 1997b; Garzon 
et al., 1997a), and there is evidence that its organization may differ between the genders 
(Bandler and Shipley, 1994; Schwartz-Giblin and McCarthy, 1995). It is possible that 
the relative importance of the G2 signalling pathway in mediating the acute analgesic 
effects of morphine may become altered as a result of these circuitry changes, resulting 
in the small gender difference observed here. 
On the whole, the fmding that acute morphine analgesia is only slightly diminished in 
the Ga2 knockout mouse support data reported in the literature that the acute analgesic 
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effects of morphine are transduced mainly through other G proteins, notably Gi2 and 
possibly G0 (Raffa et al., 1994; Standifer et al., 1996). On the other hand, it is also 
possible that G2 usually plays a greater role in acute morphine analgesia (Sanchez-
Blazquez et al., 1995; Sanchez-Blazquez et al., 2001) and the current small difference 
between wildtype and Ga2 knockout mice is due to compensatory changes occurring in 
the antinociceptive pathways of the Ga2 knockout animal. Although such an 
explanation cannot be ruled out, I have excluded compensatory changes in the levels of 
other G proteins in the brains of drug free and morphine tolerant Ga2 knockout mice as 
a possible explanation. 
Following chronic morphine treatment, the behavioural difference between Ga2 
knockout mice and wildtype controls in response to morphine becomes very distinct and 
exhibits a gene dose relationship. This confirms previous observations from my 
laboratory that Ga2 is important for the development of tolerance to the supraspinal 
analgesic effects of morphine (Hendry et al., 2000). I have further demonstrated that 
this effect is not due to pharmacokinetic or behavioural factors. The excitatory 
morphine metabolites, M3G and nor-M3G, which have been postulated to play a role in 
the development of morphine tolerance (Smith and Smith, 1995; Smith and Smith, 
1998), are present in similar concentrations in the sera of tolerant wildtype and Ga2 
knockout mice. The lack of opportunity for behavioural learning also did not prevent 
the Ga2 knockout mouse from showing greater tolerance to the analgesic effects of 
morphine on the hotplate test. These results imply that the mechanism that contributes 
to the increased morphine tolerance in the Ga2 knockout mouse differs from those 
involved in the production of pharmacokinetic or behavioural tolerance to the analgesic 
effects of morphine. 
Besides analgesia, the µ opioid receptor has also been shown to be responsible for the 
toxicity effects of morphine (Loh et al., 1998; Sora et al., 2001a). Consistent with the 
observation of greater tolerance to supraspinal morphine analgesia in the Gaz knockout 
mouse, I found a si1nilar gene dose dependent development of tolerance to the lethality 
effects of morphine. Therefore, the loss of Ga2 not only produces greater tolerance to 
the supraspinal analgesic effects of morphine, but also to its lethality effects, which 
presumably is also mediated through supraspinal brainstem mechanisms (Florez and 
Hurle, 1993; Loh et al., 1998). 
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Ga2 , Gai2 and Gao have all been shown to be capable of coupling to µ receptors in the 
brain (Garzon et al., 1997b; Garzon et al., 1997a; Garzon et al. , 1998; Jiang et al. , 2001). 
The data presented here suggests that other heterotrimeric G protein a subunits are not 
able to take over the signalling functions of Ga2 after the development of morphine 
tolerance. There 1night therefore be distinct subtypes of the µ receptor which prefer 
binding to different G proteins (Garzon et al., 1998). Recent evidence suggests that there 
are multiple splice variants of the µ receptor. These splice variants differ in their tissue 
distributions and from one another in their carboxyl terminal amino acids (Abbadie et al., 
2000; Pan et al., 1999), a region of the receptor apparently important in determining G 
protein specificity (Namba et al., 1993). Some of these splice variants have also been 
found to exhibit different agonist induced desensitization properties (Abbadie and 
Pasternak, 2001; Koch et al., 2001; Zimprich et al., 1995). Receptor desensitization is an 
important 1nechanism thought to explain morphine tolerance (Bohn et al., 2000). Thus, it 
is possible that opioid receptors that preferentially couple to Ga2 have different 
desensitization properties compared to receptors that prefer other G protein a subunits. 
The heteromeric form of the µ and 8 receptor is another possible candidate of an opioid 
receptor that might couple Ga2 to transduce the analgesic effects of morphine after 
tolerance development. Ga2 is the only pertussis toxin resistant member of the Gai protein 
family (Ho and Wong, 2001). Using pertussis toxin as a tool, George et al. (2000) found 
pertussis toxin treatment completely abolished the high affinity binding of [D-Ala2,N-Me-
Phe4, Gly5 -ol]-enkephalin (DAMGO) and [D-Pen2,D-Pen5]-enkephalin (DPDPE) to the 
ho1non1eric fo1ms of the µ and 8 receptors respectively. However, pertussis toxin did not 
affect high affinity binding of DAMGO or DPDPE to the µ - 8 heteromer (George et al., 
2000). This suggests that ho1nomeric µ and 8 receptors are coupled to pertussis toxin 
sensitive G proteins, whereas the µ-8 heteromer is coupled to a pertussis toxin insensitive 
G protein. Furthermore, it was found that the µ-8 heteromer mediates pertussis toxin 
insensitive inhibition of adenylate cyclase (George et al., 2000), a property apparently 
unique to Ga2 (Ho and Wong, 2001). Interestingly, the µ-8 heteromer was also resistant to 
receptor desensitization after chronic opioid exposure (George et al., 2000). These 
properties of the µ-8 heteromer are consistent with that of a receptor that would couple to 
Ga2 to transduce the analgesic effects of morphine in tolerant animals. 
Since the morphine receptor is potentially capable of coupling to a few other G proteins 
(Sanchez-Blazquez et al., 1995), an alternative explanation of our data may be that the loss 
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of any one of these G proteins will produce greater morphine tolerance. This explanation 
implies that in the tolerant state, the pool of G proteins that is available for coupling to 
receptors may be severely limited, such that there is no G protein remaining to compensate 
for the loss of any one of the other G proteins. Such an explanation, however, is made less 
likely by the finding of a substantial functional receptor reserve in morphine tolerant mice 
on the analgesic assay (Sora et al., 2001 a), suggesting this is normally not the limiting 
factor in tolerant animals. As there is no difference in the total number of morphine 
receptors between tolerant wildtype and Ga2 knockout mice (Hendry et al., 2000), this 
raises the question whether the identity of the G proteins that couple to the morphine 
receptor in the tolerant state could be different from the population of G proteins that 
couple to the receptor in the drug free state. The data presented here suggest that other G 
proteins (notably Gai2 and Ga0 , which are present in much larger quantities than Ga2 in the 
brain), are not capable of co1npensating for Ga2 in the tolerant animal. Although 
disruptions to the functionality of G2 coupled opioid receptors is the most likely 
explanation of the hypertolerance phenotype of Ga2 deficient animals reported here, it is 
also possible that the phenotype was caused by changes in the functions of cells up or 
downstream of those that have opioid receptors, or that the development of animals 
lacking Ga2 has been altered in such a way that morphine tolerance is more readily 
expressed. 
Despite the observation of increased morphine tolerance, naloxone precipitated jumping, a 
prominent morphine withdrawal sign in rodents, is significantly attenuated in Ga2 
knockout 1nice. This result is in direct contradiction to that obtained by Way et al. (1969), 
where a linear positive correlation between morphine tolerance and naloxone precipitated 
jumping was repo1ied. Nonetheless, the other major signs of morphine withdrawal (wet 
dog shakes, weight loss) are not significantly affected by the absence of Ga2 • This 
indicates a dissociation of not only between morphine tolerance and dependence, but also 
between the different symptoms of dependence. Such dissociations have recently been 
observed in a number of different genetically modified mice. For instance, ~ arrestin-2 
knockout mice do not develop n1orphine tolerance, but they still become physically 
dependent (Bohn et al. , 2000). Protein kinase C-y mutant mice were less tolerant to 
morphine, but exhibited significantly more naloxone precipitated jumping behaviour. 
However, the other major withdrawal sign reported by the authors, naloxone induced 
weight loss, was significantly reduced (Zeitz et al., 2001). In substance P receptor 
knockout mice, naloxone precipitated jun1ping was significantly 
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decreased, but the other withdrawal signs were unchanged (Murtra et al. , 2000). These 
dissociations suggest that morphine withdrawal is not a unitary phenomenon (Calvino et 
al., 1979). Rather, it appears to be an ensemble of signs, which reflects the 
consequences of activation of different neuronal pathways by naloxone. The 
impairment of naloxone precipitated jumping in the Ga2 knockout mouse, may 
therefore result from a decrease in functioning of one of these pathways. Since Ga2 can 
potentially couple to a number of receptors along the neuronal pathway that modulates 
naloxone precipitated jumping behaviour, it is not possible to pinpoint the particular 
receptor(s) whose function(s) has been affected. Probable candidates include the 
substance P receptor (Murtra et al., 2000; Ueda et al., 1987) and the a2 adrenergic 
receptor (Taylor et al., 1988). The substance P receptor can couple to G2 in vitro (Ho 
and Wong, 1998), while the a2 adrenergic receptor has been shown to couple to G2 both 
in vitro (Ho and Wong, 1998) and in vivo (Yang et al., 2000). Additionally, 
serotonergic and dopaminergic neurotransmission may also exert regulatory influences 
on naloxone precipitated jumping behaviour (El Kadi and Sharif, 1995; Schulz et al., 
1978; Schulz and Herz, 1977) (Caille et al., 2002). There is evidence that some 
serotonin and dopamine receptors can couple to G2 in vitro (Ho and Wong, 1998). 
When the level of cyclic AMP was measured in the periaqueductal gray and striatum of 
animals undergoing naloxone precipitated withdrawal, the level of cyclic AMP in 
chronically morphine treated animals undergoing withdrawal was not above that of 
saline treated animals. This suggests that the supersensitization of adenylate cyclase 
activity that is frequently observed in cultured cells (Finn and Whistler, 2001; Ozawa et 
al., 1999; Tso et al., 2000; Tso and Wong, 2000a; Tso and Wong, 2000b; Tso and 
Wong, 2001) does not occur in most neurons in these two brain regions. Alternatively, 
it is possible that the adenylate cyclases present in morphine tolerant tissues need to be 
stimulated with either forskolin or Gas (Avidor-Reiss et al., 1997; Hanoune and Defer, 
2001) before a compensatory increase in cyclic AMP levels above saline or untreated 1 
tissues can be observed (Duman et al., 1988; Terwilliger et al., 1991; Van Vliet et al. , 
1991). However, it is interesting that the level of cyclic AMP in the striatum of tolerant 
Ga2 knockout mice undergoing withdrawal is higher than that of tolerant wildtype mice. 
The striatum is rich in opioid receptors (Petruzzi et al., 1997), and is known to be one of 
the brain regions that mediate the locomotor effects of morphine (Stevens et al. , 1986). 
1 Untreated tissues have approxin1ately the same level of cyclic AMP as saline treated tissues ( data not 
shown). 
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The present observation of a higher level of cyclic AMP in the striatum of withdrawn 
Ga2 knockout mice chronically treated with morphine may possibly suggest that most 
striatal Gaz knockout neurons are more withdrawn compared to striatal wildtype 
neurons. Phenotypically, this may relate to the trend for greater suppression of 
locomotor activity in these mice during naloxone precipitated withdrawal. Nonetheless, 
none of the withdrawal behaviours in the Ga2 knockout animals demonstrate a clear 
increase in intensity although the animals are very tolerant to morphine. This indicates 
a dissociation between 1norphine tolerance and physical dependence in these animals. 
In summary, I have shown that G2 plays an important role in mediating the supraspinal 
analgesic and lethality effects of morphine after tolerance development. The greater 
morphine tolerance that developed in the Ga2 knockout animals were not due to 
pharmacokinetic or behavioural mechanisms. I have also demonstrated a gene dose 
dependent decrease in naloxone precipitated jumping in the Ga2 knockout mouse. My 
data provides strong support for a dissociation between the different signs of physical 
dependence, indicating that morphine withdrawal is not a unitary phenomenon. It is 
therefore very important when measuring the degree of physical dependence, to 
consider a range of different withdrawal signs. In addition, the dissociation between 
morphine tolerance and naloxone precipitated jumping suggests that different G2 
signalling pathways are involved in mediating the effects of the loss of Gaz on 
morphine tolerance and physical dependence. Clinically, it may be possible to 
selectively affect these separate pathways to prevent the development of morphine 
tolerance and physical dependence in human patients. Future investigations using the 
Ga2 knockout mouse as an animal model should provide useful insights about the 
mechanisms underlying 1norphine tolerance and physical dependence. 
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Chapter 4 
Alteration of morphine induced locomotor activation in the Gx2 
knockout mouse 
4.1 Introduction 
Morphine binds to cell surface opioid receptors to produce analgesia (Matthes et al., 
1996), immunosuppression (Gaveriaux-Ruff et al., 1998), hypothalamic-pituitary axis 
stimulation (Roy et al., 2001), and locomotor activation in rodents (Sora et al., 2001a). 
Opioid receptors are G protein coupled receptors, which consist of three subtypes, 
designated µ, 8 and K. Although morphine can bind to all three receptor subtypes, it has 
the highest affinity for the µ receptor (Goldstein and Naidu, 1989; Raynor et al., 1994). 
Target inactivation of the µ receptor shows that all of the above effects are mediated by 
theµ receptor in mice (Becker et al., 2000; Gaveriaux-Ruff et al., 1998; Matthes et al., 
1996; Roy et al., 2001; Sora et al., 2001a; Tian et al., 1997). Like other opioid 
receptors, the µ receptor couples to G proteins from the inhibitory GTP binding protein 
family (Standifer and Pasternak, 1997). Available evidence suggests that the µ receptor 
can potentially couple to a number of these G proteins, including Gi2 (Garzon et al., 
1997a), G2 (Garzon et al., 1997b; Garzon et al., 1997a; Garzon et al., 1998) and G0 
(Jiang et al., 2001). However, less is known about the specific G protein(s) that mediate 
each of the many distinct effects of morphine in vivo. 
There are three mechanisms whereby morphine stimulates locomotor activity in rodents, 
each of which may involve different G proteins. The µ receptor is essential in the 
activation via all three routes as the locomotor response is abolished in mice lacking this 
receptor (Becker et al., 2000; Sora et al., 2001a; Tian et al., 1997). The first two are 
widely referred to as a dopamine independent and a dopamine dependent mechanism 
(Kalivas et al., 1983). The dopamine independent pathways engage primarily opioid 
receptors on neurons in the nucleus accumbens (Hakan and Henriksen, 1989; 
Herkenham et al., 1984), but 1nay also involve non-dopaminergic neurons in the ventral 
tegmental area that project to the accumbens (Hakan and Henriksen, 1989). Stimulation 
of accumbens opioid receptors increases locomotor activity in rodents even in the 
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presence of the mixed D l/D2 receptor antagonist, fluphenazine or after the destruction 
of dopaminergic terminals by 6-hydroxydopamine (Kalivas et al., 1983). The dopamine 
dependent pathway relies on dopaminergic neurons in the ventral tegmental area. 
Under normal conditions, these neurons are inhibited by their GABAergic neighbours 
tonically. However, when morphine or other opioids are present, they bind to µ 
receptors located on the GABAergic neurons, suppressing their activity and causing the 
inhibition on the dopaminergic cells to be relieved (Johnson and North, 1992; Tanda 
and Di Chiara, 1998). As a result, the dopaminergic neurons become more active, and 
release more dopamine from their synaptic terminals in the nucleus accumbens (Barrot 
et al., 1999; Cadoni and Di Chiara, 1999; Tanda and Di Chiara, 1998), leading to the 
motor hyperactivity observed in the animals (Kalivas and Duffy, 1990). 
The third mechanism involves corticosterone, which has been found to be capable of 
elevating dopamine level in the shell of the nucleus accumbens (Barrot et al., 2000) 
through the glucocorticoid receptor (Marinelli et al., 1998). Since morphine stimulates 
the hypothalamic pituitary axis (Buckingham and Cooper, 1986) to induce secretion of 
corticosterone through the µ receptor (Roy et al., 2001), this morphine elicited rise in 
corticosterone level may represent another mechanism whereby morphine can produce 
an increase in locomotor activity. The essential contribution of corticosterone in 
morphine induced hyperactivity is demonstrated by the significant reduction in motor 
activation, which is brought about by adrenalectomy (Marinelli et al., 1994) and when 
glucocorticoid receptors are blocked (Marinelli et al., 1998). 
The locomotor response of the Ga2 knockout mouse to morphine was examined in this 
Chapter. The data presented here suggests that G2 plays an important and complex role 
in the regulation of morphine stimulated motor behaviour. 
4.2 Results 
4.2.1 Morphine induced locomotor activation is altered in the Gaz 
knockout mouse. 
I began by comparing the locomotor activities of adult Ga2 knockout and wildtype mice 
in response to various doses of morphine. The responses were examined over a time 
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Figure 4.1: Altered morphine induced locomotor activation in the Gaz knockout mouse. 
Adult wildtype and Gaz knockout mice were treated with either saline vehicle, 3mg/kg, 
1 Omg/kg, 3 Omg/kg, 5 Omg/kg or 1 OOmg/kg morphine hydrochloride and locomotor 
activity of the mice were monitored for 6 hours. 
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period of six hours in order to capture the full activity profi le (Figure 4.1 ). Overall, 
relative to wildtype controls, the activity profiles of mice that lack Ga2 are characterized 
by a more rapid rise to a higher peak, and a shortening of the response (Two-way 
ANOV A: genotype x dose). The initially greater loco1notor activation in Ga2 knockout 
mice is reflected by the total activity measure in the first hour after morphine injection, 
which showed a highly significant genotype main effect (F(l,61)= 28.1, p<.001) (Figure 
4.2a). Peak locomotor activity also demonstrated a very significant genotype main 
effect (F(l,61)= 27.6, p<. 001), indicating the maximum locomotor stimulation inducible 
by morphine is greater in Ga2 knockout mice (Figure 4.2b ). The duration of response 
analysis also showed a highly significant genotype main effect (F(l,61)= 15.6, p<.001), 
suggesting that the duration of the morphine response has been shortened as a 
consequence of Ga2 's absence (Figure 4.2c). The genotype by dose interactions of all 
three analyses did not reach statistical significance, indicating that the genotype main 
effect did not depend on dose. This concurred with the consistent trend for Ga2 
la1ockout mice to exhibit greater motor activity during the first hour following morphine 
injection, higher peak activity and a shorter response duration across all doses tested. 
Since morphine stimulated motor behaviour undergoes changes during the adolescent 
period (postnatal day 33-43) (Spear et al., 1982) due to brain maturation (Moll et al., 
2000), I investigated whether pre-adolescent mice (postnatal day 24-27) would have a 
si1nilar response profile to morphine. When pre-adolescent Ga2 knockout mice were 
injected with 50mg/kg of 1norphine, their locomotion was characterized by an 
instantaneous rise to the peak and a shortened duration of response (t(12) = 2.55, p<.05) 
(Figure 4.3). Loco1notor activity in the first hour following morphine treatment was also 
significantly enhanced in adolescent Ga2 knockout mice (t(12)= 2.92, p<.05). 
Therefore, the alteration in morphine stimulated motor behaviour as a result of the 
absence of Ga2 developed early in life. 
4.2.2 The enhanced locomotor activation to morphine cannot be explained 
by an increase in plasma corticosterone levels 
The initial climb to the peak in motor activity after morphine administration is likely to 
be contributed by a nu1nber of factors. One of them may be the plasma level of 
corticosterone, which exerts a profound influence on morphine stimulated motor 
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Figure 4.2: Analyses of morphine induced locomotor activation in the Ga2 knockout 
mouse. (A) Total activity (beam breaks) in the first hour following morphine injection. 
(B) Peak activity (C) Duration of the morphine induced response. The statistical 
analyses here were performed using the student's t test +/+ vs -/-: *p<.05, ** p<.01, 
***p<.001. Due to the small number of animals at some of the doses assessed (see 
Figure 4.1 ), there was insufficient power to detect a significant difference using this 
statistical tool. However, the significant trend due to the effect of genotype across all 
doses, result in a significant main effect for genotype, and no interaction with dose in 
the overall ANOVA (see Results). 
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Figure 4.3: Altered morphine induced locomotor activation in adolescent wildtype and 
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Figure 4.4: Morphine induced significantly greater corticosterone secretion in the Ga2 
knockout mouse. (A) Corticosterone levels were determined in mice that were not 
treated (14 +/+, 19 -/-), mice treated with saline vehicle (10 +/+, 12 -/-); and mice 
treated with 50mg/kg morphine and bled 30 minutes (8 +/+, 8 -/-) or 60 minutes (7 +/+, 
7 -/-) after the injection. (B) Pretreatment of mice (7 +/+, 7 -/-) 2 hours beforehand with 
1 00mg/kg metyrapone abolished the corticosterone rise induced by morphine. 
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behaviour (Deroche et al. , 1995; Frances et al., 2000; Marinelli et al. , 1994; Stohr et al. , 
1999). I 1neasured the levels of plasma corticosterone in wildtype and Ga2 knockout 
1nice after 1norphine administration and found the levels to be significantly augmented 
in the mutant 1nice (Figure 4.4a). Therefore, I proceeded to investigate whether this 
higher plasma corticosterone level is responsible for the greater initial locomotor 
activation in the Gaz knockout mouse. The corticosterone synthesis inhibitor, 
1netyrapone, was used to prevent the elevation of corticosterone produced by morphine 
in mice of both genotypes (Figure 4.4b ). Consistent with a role for corticosterone in 
morphine sti1nulated motor behaviour (Two-way ANOV A: genotype x dose), 
metyrapone caused a dose dependent reduction in peak activity (F(2,35)= 8.04, p<.002) 
and locomotor activity during the first hour after morphine administration (F(2,35)= 
11.8, p<.001) in mice of both genotypes (Figure 4.5). However, the Ga2 knockout 
1nouse still demonstrated greater locomotor activation (F(l,35)=38.5, p<.001: 
significant genotype main effect for total activity during the one hour after morphine 
treatment and F(l,35)= 20.6, p<.001: significant genotype main effect for peak activity, 
the interaction terms in both analyses were not significant). Therefore, there are other 
more pertinent factors that contribute to the enhanced locomotor stimulation by 
morphine in the Ga2 knockout mouse. 
4.2.3 Examination of K opioid receptor mediated inhibition of locomotor 
activity in the Ga2 knockout mouse. 
Although morphine stimulated locomotor activity has been attributed to the µ receptor 
at morphine doses< l0mg/kg (Becker et al., 2000; Sora et al. , 2001a; Tian et al. , 1997), 
it is possible that at the higher morphine doses employed in the present study, morphine 
which has lower affinities for the 8 and K receptors (Goldstein and Naidu, 1989; Raynor 
et al. , 1994), also activated these receptors (Nari ta et al., 1993). Since stimulation of the 
8 receptor increases locomotion (Negri et al. , 1999) while stimulation of the K receptor 
depresses motor activity (Simonin et al., 1998), the locomotor response profile elicited 
by high morphine doses might be the sum of the stimulatory and inhibitory influences 
caused by the activation of all three opioid receptor subtypes. Accordingly, I surmised 
that if the K receptor n1ediated locomotor suppression is transduced through Gz, then the 
absence of G2 signaling in the Ga2 knockout mouse might explain their greater motor 
activity through removal of a source of inhibitory influence. 
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Figure 4.5: The corticosterone synthesis inhibitor, metyrapone reduces locomotor 
activity in mice. Wildtype and Ga2 knockout mice were either pre-treated with 
50mg/kg (6 +/+, 6 -/-) or 100 mg/kg (6 +/+, 6 -/-) metyrapone, followed by 50mg/kg 
morphine hydrochloride 120 minutes later. (A) Locomotor activity profile monitored 
over 240 minutes after morphine injection. (B) Locomotor activity of mice in the first 
60 1ninutes after morphine injection. (C) Maximum activity inducible by morphine 
within any 15 minute time bin. The data of mice (10 +/+, 7 -/-) not pre-treated with 
metyrapone in Figures 4.5b and 4.5c were taken from Figure 4.2. *p<.05, ** p<.01, 
***p<.001 
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Figure 4.6: Suppression of locomotion by the K receptor agonist, U-50,488H. Wildtype 
and Ga2 knockout mice were injected subcutaneously with either saline vehicle or 
3mg/kg, 1 0mg/kg U-50,488H. (A) Time course of U-50,488H effects on locomotor 
activity in wildtype and Ga2 knockout mice. (B) Dose dependent depression of 
locomotor activity in wildtype and Ga2 knockout mice by U-50,488H. 
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To test this hypothesis, I investigated the locomotor responses of wildtype and Ga2 
knockout mice to the K receptor agonist, U-50,488H (Two-way ANOV A: genotype x 
dose). The administration of U-50,488H produced a dose dependent inhibition of 
locomotor activity (Drug dose main effect: F(2,38)= 17.0, p<.001) (Figure 4.6). 
However, there was no difference in the responses of mice from the two genotypes 
(Genotype main effect: F(l,38)<1, NS). 
4.2.4 Duration of morphine induced analgesia in the Gaz knockout mouse 
Besides stimulating locomotor activity in rodents, morphine is also well known as a 
powerful analgesic. Since the duration of morphine stimulated locomotor activity appear 
to be slightly but significantly reduced in Ga2 knockout mice (Figures 4.1 to 4.3), I 
wondered whether the duration of the effects of morphine analgesia would be similarly 
decreased in these mice. To investigate this possibility, wildtype and mutant mice were 
administered 50mg/kg of morphine acutely, and morphine analgesia was evaluated using 
the hotplate test. Intriguingly, relative to wildtype mice, the duration of morphine 
analgesic effects also appeared to be slightly but significantly reduced in Ga2 knockout 
mice (Genotype main effect: F(l,21)= 8.99, p<.01) (Figure 4.7). 
4.3 Discussion 
Mice deficient in Ga2 exhibit a complex alteration in morphine stimulated locomotor 
behaviour, which is characterized by a greater increase in motor activity in the immediate 
time period following morphine injection and a shortened duration of the morphine 
response. I have also found morphine to stimulate greater corticosterone secretion in the 
Gaz knockout mouse. However, this larger rise in plasma corticosterone is likely to play 
only a secondary role in explaining the increased morphine sti1nulated motor activity in 
mutant mice. The augmented locomotor responses of mutant mice were still present even 
after the differences in n1orphine induced corticosterone levels have been suppressed by 
pre-treatment with the corticosterone synthesis inhibitor, metyrapone. I have also shown 
that there was no difference between mutant and wildtype mice in the inhibition of motor 
activity caused by activation of the K receptor. Accordingly, even if high doses of 
morphine stimulate K receptors, the greater locomotor activation in Ga2 knockout mice is 
not due to an impairment of K receptor function. 
92 
I-+-+/+ -o- -1- I 
100 
80 
w 60 
a.. 
~ 40 ~ 0 
20 
0 
0 50 100 150 200 250 300 
Time after 50mg/kg morphine hydrochloride {minutes) 
Figure 4. 7: The duration of morphine analgesia is reduced in Ga2 knockout mice. 
Wildtype and Ga2 knockout mice (12 +/+, 11 -/-) were injected subcutaneously with 
50mg/kg morphine hydrochloride and morphine analgesia was evaluated using the 
hotplate test at 30 minutes, at 120 minutes, and then every half hour thereafter. 
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Despite the purported involvement of dopamine independent pathways in the locomotor 
activity stimulated by morphine (Kalivas et al., 1983), the importance of dopamine 
dependent mechanisms is highlighted by the abolition of the response in mice lacking 
either the dopamine transporter (Spielewoy et al., 2000) or the dopamine Dl receptor 
(Becker et al., 2001). Coincidentally, cocaine which increases locomotor activity via a 
dopaminergic mechanism (Uhl et al., 2002), also stimulates greater locomotor activation 
in Gaz knockout mice (Yang et al., 2000). An alteration of dopaminergic 
neurotransmission in mutant mice might therefore account for their augmented response 
to both morphine and cocaine. Although there is currently no evidence that Gz couples 
to dopamine receptors in vivo, in vitro experiments have shown Gz to be capable of 
coupling to dopamine D2, D3, D4 (Obadiah et al., 1999) and D5 receptors (Sidhu et al., 
1998). Morphine and cocaine have been reported to induce a greater elevation of 
extracellular dopamine concentration in the striatum when presynaptic dopamine D2 
autoreceptors are absent (Rouge-Pont et al., 2002). Since dopamine D2 and D3 
receptors are present in the nucleus accumbens (Bancroft et al., 1998; Le Moine and 
Bloch, 1996; Levant, 1998) where some may serve as autoreceptors (Cragg and 
Greenfield, 1997), and an elevated extracellular dopamine level in the accumbens is 
related to higher locomotor activity in mice (Kalivas and Duffy, 1990), an impairment 
of dopamine autoreceptor function in Gaz knockout mice, would help explain their 
greater locomotor activation by both morphine and cocaine. 
The duration of morphine induced locomotor and analgesic effects also appears to be 
shortened in Gaz knockout mice. The two effects exhibit different time courses 
( compare Figures 4.1 and 4. 7) and are mediated by opioid receptors ( of predominantly 
theµ subtype) in different parts of the brain (Pavlovic and Bodnar, 1998; Tanda and Di 
Chiara, 1998). The coincidental shortening in the duration of both responses is 
therefore intriguing and may reflect a unique sequel following the loss of Gaz signaling. 
Evidence currently available suggests that the µ receptor signals through both Gz and 
Gi2 in the brain (Garzon et al., 1997a; Garzon et al., 1997b; Garzon et al., 1998). In the 
absence of Gz, µ receptor signaling can still occur via Gi2. However, compared to Gai2 
and other G protein a subunits, Gaz is unusual in possessing a very sluggish rate of 
GTP hydrolysis (Casey et al., 1990). This unique biochemical property allows the 
activated form of Gaz to remain in the active state for a relatively long period of time 
until it encounters a Gaz specific GTPase activating protein (Wang et al., 1997). The 
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data presented here is consistent with the shortened duration of the morphine responses 
being related to the loss ofµ receptor mediated Ga2 signaling. 
Another notable finding in the present study is the greater stimulation of corticosterone 
release by morphine in Ga2 knockout mice. The mechanism by which morphine 
elevates plasma corticosterone levels is not well understood and could be mediated 
indirectly through the effects of morphine on other neurotransmitter systems (Pechnick, 
1993). However, the µ receptor is clearly essential for this effect as it was abolished in 
mice lacking the receptor (Roy et al., 2001). On the other hand, two recently discovered 
opioid peptides, endomorphin-1 and endomorphin-2, which bind with high specificity 
and affinity to the µ receptor (Zadina et al., 1997), failed to stimulate plasma 
corticosterone levels when injected intracerebroventricularly (Coventry et al., 2001). 
This led the authors to propose that morphine may activate a different subset of µ 
receptors compared to the endomorphins (Coventry et al., 2001). Notwithstanding, the 
current result cannot be explained by a decrease in µ receptor signaling as a result of the 
loss of Ga2 • The data suggests indirectly that the morphine stimulated corticosterone 
response must involve at least one other G2 coupled receptor, which normally inhibits 
corticosterone secretion. 
In conclusion, I have shown that G2 is involved in the regulation of morphine stimulated 
locomotor responses. The locomotor activating effects of psychostimulants are often 
related to their rewarding effects (Wise, 1987). G2 may therefore play a role 1n 
determining the vulnerability of drug users to become dependent on addictive drugs. 
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Chapter 5 
G2 couples to dopamine D2-like receptors in vivo. 
5.1 Introduction 
Dopamine is involved in the regulation of many behavioural and physiological 
functions within the body, including motor processes (Gerfen, 1992; Jackson et al., 
1989), learning (Graybiel, 1995), motivated behaviour (Kelley and Berridge, 2002), 
body temperature regulation (Boulay et al., 1999a; Lipton and Clark, 1986) and 
pituitary hormone release (Borowsky and Kuhn, 1992; Diaz-Targa et al., 2002; Durham 
et al., 1998). Dopaminergic pathways also participate in the locomotor stimulating and 
rewarding effects of addictive drugs (De Vries and Shippenberg, 2002; Everitt and 
Wolf, 2002; Herz, 1998; Spanagel and Weiss, 1999). The effects of dopamine on 
nervous tissues are exerted through cell surface receptors coupled to G proteins. To 
date, a total of five dopamine receptors have been cloned in mammals, and they have 
been classified to belong to one of two families according to their pharmacological 
profiles, amino acid sequence homology in their hydrophobic domains and the structure 
of their genes (Missale et al., 1998). The dopamine Dl-like receptor family consists of 
dopamine D 1 and D5 receptors. They are coupled to G proteins from the Gs family to 
mediate stimulation of adenylate cyclase (Corvol et al., 2001; Sidhu and Niznik, 2000). 
Additionally, the D 1 receptor may also couple to G0 (Kimura et al., 1995), Gi (Uh et al., 
1998) and Gq (Jin et al., 2001) and the D5 receptor may couple to G2 (Sidhu et al., 1998) 
and Gq (Jin et al., 2001). The dopamine D2-like receptor family comprises the 
alternatively spliced D2 long and D2 short receptors (Monsma, Jr. et al., 1989), D3 long 
and D3 short receptors (Fishburn et al., 1993), as well as D4 receptors (Oak et al., 
2000). All of these receptors are coupled to members of the inhibitory GTP binding 
protein fainily to mediate inhibition of adenylate cyclase (Obadiah et al., 1999; Sidhu 
and Niznik, 2000). In addition, there is also evidence that the D3 receptor may couple 
to Gs (Obadiah et al., 1999) and Gq (Newman-Tancredi et al., 1999). 
Most of the studies on G protein coupling of dopamine receptors have either been 
performed in cell lines by transfection of the receptors and G protein a subunits or in 
tissues using broken membrane preparations. Although these methods are very useful 
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for preliminary identification of possible G proteins that a receptor can couple to, the 
results obtained must be confirmed in intact cells from body tissues, where the presence 
or absence, as well as the levels of expression of various components in the G protein 
signaling cascade are tightly regulated (Mende et al., 1998; Zelenin et al., 2002) and the 
existence of cellular compartments may restrict receptors from accessing G proteins in 
other parts of the cell (Allgeier et al., 1997; Degtiar et al., 1997; Ostrom et al., 2000). 
Both of these factors are known to play an important role in determining the specificity 
of G protein signaling in native tissues (Dumont et al., 2002). In addition, the 
constitution of the ~y subunits that associate with the a subunit can also have a 
significant impact on the specificity of receptor coupling (Hou et al., 2000; McIntire et 
al., 2001; Wang et al., 2001). Differences in the ~y subunit composition of G proteins 
in various cell lines and tissue types may potentially explain the many discrepant 
findings in the literature. For instance, whereas G0 but not Gq was found to couple to 
D 1 receptors in one study (Kimura et al., 1995), the reverse conclusion was arrived in 
another study (Jin et al., 2001). Similarly, Gs could couple to the D3 receptor in one 
study (Obadiah et al., 1999), but not in another (Newman-Tancredi et al., 1999). The 
use of native tissues may obviate the laborious task of identifying the specific ~y dimer 
that associate with the transfected a subunit since the observed receptor G protein 
coupling would be natural. 
For members of the dopamine D2-like receptor family, G0 has been proposed to be the 
predominant G protein that couple to most receptors in the brain, with Gi1, Gi2 and Gi3 
playing a minor role (Jiang et al., 2001 ). This conclusion is based on the inability of 
GTP to displace 125I-sulpiride binding in brain sections from the Ga0 knockout mouse 
when dopamine is present. This suggests that in the absence of Ga0 , almost all sulpiride 
sensitive dopamine receptors are in the low affinity G protein uncoupled form, which 
implicates the involvement of Ga0 in receptor coupling. In contrast, high affinity 
dopamine binding is not affected in mice lacking both Gail and Gai2 or when Gai1 and 
Gai3 are absent. In the Gai mutant animals, dopamine retains its ability to catalyse the 
exchange of GDP for GTP on the receptor bound G protein. In doing so, the receptor 
converts to the low affinity form due to G protein uncoupling and this is visualized as 
the rightward displacement of the 125I-sulpiride binding curve (Jiang et al., 2001). 
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Since sulpiride and dopamine bind to all D2-like receptors with si1nilar affinities 
(Missale et al., 1998), the result implies that G0 couples to most D2, D3 and D4 
receptors in the brain. However, these data do not preclude the coupling of D2-like 
receptors to other G proteins. G0 is by far the most abundant G protein in the brain 
(Stemweis and Robishaw, 1984), and the radiobinding technique used is unlikely to 
possess sufficient sensitivity to detect dopamine receptor coupling attributed to other 
significantly less abundant G proteins like G2 • Furthermore, the high affinity receptor 
binding state of some D2-like receptors is known to be critically dependent on subtle 
changes in assay conditions, such as magnesium concentration (Bancroft et al., 1998). 
The data presented in Chapter 4 suggested that the peak locomotor response to 
morphine was significantly increased in Gcx2 knockout mice, and the result could not be 
explained by the higher morphine induced corticosterone secretion in these mice. Gcx2 
knockout mice also showed a similarly enhanced locomotor stimulatory response to the 
psychostimulant (Yang et al., 2000). Since the augmentation of locomotor activity 
elicited by cocaine (Uhl et al., 2002; Xu et al., 1994) and to a certain degree, morphine 
(Barrot et al., 1999; Cadoni and Di Chiara, 1999; Kalivas et al., 1983; Kalivas and 
Duffy, 1990) was dependent on central dopaminergic neurotransmission, the increased 
locomotor activity to both drugs in .Ga2 knockout mice could imply an alteration in the 
dopaminergic pathways of these mice. The present study was therefore conducted to 
exainine whether dopamine receptor functions were altered in the Gcx2 knockout mouse. 
5.2 Results 
5.2.1 Locomotor activation by amphetamine in the Gcxz knockout mice 
Since mice lacking Gcx2 have_ been reported to demonstrate greater cocaine induced 
locomotor activation (Yang et al., 2000), I began by examining whether amphetamine 
stimulated locomotor activity are also augmented in these mice. Both amphetamine and 
cocaine produce an elevation of extracellular dopamine concentrations in the nucleus 
accumbens, which is believed to contribute to the motor activating effects of these drugs 
(Pontieri et al. , 1995). As shown in Figure 5 .1 , amphetamine caused a significantly 
greater locomotor response in Gcx2 knockout mice (Genotype main effect: F(l ,25)= 17 .1 
, p<.001 compared to wildtype controls). This increase in locomotor activity of Gcxz 
knockout mice occurred throughout most of the duration of the drug effect (Genotype 
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Figure 5 .1: Locomotor activation induced by amphetamine is significantly increased in 
Gaz knockout mice. Mice were given subcutaneous injection of either saline vehicle, 
lmg/kg or 3mg/kg d-amphetamine and the locomotor activity of the mice was 
1nonitored over 4 hours. The values shown are the means± SEM. (A) Time course and 
(B) total activity of Ga2 knockout and wildtype mice in 4 hours. +/+ vs -/-: *p<.05, 
**p<.01 
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by Time interaction: F(3.9,96.7)=1.8, NS). 
5.2.2 The locomotor response of the Gaz knockout mouse to SKF 38393 
The motor activating effects of psychostimulants are mediated through dopamine 
receptors (Ushijima et al., 1995; van den et al., 1988; Xu et al., 1994) (Neisewander et 
al., 1995; Xu et al., 2000b). The simultaneous activation of postsynaptic Dl and D2-
like receptors are believed to be required for stimulation of locomotor activity in 
rodents (Dreher and Jackson, 1989). Activation of presynaptic D2-like autoreceptors, 
on the other hand, appear to curb locomotor activity by decreasing dopamine release 
(Starr and Starr, 1986; Usiello et al., 2000). I tested the locomotor response of the mice 
to the Dl-like receptor agonist, SKF 38393 (Tirelli and Terry, 1993). At l0mg/kg and 
1 00mg/kg, SKF 38393 caused a significant enhancement of locomotor activity in both 
wildtype and Gaz knockout mice (Figure 5.2) (Drug dose main effect: F(2,38)= 16.5, 
p<.001). However, there was no significant difference in the magnitude of locomotor 
responses between mice of the two genotypes (Genotype main effect: F(l,38)<1, NS). 
5.2.3 The locomotor response of the Gaz knockout mouse to quinpirole 
Since the inhibition of presynaptic D2-like autoreceptors has been shown to increase 
locomotor activation induced by psychostimulants (Ushijima et al., 199 5; van den et al., 
1988), I speculated that if the receptor is coupled to Gz, the absence of Gz may lead to 
an impairment of receptor function, and hence explain the greater locomotor activity in 
Gaz knockout mice. Therefore, I examined the responses of Gaz knockout mice to low 
doses of quinpirole, which preferentially act on presynaptic D2-like receptors to inhibit 
locomotor activity (Usiello et al., 2000; Wang et al., 2000; Zhuang et al., 2001). 
Consistent with my hypothesis, a significant reduction in the locomotor suppressive 
effects of quinpirole in Gaz knockout mice was observed (Figure 5.3) (Genotype main 
effect: F(l,41)=12.5, p<.01). 
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Figure 5 .2: Locomotor responses of wild type and Ga2 knockout mice to the DI-like 
receptor agonist, SKF 38393. Means ± SEM are shown. Mice were injected 
subcutaneously with saline vehicle (10 +/+, 10 -/-), 10 mg/kg (6 +/+, 6 -/-) or 100 mg/kg 
(6 +/+, 6 -/-) SKF 38393 and total locomotor activity over 4 hours was measured. 
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Figure 5.3: Locomotor responses of wildtype and Ga2 knockout mice to the D2-like 
receptor agonist, quinpirole. Means ± SEM are shown. Mice were given a 
subcutaneous injection of either saline vehicle (10 +/+, 10 -/-) , 0.3mg/kg (5 +/+, 7 -/-), 
lmg/kg (11 +/+, 12 -/-) or 2mg/kg (5 +/+, 7 -/-) quinpirole, and locomotor activity was 
monitored for 90 minutes. +/+vs-/-: *p<.05. 
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5.2.4 Quinpirole induced inhibition of dopamine release in the nucleus 
accumbens 
Quinpirole has been repo1ied to suppress locomotor activity by acting on dopamine D2-
like receptors in the core of the nucleus accumbens (Swanson et al., 1997). To confinn 
that presynaptic D2-like receptor function has been compromised in the Gcx2 knockout 
1nouse, the inhibition of electrically evoked dopamine release by quinpirole in the 
nucleus accu1nbens core was 1neasured (Figure 5.4). While the infusion of l00ng of 
quinpirole into the accu1nbens core inhibited dopamine release by 79.5 ± 1.8% in 
wildtype mice (n=7) after 15 minutes, the same dose of quinpirole caused only 60.6 ± 
4.2% inhibition of dopainine release in Gcx2 knockout mice (n=8) (t(l3)= 3.88, p<.01) 
(Figure 5.5). All but one of the mutant mice demonstrated lesser inhibition than 
wildtype mice 15 minutes after quinpirole infusion. At 30 minutes post-infusion, the 
difference between the genotypes remained significant (t(l3)= 2.67, p<.05). After 45 
1ninutes, the difference gradually diminished due to data variability caused mainly by a 
rapid recovery seen in one wildtype mouse. Pre-treatment with 1 µg of haloperidol 15 
1ninutes before quinpirole infusion abolished the inhibition of dopamine release by 
quinpirole ( data not shown), suggesting the effect is specific to dopamine D2-like 
receptors. 
5.2.5 Quinpirole induced hypothermia 
Sti1nulation of dopan1ine D2 receptors also produce hypothermia in mice (Boulay et al., 
1999a). There is controversy whether this is mediated via a presynaptic (Zarrindast and 
Tabatabai, 1992) or postsynaptic (Boulay et al., 1999a; Sanchez and Arnt, 1992) D2 
mechanism. I evaluated the hypothermic effects of quinpirole and found the lack of 
Gcxz to significantly attenuate the decrease in body temperature elicited by the dn1g 
(Figure 5.6) (Genotype main effect: F(l,38)= 27.3, p<.001), which occurred at all 
quinpirole doses tested (Genotype by Dose interaction: F(2,38)=1.72, NS). 
5.2.6 Quinpirole induced ACTH release 
Dopaininergic pathways also participate in the regulation of hormone release. Systemic 
administration of quinpirole caused a dose-dependent increase in plasma 
adrenocorticotropic hom1one (ACTH) level, which can be antagonized by the D2-like 
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Nucleus Accumbens 
+1.54 
Medial Forebrain Bundle 
-1.94 
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Figure 5.4: Representative coronal sections of the brain showing placement of 
ainperometric recording electrodes in the nucleus accumbens (gray area) and 
stimulating electrodes in the medial forebrain bundle (gray area) of wildtype ( closed 
circles) and Gaz knockout ( closed triangles) mice. The numbers correspond to distance 
(mm) from Bregma. Abbreviations: NAc, nucleus accumbens core; NAs nucleus 
accumbens shell; ac, anterior commissure; MFB, medial forebrain bundle; mt, 
mammillothalamic tract; cp, cerebral peduncle. (The figures are adapted from Franklin 
and Watson, 1997). 
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Figure 5.5: Quinpirole inhibition of dopamine release is significantly attenuated in the 
nucleus accumbens of the Ga2 knockout mouse. The release of dopamine from synaptic 
terminals in the core of the nucleus accumbens was electrically evoked by stimulation 
of their axons in the medial forebrain bundle. After pre-drug baseline responses have 
been recorded, 1 00ng of quinpirole was infused via a cannula into the nucleus 
accumbens, and dopamine release in the nucleus accumbens core was recorded every 15 
minutes for a total duration of 90 minutes. The mean ± SEM responses from 7 +/+ and 
8 -/- mice are shown. +/+vs-/-: *p<.05, **p<.01. 
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Figure 5.6: Hypothermia induced by quinpirole is significantly reduced in the Gaz 
knockout mouse. Mice were injected subcutaneously with saline vehicle (7 +/+, 7 -/-), 
0.1 mg/kg (8 +/+, 8 -/-), 0.3mg/kg (7 +/+, 7 -/-) or 1 mg/kg (7 +/+, 7 -/-) quinpirole and 
their body temperatures were measured using a rectal thermistor probe. (A) Change in 
body temperature of+/+ and-/- mice in response to lmg/kg quinpirole injected at time 
0. The plotted values are the mean body temperatures ± SEM. (B) Hypothermia 
induced by various doses of quinpirole 15 minutes after injection. +/+ vs -/-: * p<.05, 
**p<.01. 
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Figure 5. 7: Quinpirole stimulation of plasma ACTH is significantly attenuated in the 
Ga2 knockout mouse. Mice were injected with saline vehicle (8 +/+, 8 -/-), l0µg/kg 
corticotropin releasing hormone (CRH) (8 +/+, 8 -/-), lmg/kg quinpirole (7 +/+, 6 -/-) or 
0.5mg/kg 8-hydroxy-dipropylamino-tetralin (8OH-DPAT) (8 +/+, 9 -/-), and blood were 
collected via the retro-orbital route either 15 (all drugs except CRH) or 30 minutes 
(CRH) after the injection. ACTH levels in blood plasma were determined using a 
commercial RlA kit. The mean plasma ACTH levels± SEM are shown. +/+vs-/-: * 
p<.05. 
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specific antagonist, sulpiride (Borowsky and Kuhn, 1992). This quinpirole induced increase in 
ACTH level is also significantly attenuated in Ga2 knockout mice (Genotype main effect: 
F(l,25)= 5.36, p<.05) (Figure 5.7). The mechanism by which dopamine agonists stimulate 
ACTH release remains obscure, but may depend on corticotrophin releasing honnone (CRH) 
secreted by hypothalamic neurons. As an additional control, we also examined CRH stimulated 
ACTH release. Intraperitoneal administration of 1 0µg/kg CRH produced a significant rise in 
plasma ACTH (Drug dose main effect: F(l,28)= 12.5, p<.01), as previously described (Muglia 
et al., 2000). However, there was no significant difference observed between wildtype and Ga2 
knockout mice (Genotype main effect: F(l,28)<1, NS) (Figure 5.7). The serotonin lA receptor 
agonist, 8-hydroxy-dipropylamino-tetralin (8OH-DPAT), is known to stimulate plasma ACTH 
via hypothalamic CRH (Serres et al., 2000). As expected, 0.5mg/kg of 8OH-DPAT caused a 
significant rise in plasma ACTH fifteen minutes after the injection (Figure 5.7) (Drug dose 
main effect: F(l,29)= 50.5, p<.001). However, there was no difference between wildtype and 
Ga2 knockout mice (Genotype main effect: F(l,29)<1, NS), suggesting the CRH receptor 
involved in ACTH secretion is not impaired in the Ga2 knockout mouse. 
5.2. 7 Absence of compensation by other G protein a subunits 
Finally, I examined whether the alteration of dopamine D2-like receptor function could be 
explained by changes in the expression levels of other G protein a or ~ subunits. Western blot 
analyses did not reveal compensatory changes in the levels of any of these proteins (Figure 5.8). 
5.3 Discussion 
Mice deficient in Ga2 demonstrate hyperactivity to morphine (Figure 4.1 and 4.2) and to the 
psychostimulants, cocaine (Yang et al., 2000) and d-amphetamine (Figure 5 .1 ). Since central 
dopaminergic pathways participate in the motor activating effects of morphine (Barrot et al. , 
1999; Cadoni and Di Chiara, 1999; Kalivas et al., 1983; Kalivas and Duffy, 1990) and these 
psychostimulants (Ushijima et al., 1995; van den et al., 1988; Xu et al., 1994) (Neisewander et 
al., 1995; Uhl et al., 2002; Xu et al., 2000b), I have examined the involvement of Gz in 
signaling mediated by dopamine receptors. G2 is a member of the inhibitory guanine nucleotide 
binding protein family. It is widely found in many regions of the brain where dopamine 
receptors are located, including the cerebral cortex, amygdala, caudate nucleus, putamen, 
nucleus accumbens, substantia 
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Figure 5.8: Levels of Gail, Gai2, Gai3, Ga0 , Gas, Gag, Ga2 , and Gp in the brains from 
wildtype and Ga2 knockout mice. The proteins from the brains of wildtype and Gaz 
knockout mice were analysed by SDS-polyacrylamide gel electrophoresis, electro-
transferred onto nitrocellulose, and blotted with antibodies specific for Gai1, Gai2, Gai3, 
Gao, Gas, Gag, Ga2 , and GPcommon• The experiment was repeated twice. There was 
some slight variation in the intensity of the protein bands due to protein transfer and 
blotting (see also Figures 3.8 and 3.9). However, no discernible difference could be 
observed between any of the Ga and Gp subunits. 
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nigra, hypothalamus and hippocampus (Glick et al., 1998; Hinton et al., 1990; Serres et 
al., 2000; Wang et al., 1998). In vitro experiments suggest that G2 can couple to many 
of the same receptors as Gila, including dopamine D2-like receptors (Ho and Wong, 
1998; Sidhu and Niznik, 2000). The data presented here demonstrate for the first time, 
that G2 is coupled to D2-like receptors in multiple dopaminergic pathways in vivo. 
In COS-7 cells, Gz derived from transfection of the Ga2 subunit, has been shown to be 
capable of coupling to both the long and short isoforms of the D2 and D3 receptors, and 
the D4 receptor, with the D4 receptor demonstrating the strongest coupling (Obadiah et 
al., 1999). Interestingly, D4 receptor knockout mice are also more responsive to the 
locomotor stimulating effects of ethanol, cocaine and methamphetamine (Rubinstein et 
al., 1997). D4 receptors are predominantly found in cerebral cortex (particularly the 
pre-frontal cortex), amygdala, hypothalamus and pituitary (Oak et al., 2000). They are 
also present at moderate to low levels in the caudate-putamen and nucleus accumbens, 
respectively (Rivera et al., 2002). In the nucleus accumbens, their presence in the core 
region has not been investigated. However, in the shell region, the majority of D4 
receptors appear to serve as presynaptic heteroreceptors (Svingos et al., 2000), where 
they regulate the release of other neurotransmitters such as glutamate (Tarazi et al., 
1998). It is therefore less likely that the attenuated locomotor suppressive effects of 
quinpirole in the Ga2 knockout mouse is due to impairment of D4 receptor function 
since the inhibition of locomotor activity by quinpirole has been widely attributed to 
activation of dopamine autoreceptors (Lappalainen et al., 1990; Van Hartesveldt et al., 
1994; Wang et al., 2000; Zhuang et al., 2001). 
Among other members of the D2-like receptor family, both D2 and D3 receptors have 
been proposed to be capable of functioning as autoreceptors to inhibit dopamine release. 
However, studies of D2 and D3 receptor knockout mice have found the D2 receptor to 
be prominent in this role (Benoit-Marand et al. , 2001; L'hirondel et al., 1998; Rouge-
Pont et al., 2002; Schmitz et al., 2001), with the D3 receptor making only a minor 
contribution (Joseph et al., 2002). While most of these studies have been performed in 
the dorsal striatum, D2 receptors are also present in the nucleus accumbens (both core 
and shell) (Bancroft et al., 1998; Le Moine and Bloch, 1996; Levant, 1998), and are 
likely to perform the same role. D3 receptors are also found in the core and shell 
regions of the nucleus accumbens (Bancroft et al., 1998). However, these may be 
postsynaptic receptors coupled to short-loop negative feedback pathways that exert an 
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inhibitory influence on dopamine release (Koeltzow et al., 1998). Therefore, a partial impairment in 
the function of the D2 autoreceptor and to a lesser likelihood, the D3 receptor can contribute to a 
decrease in electrically evoked dopamine release produced by quinpirole in the Ga2 knockout 
mouse. An alternative explanation of the data presented in Figure 5.5 is that the dopainine released 
by electrical stimulation was acting more efficiently on D2 autoreceptors in Ga2 knockout ani1nals, 
therefore partially occluding the effects of quinpirole added on top of natural dopamine. However, 
this explanation is unlikely as D2 autoreceptors in Ga2 knockout animals are not fully saturated and 
can cause further depression of dopamine release with higher quinpirole doses ( data not shown). 
On the other hand, the hypothermic and hypolocomotor effects induced by D2-like agonists have 
been attributed solely to the D2 receptor, as these are abolished in the D2 receptor knockout mouse 
and retained in mice that lack the D3 receptor (Boulay et al., 1999a; Boulay et al., 1999b ). The 
present observations of an attenuation in both the hypothermic and locomotor depressing effects of 
quinpirole suggest that G2 is coupled to D2 receptors to mediate these effects. Since these effects 
are not completely abrogated, the results also suggest that D2 receptors can couple to more than one 
G protein in vivo. However, whether the D2 receptors represent a single homogeneous receptor type 
is unclear. There is now evidence that the D2 receptor can form homomers among themselves and 
heteromers with other receptors in neurons (Franco et al., 2000; Lee et al., 2000). These D2 receptor 
homomers and heteromers would also be abolished in the D2 receptor knockout animal, and are 
therefore possible candidates for coupling to G2 to mediate the hypothermic and hypolocomotor 
effects of D2-like agonists. In addition, there are also two alternatively spliced forms of the D2 
receptor. Mice that lack the long isoform of the D2 receptor have been successfully produced. The 
locomotor suppressive effects of quinpirole, as well as the autoreceptor function of the D2 receptor 
are not affected in these mice (Rouge-Pont et al., 2002; Usiello et al., 2000; Wang et al., 2000). This 
suggests that G2 is not coupled to the D2-long receptor. 
The current results also suggest that the loss of G2 cannot be compensated by the presence of other 
G protein a subunits. Since G0 can couple to the D2 receptor (Jiang et al., 2001) and is probably 
found in all neurons, this inability of G0 to compensate for the absence of G2 is consistent with the 
existence of cellular compartments in intact cells, which restrict the pool of G proteins to which a 
receptor can gain access (Allgeier et al., 1997). It is not known whether G2 is localized in the same 
membrane compartment as G0 , as a consensus binding motif implicated in caveolin binding (Ostrom 
et al., 2000), is present in Ga0 and 1nost other Gai family members, but is absent in Gaz. 
Furthermore, the localization of G2 could also depend on the particular scaffold proteins expressed 
in the G2 containing cell, as scaffold proteins such as caveolin are not found in all cells (Galbiati et 
al., 1998). Moreover, the ~y dimer that Ga2 associates with can also 
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influence the targeting of Gaz and the affinity of G2 for receptors (Vanderbeld and 
Kelly, 2000). Whether Gao and Gaz share the same ~y subunits or ~y subunits with 
similar biochemical properties is presently unknown. 
Finally, Gz is also involved in mediating the secretion of ACTH caused by activation of 
D2-like receptors. This effect is believed to occur via dopamine receptors in the 
hypothalamus (Borowsky and Kuhn, 1992). Cocaine, an indirect dopamine agonist at 
both DI and D2-like receptors, has also been found to stimulate ACTH release (Rivier 
and Vale, 1987). The mechanism involves CRH from the hypothalamus as the effect of 
cocaine can be blocked by a CRH antiserum (Rivier and Vale, 1987). Quinpirole 
induced ACTH release may also operate via a similar mechanism and there is recent 
evidence that stimulation of cortical CRH receptors results in the incorporation of a 
photo-reactive form of GTP, [a-32P]-GTP-y-azidoanlide into Ga2 (along with Gas, Gai, 
Gaq/ll, Ga0 ) (Grammatopoulos et al., 2001). As such, the present study examined 
whether G2 is coupled to CRH receptors to mediate ACTH release. My data did not 
reveal any significant difference between wildtype and Ga2 knockout mice in CRH 
stimulated ACTH secretion. Additionally, stimulation of ACTH released by the 
serotonin IA agonist, 8-hydroxy-dipropylamino-tetralin (8OH-DPAT), which is known 
to occur via a CRH mechanism (Serres et al., 2000), also did not differ between mice of 
the two genotypes. This suggests that CRH receptors in the pituitary, and serotonin IA 
receptors in the hypothalamus that mediate ACTH secretion, are not coupled to Gz. 
This is in contrast to the findings of Serres and colleagues (2000) where the 
employment of Ga2 antisense oligonucleotides was found to partially counteract the rise 
in plasma ACTH levels caused by 8OH-DPAT in rats. The difference may be attributed 
to species differences, general oligonucleotide toxicity or non-specificity in their Gaz 
antisense, which they have alluded to in one of their experiments. Alternatively, it is 
also possible that there · are subtle developmental compensation in the Gaz knockout 
mouse that prevents the phenotype from being expressed. Nonetheless, taken together, 
these results suggest that pituitary CRH receptors are not impaired in the Gaz knockout 
mouse. 
One common criticism of gene knockout studies is that there may be compensations in 
other parts of the system as a result of inactivation of the gene. However, my results 
clearly show that the absence of Ga2 cannot be compensated for by Gao and other more 
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abundant Gai family members in the dopaminergic pathways examined. Such 
'compensation' is more likely to be observed when receptor G protein coupling is 
studied in broken membrane preparations. The 'compensation' observed can be an 
artifact that results from disruptions to membrane compartments and scaffolds, which 
play an important role in determining signaling specificity in vivo (Hur and Kim, 2002; 
Tsunoda and Zuker, 1999). Indeed, in membranes prepared from rat RlNm5F 
neuroendocrine cells, the galanin and somatostatin receptors showed promiscuous 
coupling to various Gi and G0 isoforms (Degtiar et al., 1997; Schmidt et al., 1991). In 
contrast, when the G protein coupling of the galanin and somatostatin receptors was 
examined in whole RINm5F cells by electrophysiology, the galanin receptor coupled 
specifically to G01 and the somatostatin receptor to G02 (Degtiar et al., 1997) to inhibit 
calcium channels. Similarly, in dog thyroid membranes, stimulation of the thyrotropin 
receptor was found to cause the incorporation of [ a-32P]-GTP-y-azidoanlide into Gas, 
Gai, and Gaq111 , suggesting that activation of the thyrotropin receptor would normally 
stimulate these G proteins (Allgeier et al., 1997). However, in the same experiment, 
when intact thyrocytes were used, the thyrotropin receptor could only couple to Gs and 
Gi (Allgeier et al., 1997). This indicates that although the thyrotropin receptor can 
recognize Gq111 in disrupted membranes, membrane compartmentalization in an intact 
cell prevents the receptor from interacting with Gq11 1 in vivo. Consistent with this idea, 
there is now evidence that Gs, Gi, and Gq;11 may be targeted to distinct microdomains 
within the plasma membrane of a cell (Oh and Schnitzer, 2001), which is likely to affect 
their interactions with different receptors. 
In summary, I have demonstrated that G2 can couple to D2-like receptors in vivo. Since 
disturbances in dopaminergic networks are implicated in a number of debilitating 
human conditions and diseases, including Parkinson's disease, schizophrenia, and drug 
addiction, G2 might serve as a potential drug target when subtle fine tuning of 
dopaminergic functions are required. 
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Chapter 6 
The regulation of body temperature by opioids in the Gx2 deficient 
mouse 
6.1 Introduction 
Morphine is a powerful analgesic. It is widely employed to successfully relieve pain 
during and after surgery, but also produces a number of undesirable side effects. One 
perioperative side effect is the alteration of body temperature (Su et al., 1987). 
Perioperative hypothermia can result in complications such as myocardial ischemia 
(Frank et al., 1993), reduced resistance to wound infection (Kurz et al., 1996) and 
impaired coagulation of blood platelets (Schmied et al., 1996). Understanding and 
preventing this and other side effects of morphine is therefore one of the challenges of 
modem medical science. 
Morphine produces all its effects through opioid receptors in our body. There are three 
main classes of opioid receptors, and they have been designated using the Greek letters, 
µ, 8 and K (Kieffer, 1999). Morphine binds to the µ receptor with the highest affinity, 
and to the 8 and K receptor with lower affinities (Goldstein and Naidu, 1989; Raynor et 
al., 1994). The effects of morphine on body temperature are thought to be mediated 
primarily through the µ and K receptors, with the 8 receptor playing an insignificant role 
(Chen et al., 1996; Sarton et al., 2001). 
Following morphine binding, opioid receptors become activated and the activation 
signals are transduced through heterotrimeric G proteins. The G protein( s) responsible 
for transducing the thermoregulatory effects of morphine are currently unknown. 
However, µ receptors in the brain have been found to be capable of coupling to the G 
proteins G2 , Gi2 and G0 in vivo (Garzon et al., 1997b; Garzon et al., 1997a; Garzon et al., 
1998; Jiang et al., 2001). On the other hand, the K receptor can couple to Gs in cultured 
neurons (Hampson et al., 2000) and to pertussis toxin sensitive G1;0 proteins in the brain 
(Dar, 1998; Konkoy and Childers, 1993). However, there is only in vitro evidence that 
the K receptor can couple to G2 when both proteins were transfected into human 
embryonic kidney 293 cells (Lai et al., 1995). 
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In Chapter 3, I have demonstrated that supraspinal morphine analgesia is impaired in 
the Gcx2 knockout mouse after chronic morphine treatment, suggesting that G2 is 
involved in transducing the analgesic effects of 1norphine. In this Chapter, my aim is to 
examine whether the thermoregulatory effects of morphine are also affected by the loss 
ofG2 • 
6.2 Results 
6.2.1 Stress induced hyperthermia 
It is well known that the repeated use of a rectal probe to 1neasure body temperature 
causes stress induced hyperthermia in rodents (van der Heyden et al., 1997). Since the 
experimental procedure requires multiple temperature measurements to be 1nade in the 
same mouse, I began by analysing how the body temperature of mice changes with 
repeated measurements. The results reveal a tendency for the Gcx2 knockout mouse to 
exhibit a slightly higher body temperature. However, the difference in body 
temperature between mice of the two genotypes was not statistically significant 
(Genotype main effect: F(l,57)= 2.55, NS). Repeated use of the rectal probe caused a 
sharp rise in body temperature that is similar in both wildtype and Gcx2 knockout mice 
(Genotype main effect: F(l ,57)= 1.17, NS), which peaked and stabilized after the 
second measurement (Figure 6.1). Therefore, to calculate the pre-drug body 
temperature baseline for each mouse, the first reading was discarded and the last three 
readings recorded immediately before drug ( or vehicle) administration were averaged. 
6.2.2 Morphine induced hypothermia is attenuated in the Gcxz knockout 
mouse. 
When wildtype and Gcx2 knockout mice were administered morphine, there was a slight 
hype1ihem1ia at the low morphine dose of 3mg/kg (Drug dose main effect: F(l,34) = 
12.4, p<.002) and considerable hypothermia at higher doses (Chen et al., 1996; Geller et 
al., 1983). The hypothermic effect of morphine was found to depend on genotype 
(Genotype by Dose interaction: F(2,36)= 25.2, p<.001), such that mice deficient in Gcxz 
showed a significantly attenuated response (Figure 6.2). 
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temperature of wildtype and Ga2 knockout mice were measured at 15 minute intervals 
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6.2.3 The K opioid receptor antagonist, Nor-BNI, does not affect morphine 
induced hypothermia 
Since there is evidence that the hypothermic effect of morphine at high doses may be 
attributed to morphine sti1nulation of the K opioid receptor (Chen et al., 1996), the role 
of the K receptor in morphine induced hypothermia was next examined. Mice were pre-
treated for 24 hours with 20mg/kg of the K receptor antagonist, nor-binaltorphimine 
(Nor-BNI). This dose and pre-treatment time period were chosen based on previous 
work showing its effectiveness in preventing the analgesic and thermic effects of K 
receptor activation in mice (Endoh et al., 1992). The nor-binaltorphimine treated mice 
were then tested with 30mg/kg morphine 24 hours later. The data obtained shows that 
nor-binaltorphimine pre-treatlnent does not significantly affect morphine induced 
hypothennia in wildtype mice (Drug main effect: F(l,11)=0.011, NS) (Figure 6.3). 
Similar data was obtained when the nor-binaltorphimine pre-treatment ti1ne period was 
shortened to 0.5 hour (Drug main effect: F(l, 12)= .234, NS) (Figure 6.3). 
6.2.4 Activation of the K opioid receptor does not produce hypothermia in 
C57 /BL6 mice 
Since pre-treatment with nor-binaltorphi1nine has no effect on the hypothermic response 
produced by morphine, it may be possible that activation of the K receptor does not 
cause hypothermia in the C57BL/6 mouse strain. Indeed, there is evidence of variations 
in responses between 1nouse strains to stimulation of the K receptor (Itoh et al. , 1993 ; 
Thorat et al., 1993). To test this hypothesis, the thermic response of wildtype and Gaz 
knockout 1nice to 30mg/kg of the K receptor agonist, U50,488H was measured. This 
high dose of U50,488H has previously been found to induce significant hypothermia in 
Swiss-Webster mice (Thorat et al., 1993), but not in mice of the ddY strain (Itoh et al., 
1993). When wildtype and Gaz knockout mice were treated with 30mg/kg U50,488H, 
severe motor retardation was observed (see Figure 4.6 for the locomotor inhibitory 
effects of 3mg/kg and 1 0mg/kg U50,488H), indicating that the drug was producing an 
effect. However, body temperature was not significantly affected in either wildtype or 
Gaz knockout mice (Drug main effect: F(l,22)=0.051, NS) (Figure 6.4). Therefore, 
similar to the ddY mouse, activation of the K receptor does not induce significant 
hypothennia in C57BL/6 mice. The decrease in hypothermic response in the Gaz 
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Figure 6.3 : Blocking of the K opioid receptor does not significantly affect the 
hypothermic response produced by morphine. Wildtype and Ga2 knockout mice were 
administered 20mg/kg of the K receptor antagonist, nor-binaltorphimine (Nor-BNI) 
either (A) 24 hours or (B) 0.5 hours prior to morphine treatment. Following the 
injection of 30mg/kg morphine hydrochloride, the body temperature of the mice was 
measured every 15 minutes for 1 hour (C) The change in rectal temperature of 
untreated and nor-BNI pre-treated mice, 30 minutes after 30mg/kg morphine 
hydrochloride. *p<.05, **p<.01, ***p<.001 
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mouse is therefore, unlikely to be due to an impairment of K receptor function. 
6.3 Discussion 
The results presented in this chapter clearly demonstrate the involvement of Ga 2 in 
mediating the thennoregulatory effects of morphine. At a dose of 30mg/kg, morphine 
does not significantly alter the body temperature of Ga2 knockout mice, while 
producing hypothermia in wildtype mice. When the morphine dose is increased to 
1 00mg/kg, both wildtype and Ga2 knockout mice show hypothermia, but the response 
is very much attenuated in the mutant mice. 
The receptor pathway( s) affected by the absence of Ga2 to cause the observed reduction 
in the hypothermic response to morphine is currently obscure. In rats, the biphasic 
thermoregulatory effect of morphine is known to be mediated by two different opioid 
receptors. Low doses of morphine produced hyperthermia through the µ receptor while 
high doses caused hypothermia through the K receptor (Chen et al., 1996). This is 
consistent with findings in the literature, where stimulation of the µ receptor mediates 
hyperthermic responses while activation of the K receptor produces hypothermia in rats 
(Adler and Geller, 1993). 
In mice, the picture appears more complicated. A survey of fifteen mouse strains found 
large strain variations in their thermic responses to morphine, with several strains 
responding only with hypothermia, some strains showing the same biphasic response as 
rats and one strain failing to respond across all morphine doses tested (from 4mg/kg to 
32mg/kg) (Belknap et al. , 1998). While sti1nulation of the µ receptor appears to elicit 
either a biphasic (Rosow et al., 1980) or hypothermic response in mice (Baker and 
Meert, 2002), activation of the ·K receptor results in different responses across mouse 
strains. For instance, the K receptor agonist U50,488H produced a biphasic response in 
NMRI mice (from 2.5n1g/kg to 40mg/kg) (Baker and Meert, 2002), but only 
hypothermia in Swiss-Webster mice (from 8mg/kg to 32 mg/kg) (Bhargava and Thorat, 
1993). In ddY mice, U50,488H produced hyperthermia at 5mg/kg (Endoh et al. , 1992) 
and no significant thermic effect at 30mg/kg (Itoh et al., 1993). Although some of these 
disparities may be attributed to differences in experimental conditions between 
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laboratories such as ambient temperature, mouse handling and perhaps the dose of the 
drug, it is clear that at least part of the response variation is contributed by 
idiosyncrasies between mouse strains. It is also evident that mice do not respond to 
U50,488H in the same way as rats since U50,488H can cause hyperthermia in mice 
(Endoh et al., 1992), but it only produces hypothermia in rats (Adler and Geller, 1993). 
It is important therefore to be careful when extrapolating results from rats to mice and 
across different mouse strains. 
In 129/SV:C57BL/6 F2 mice, morphine induced a hypothermic response across a very 
wide dose range (6mg/kg to 1 00mg/kg), which was completely abolished in mice 
lacking theµ opioid receptor (Sarton et al., 2001). This suggests an essential role of the 
µ receptor in mediating the hypothermic response to morphine. The present observation 
of considerable hypothermia caused by 30mg/kg and 1 00mg/kg morphine in wildtype 
C57BL/6 mice may therefore be due to morphine activation of the µ receptor. If this is 
the case, the significant attenuation of the hypothermic response in the Ga2 knockout 
mouse may indicate an in1pairment ofµ receptor function. This in tum, would suggest 
that the µ receptor is normally coupled to G2 to mediate hypothermia in this mouse 
strain. Since many of the agonists selective for the µ receptor are peptides, a test of this 
hypothesis will require direct intracerebroventricular injection of the peptide agonist 
into the mouse brain (which my laboratory is currently still trying to set up to do). In 
addition, one could also employ a µ selective antagonist to check whether it will prevent 
the morphine induced hypothermic response in wildtype C57BL/6 mice. 
Alternatively, it is possible that the attenuation of morphine hypothermia in the Gaz 
knockout mouse is due to some alteration of neurotransmission downstream from the 
opioid receptors. There is evidence that dopamine and adenosine receptors may be 
involved in the hypothermia induced by morphine in Swiss albino mice. Pre-treatment 
with the adenosine receptor antagonist, theophylline and the dopamine D2-like receptor 
antagonists, sulpiride and pimozide (but not the dopamine D 1-like receptor antagonist 
SCH 23390) caused a dose dependent decrease in the hypothermic response to 
morphine (Zarrindast et al., 1994). Both the adenosine Al and dopamine D2-like 
receptors are capable of coupling to G2 in vitro (Obadiah et al., 1999; Wong et al., 
1992). Furthermore, I have demonstrated that the hypothermic response induced by the 
D2-like receptor agonist, quinpirole, is significantly attenuated in the Gaz knockout 
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mouse (Chapter 4), suggesting that D2-like receptors in the thermoregulatory pathway 
are probably coupled to G2 • Accordingly, an impairment of D2-like receptor function in 
the Ga2 lmockout mouse may also contribute to the observed attenuation of morphine 
hypothermia. 
In conclusion, this chapter demonstrates that morphine induced hypothermia, a major 
undesirable side effect of morphine during its surgical use, is significantly attenuated in 
mice lacking Ga2 , and therefore suggests a potential site for therapeutic clinical 
intervention. However, the mechanism underlying this phenomenon is currently 
restricted to this mouse strain and whether the inactivation of Ga2 mediated signal 
transduction pathways can prevent morphine hypothermia in other mouse strains and 
humans would need to be further explored. 
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Chapter 7 
General Discussion 
In this thesis, I have examined the consequences of disrupting the gene that codes for 
Ga2 , which results in the absence of signalling through the heterotrimeric G protein, G2 , 
in mice. I have presented evidence suggesting that G2 signalling is impo1iant in the 
development of tolerance to the analgesic and lethality effects of morphine, such that in 
Gaz's deficiency, greater tolerance develops. I have also employed a number of 
converging lines of evidence suggesting for the first time that G2 is coupled to D2-like 
receptors in vzvo. This impairment of D2-like receptor function in the nucleus 
accumbens, may explain the enhanced stimulation of locomotor activity by 
psychostimulants and morphine in the mutant mouse. I have also demonstrated that G2 
signalling is involved in the hypothermic response to morphine. Physical dependence on 
morphine is also altered in the mutant mouse, suggesting the participation of G2 
mediated pathways in the opioid withdrawal phenomenon. 
7.1 Compensation at the molecular level 
7.1.1 Compensation by upregulation of another G protein 
One cormnon criticism of gene knockout studies is the issue of compensation by other 
proteins for the inactivation of the protein encoded by the disrupted gene (Nelson, 
1997). At the level of gene transcription, this compensation can happen when a number 
of genes are co-regulated together. I have examined the expression of Gas, Gai1, Gai2, 
Gai3, Ga0 and Gaq in the brains of Ga2 mutant mice, and my results did not reveal any 
noticeable change in the quantities of these other G protein a subunits (Figure 5.8). 
This result is in agreement with a similar lack of compensation of other G protein a 
subunits in the Ga0 knockout mouse (Mende et al., 1998), but differs from the 
observation of a compensatory increase in Gai3 in the Gai2 knockout mouse (Rudolph et 
al., 1996), indicating that the expression levels of some G protein a subunits are 
regulated independently while others are not. 
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7.1.2 Compensation by functional redundancy between G proteins 
In the absence of upregulation, other G protein a subunits may still compensate for the 
absence of Ga2 at the functional level. Gaz is expressed at a relatively low level 
compared to Gai and Ga 0 in the brain 2 (Stemweis and Robishaw, 1984) and in vitro 
experiments have shown Gai/o to be capable of coupling to the same receptors and 
effectors as Ga2 (Ho and Wong, 1998). Accordingly, one may expect the deficiency of 
Ga2 at the receptor, to be easily compensated by the presence of Gai/o, since Gai/o are 
present in substantial excess compared to the number of receptors and effectors 
(Milligan, 1996). Functionally, this compensation may possibly have occurred to a 
certain degree, as evidenced by the small difference between the acute analgesic effects 
of morphine in wildtype and Ga2 knockout mice (Figure 3.2a), despite evidence 
suggesting that G2 is the 'preferred' G protein at morphine receptors (Garzon et al., 
1998). Nonetheless, the consequences of the absence of Ga2 can still be felt as 
suggested by the shortened duration of the analgesic response in the Ga2 knockout 
mouse (Figure 4. 7). 
Functional compensation by other G protein a subunits may also have occurred during 
development. Although Ga2 knockout mice are smaller than the wildtype control mice 
at weaning, the difference seems to disappear in adult mice (Figure 7 .1 ). Moreover, no 
gross morphological abnormalities have been observed in either the brain or in other 
parts of the Ga2 knockout mouse, despite evidence suggesting that Ga2 may be 
involved in developmental signalling (Chapter 1, Sections 1.5.2, 1.5.3, 1.5.4). Since the 
molecular targets of Ga2 during development are shared with other Gai/o family 
2 Due to the differential affinity of antibodies for proteins on Western blots, a direct con1parison of the 
amount of different G protein n subunits present in the brain cannot be made without the use of known 
levels of pure recombinant a subunits as standards. However, Sternweis and Robishaw (1984) have 
provided data showing that Gai and Ga0 , together, accounted for half of the total GTPyS binding to all 
guanine nucleotide binding proteins in brain membranes. Since guanine nucleotide binding proteins 
include not only heterotrimeric G proteins, but also a large nun1ber of other GTPases ( see Chapter 1, 
section 1.1.2), the data suggests that Gai and Ga0 exist in large quantities relative to other G protein a 
subunits in the brain. Indeed, Asano et al.. (1988) found Ga 0 alone to account for 0.5% of all brain 
n1embrane proteins. Another piece of evidence comes from the study of the expression of G~ subunits. 
The level of expression of the G~ protein is known to be co-regulated with the a subunit as the absence of 
Ga0 caused the amount of G~ subunits in the brain to be reduced to just 32% of the level in wildtype 
brains (Mende et al., 1998). Similarly, in Gai2 deficient embryonic fibroblasts, there is a parallel 
reduction of G~ to 50% of wildtype levels (Rudolph et al., 1996). In contrast, the loss of Gaz did not 
result in any detectable change in the quantity of G~ subunits (Figures 3.8 and 5.8). This suggests that the 
overall level of expression of Ga2 is low compared to the sum total of all G protein a subunits in the 
brain. 
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111embers (Chapter 1, Sections 1.5.2, 1.5.3, 1.5.4), it is likely that some form of 
compensation by other Gai/o proteins has occurred. For instance, nerve growth factor 
(NGF) dependent neuronal survival is decreased in Ga2 deficient sympathetic neurons 
only after the addition of pertussis toxin, suggesting that Gai/o can compensate for the 
absence of Gaz in this system (Powell et al., 2002). This kind of compensation may 
occur either through Gai/o binding directly to the same molecular partners and effectors 
as Gaz or through its mediation of a signalling cascade that produce the same functional 
outcomes as activation of the G2 cascade. 
7.1.3 Failure of compensation and its implications 
Given the relative abundance of Gai/o in the brain, it is surpns1ng that functional 
compensation either does not occur or it occurs to an insignificant extent under most 
conditions examined in the present thesis. The observations in the Ga2 knockout mouse 
of a marked attenuation in morphine induced hypothermia, as well as a significant 
reduction in the effects of D2-like receptor activation, suggest that in the signalling 
pathways mediating these other functions, the presence of Ga2 is critical for normal 
signalling. As Gai/o are very likely to be also expressed in the cells containing the 
'affected' signal transduction pathways (given their ubiquitous and high expression 
level in the brain), the lack of significant compensation by Gai/o provides illuminating 
insights about the organization of cellular signalling, as well as a possible mechanism of 
functional compensation. 
7.1.3.1 Cellular signalling is compartmentalized in native cells 
One question that needs to be answered concerns why Gai/o can couple to most (if not 
all) Ga2 receptors in transfected cells in vitro (Ho and Wong, 1998) but frequently fail 
to compensate for the absence of Ga2 in native cells in vivo. An important clue to the 
answer of this question comes from a study comparing G protein activation in COS-7 
cells that have been transfected with µ and 8 opioid receptors, with SK-N-SH 
neuroblastoma cells, which naturally co-express the two receptors. In the artificially 
transfected cells, stimulation of either the µ or 8 receptor activates a common pool of G 
proteins that is shared between the two receptors; while in native cells, each receptor 
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Figure 7 .1: Developmental compensation in the Gaz knockout mouse. Wildtype and 
Gaz knockout mice from mainly heterozygous matings were weighed on various days 
after birth. The data for mice less than 2 months old were collected by Dr. Kim 
Kelleher while she was doing her Ph.D. The data for some of the adult mice were 
collected by myself in collaboration with her. 
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activates its own pool of G proteins. This occurs even though the two pools of G 
proteins in native cells contain Gila, which presumably share a similar capacity to couple 
to identical receptors (Shapira et al., 2000). To reconcile these observations, the authors 
proposed the existence of cellular compartments in native cells, which restrict the access 
of receptors to only those G proteins that lie in close proximity (Shapira et al., 2000). 
Consistent with this idea, there is now evidence that receptors, G proteins and effectors 
may be organized into large signalling complexes (Chidiac, 1998; Slesinger et al., 1995) 
with the help of scaffolding proteins (Ostrom et al., 2000; Scott and Zuker, 1998). This 
would help to explain the capacity of type V adenylate cyclase, a G protein effector, to 
enhance receptor mediated activation of Gi and Gs (Scholich et al., 1999; Wittpoth et al., 
2000), as it can occur only if the three proteins (receptor, G protein and effector) lie in 
close association with one another. It would also explain the exclusive specificity of 
receptor-G protein-effector coupling observed in intact cells (such as those obtained by 
employing electrophysiological methods (Kleuss et al., 1993)), which were lost 
following membrane disruption (Allgeier et al., 1997; Degtiar et al., 1997). The 
findings also provide a much needed theoretical framework for understanding the 
rapidity and specificity of signalling processes in cells (Albert and Robillard, 2002). 
7.1.3.2 Over-expression of receptors or G proteins can potentially 
disrupt cellular compartments leading to promiscuous signalling 
Currently, the stoichiometry and composition of such signalling complexes are largely 
unknown. It may vary between different receptor and cell types, partially dependent on 
the level of expression of each component in the complex. Estimates of the number of 
G proteins to receptors in such complexes have ranged from one G protein to one 
rhodopsin receptor in drosophila photoreceptor cells (Scott and Zuker, 1998) to four G 
proteins to one µ opioid receptor in C6 glioma cells stably expressing the µ receptor 
(Remmers et al., 2000). Compared to native cells, the over-expression of receptors or G 
proteins may produce two potential problems, hinging on the level of over-expression. 
Firstly, since endogenous signalling complexes assemble with the help of scaffolding 
proteins, if the transfected receptor or G protein can bind to the scaffolding protein, 
there will be competition for these scaffolding proteins. As a result of this competition 
and over-crowding at the plasma membrane, the scaffolding proteins may no longer be 
effective in their role of segregating the cell into distinct signalling compartments. 
Consequently, receptors and G proteins that normally do not interact, may now come 
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into contact with one another. Next, the over-expression of receptors or G proteins may 
decrease the specificity of the over-expressed molecule in its interaction with other 
proteins. For instance, a receptor and a G protein that have a weak affinity for one 
another, may interact when over-expressed due to an abnormally high concentration of 
the over-expressed protein (Dumont et al., 2002). Accordingly, although in vitro studies 
have suggested that Ga2 and Gai/o share similar structural elements required for 
recognition by receptors and effectors, the caveats highlighted above emphasized the 
importance of verifying these interactions in vivo. 
7.1.3.3 Other factors that contribute to the occurrence of functional 
compensation 
Besides the capacity to bind to the same receptors and effectors, the ability of Gai/o to 
compensate for the absence of Ga2 in vivo depends on a number of other factors. These 
include whether Gai/o and Ga2 are targeted to the same region of the cell ( e.g. axon 
terminal versus cell body) where 'Ga2 receptors and effectors' are located, as well as 
their capacity to share similar G protein ~y subunits and scaffolding proteins, which are 
involved in receptor recognition (Gautam et al., 1998), and assembly of signalling 
complexes respectively (Albert and Robillard, 2002; Huang et al., 1997a; Milligan and 
White, 2001). To date, very little is known about the co-localization of Gai/o and Gaz, 
their ~y partners, as well as the scaffolding proteins to which they may bind. However, 
a putative caveolin binding motif conserved among all Gai/o is found to be slightly 
altered in Ga2 (Ostrom et al., 2000). This may result in Ga2 being targeted to a 
different cellular environment in some cells. Any of the above factors may explain the 
lack of compensation by Gai/o in the Ga2 knockout mouse. 
7.1.3.4 A possible mechanism of functional compensation 
If Gai/o cannot replace Ga2 in the assembly of the 'Ga2 signalling complex', how does 
functional compensation for the absence of Ga2 take place ? One mechanism may be 
the existence of a reserve pool of 'Gai/o signalling complexes' that can bind to the same 
agonists and produce similar functional consequences as 'Ga2 signalling complexes' 
when the former are stimulated. These spare 'Gai/o signalling complexes' may then 
compensate for the lack of 'Ga2 signalling complexes', resulting in a similar functional 
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outcome in those behavioural responses that exhibit a functional receptor reserve (such 
as acute morphine lethality or analgesia) (Sora et al., 2001a). However, as Gai/o and 
Ga2 differ biochemically (Casey et al., 1990), the resultant 'Gai/o and Ga2 signalling 
complexes' may possess different properties ( e.g. desensitisation or internalisation 
properties), such that the 'Gai/o signalling complex' is no longer able to compensate for 
the absence of the 'Ga2 signalling complex' after chronic morphine treatment. 
7.2 Compensation at the system level 
In addition to compensation by other molecules within the same cell, the chronic 
absence of a protein as a result of gene targeting may trigger compensatory changes in 
other parts of the system linked to the function of the protein. For example, in mice 
lacking the norepinephrine transporter, there was an enhancement of post-synaptic 
D2/D3 receptor function (Xu et al., 2000a). This was explained by the authors to be due 
to downregulation of presynaptic dopamine neurotransmission, which in tum may be 
indirectly attributed to the possible absence of dopamine clearance by the transporter in 
the region of the dopamine cell body (Xu et al., 2000a). Although this form of 
compensation can potentially happen in the studies of all gene knockout mice, due to its 
complexity, it has rarely been reported. However, given the low level of expression of 
Ga2 relative to Gai/o in the brain (Stemweis and Robishaw, 1984) and most of Gaz's 
signalling functions also appeared to be performed by Gai/o (Ho and Wong, 1998), the 
effect of Ga2 inactivation may generally not be large enough to trigger system wide 
compensation. 
7.3 Assignment of the signalUng pathway affected by the absence of Gaz 
G protein coupled receptors (GPCRs) comprise one of the largest and most diverse 
superfamily of proteins in our body, with over a thousand members (Bockaert et al., 
2002). In contrast, there are only an estimated twenty seven G protein a subunits in the 
human genome (Venter et al., 2001). Hence, with the exception of a few highly 
specialized G protein a subunits with restricted tissue distribution (Table 1.1 ), most G 
protein a subunits are likely to couple to quite a number of different receptors. 
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Although Gaz appears to have a relatively limited tissue distribution (Chapter 1, Section 
1.3), in vitro experiments have suggested that it can couple to more than fifteen different 
GPCRs (Chapter 1, Section 1.4.1 ), and has the potential of coupling to all Gai/o coupled 
receptors when over-expressed (Ho and Wong, 1998). Accordingly, disruption of the 
gene coding for Gaz, may cause the functions of a number of GPCRs to be impaired. 
However, most of this impairment of GPCR function is likely to be only partial since 
Gai and Ga0 are believed to normally play a role in transducing the activation signal of 
these GPCRs as well. 
In this thesis, I have focussed on examining whether G2 is involved in transducing the 
signals caused by stimulation of opioid receptors, as well as activation of the dopamine 
D2-like family of receptors. Due to limitation in the number of age and gender matched 
Ga2 knockout and wildtype control mice available for experimentation ( caused 
primarily by problems with Ga2 knockout mice breeding in the C57BL/6 background) 
(Kelleher, 2000), I have chosen morphine as the agonist for investigation of the opioid 
receptor due to its clinical relevance and its purported 'G2 preferring characteristics' 
(Garzon et al., 1998) in order to maximize the chances of seeing an effect. Although 
morphine can bind to µ, 8 and K receptors, it has the highest affinity for the µ receptor 
(Goldstein and Naidu, 1989; Raynor et al., 1994). In an attempt to define the particular 
opioid receptor that produce an effect in the Ga2 knockout animals, I have tried to 
employ morphine within doses where receptor knockout studies have shown it to be 
receptor specific for the particular effect being investigated. For instance, it is possible 
that 1 00mg/kg of morphine may still act specifically at the µ receptor for the 
hypothermic response to morphine since this dose of morphine produced hypothermia 
in wildtype animals that was abolished in the µ receptor knockout mouse (Sarton et al., 
2001 ). In instances where a difference between wildtype and Ga2 knockout mice was 
observed only at a higher morphine dose, which can potentially be due to a large reserve 
of G ila coupled receptors present, I attempted to rule out that the effect seen was not 
occurring at another opioid receptor by using an agonist specific for that receptor ( e.g. 
the greater locomotor activation by morphine in the Ga2 knockout mouse is not due to 
morphine acting at the K receptor). Although this approach is not fool-proof, my ability 
to experiment with other opioid agonists is limited by the number of animals available 
to me and at ti1nes by the availability of the drug (which sometimes require importation 
and possession permits) or the injection technique required ( e.g. intracerebroventricular 
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injection in mice). For the dopamine receptor experiments, quinpirole was chosen as its 
effects on dopamine D2-like receptors is very well characterized. Nonetheless, there are 
plans to extend the studies reported here to other dopa1nine D2-like agonists once the 
animals become available. 
Given the problem that a deficiency of Ga2 is likely to affect a number of different 
GPCRs, and behavioural outcomes are the result of activation of neuronal networks that 
typically involve multiple receptors, the use of multiple agonists acting at the same 
receptor to investigate one particular behavioural phenomenon would still not prove that 
the receptor is coupled to G2 • In an attempt to define the particular signalling pathway 
affected by the absence of G2 , the approach employed here was to investigate the system 
with a variety of different measures, each of which has been clearly established to be 
mediated by stimulation of a particular receptor in receptor knockout studies. For 
instance, the µ opioid receptor is known to mediate morphine analgesia, physical 
dependence (Matthes et al., 1996) and lethality (Loh et al., 1998), as well as the 
hypothermic (Sarton et al., 2001) and locomotor stimulating (Sora et al., 2001a) effects 
of the drug in mice. Accordingly, I have examined the responses of Ga2 knockout mice 
to morphine on all of these measures. Assuming that G2 and Gi/o are both coupled to the 
µ opioid receptor across the variety of neuronal networks that produce these distinct 
behavioural outcomes, I would expect the absence of Ga2 to be felt in some way in all 
of these different measures. Indeed, I found that morphine analgesia and lethality are 
decreased in Ga2 knockout mice after the development of morphine tolerance. The 
hypothermic response to morphine was also attenuated in mutant mice, and the duration 
of acute morphine analgesia and locomotor activation were also slightly reduced. 
Similarly, the coupling of D2-like receptors to G2 was demonstrated by an attenuation 
of quinpirole induced hypothermia, ACTH release and locomotor activity depression, 
all of which are known to be mediated through stimulation of dopamine D2-like 
receptors. To further strengthen the findings, I also showed that the quinpirole 
inhibition of dopamine release caused by sti1nulation of the medial forebrain bundle is 
significantly reduced in Ga2 knockout mice. 
An unexpected result that was produced from the use of such an approach is the 
increase in locomotor stimulation during the early phase of morphine stimulation. This 
demonstrates · the caveat of using just one behavioural measure and the general 
employment of behavioural outcomes as a way of defining the receptor that Gz is 
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coupled to since an effect of the absence of Gaz could be due to an impairment 
downstream from where the agonist acts. Fortunately, in this case, the neuronal 
circuitry involved in morphine induced locomotor stimulation is quite well known, and 
it is possible that the greater locomotor stimulation caused by morphine in the Ga2 
knockout animals is due to an impairment of downstream dopamine D2-like receptors. 
Given the difficulties with interpretation of behavioural outcomes and the limitation in 
the number of Ga2 knockout mice available, a more direct biochemical or 
electrophysiological demonstration of G2 coupling to these receptors would have been 
preferred. The bioche1nical approach has been pursued relentlessly by my predecessor 
(Dr. Kim Powell nee Kelleher) and myself for more than a year. However, we were not 
able to observe any reliable difference between wildtype and Ga2 knockout mice in 
membrane preparations. Thus far, the only biochemical demonstration of G2 producing 
an effect in vivo, is its ability to mediate epinephrine induced inhibition of cyclic AMP 
formation (Yang et al., 2000) and activation of Rapl (Woulfe et al., 2002) in intact 
blood platelets, where Ga2 is the second most abundant G protein a subunit after Gai2 
(Woulfe et al., 2002). One of the major problems with working on G2 in brain 
membrane preparations is the relative abundance of Gi/o, which is expected to easily 
compensate for the absence of G2 once membrane compartments are destroyed (Allgeier 
et al., 1997; Degtiar et al., 1997). 
On the other hand, the pursuit of an electrophysiological approach to the study of G2 
function has been hampered by the absence of good hypotheses of the role performed by 
Gz and data on its precise localization in the brain ( e.g. nerve terminal versus cell body). 
In this respect, the data presented in the present thesis may serve as a useful starting 
point for the further examination of Gz' s functions in the brain via electrophysiology. 
Ga2 has been reported to be widely present in many parts of the brain (albeit at a low 
concentration relative to Gai/0 ) (see section 1.3). Currently, we are in the process of 
developing an antibody to verify these findings using the Ga2 knockout mouse, and to 
more precisely locate the particular populations of neurons that contain Gaz. 
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7.4 Future directions 
All the data presented in this thesis were based on the study of wildtype and Ga2 
knockout mice in pure C57BL/6 genetic background. The use of a pure genetic 
background avoids the 'hitchhike donor gene' confound that is often associated with 
comparing knockout and wildtype littermates in a mixed genetic background, where 
phenotypic differences may be attributed to a background gene that 'hitchhikes' along 
with the mutated gene by virtue of their positional proximity on the chromosome 
(Lariviere et al., 2001). Despite this major advantage, the generalizability of these 
results to mice of other strains and ultimately to humans will need to be tested. For 
certain physiological processes like thermoregulation, widespread strain and species 
differences are known to exist (Adler and Geller, 1993; Belknap et al., 1998; Lipton and 
Clark, 1986). To address the issue of strain variation, my laboratory has just 
successfully created a congenic line of Ga2 knockout mice in the BALB/c background 
through twenty repeated back-crossings with wildtype BALB/c mice. These N20 
BALBI c Ga2 knockout mice will be useful in the future for assessing the 
generalizability of the current results. 
Despite some of the limitations of a gene knockout approach as discussed in the earlier 
sections, the technique allows a very 'clean' and precise inactivation of the Ga2 protein, 
which would not be achievable by the use of other methods ( antibodies, antisense 
oligonucleotides). This is probably one of the few methods currently available for 
studying an intracellular factor like Ga2 in vivo, which shares about 66-67% amino acid 
identity with its more abundant Gai relatives (Simon et al., 1991). To confirm that the 
phenotypes observed in Ga2 knockout mice were due to the absence of Ga2 and not a 
result of developmental abnormality in mutant mice, I have also attempted to 
reconstitute the Ga2 knockout mouse by making transgenic mice that over-express Gaz. 
I have made two constructs, one containing a mutationally activated form of Gaz (Gaz 
Q205L) (Wong et al., 1992), and one containing wildtype Ga2 , both under the control of 
the human elongation factor la promoter (Kim et al., 1990; Uetsuki et al., 1989). Both 
of these constructs also contain an internal ribosomal entry site (Wong et al. , 2002), 
which allows the co-expression of Ga2 with Enhanced Green Fluorescent Protein 
(EGFP) (Zhang et al., 1996; Zhu et al., 1999a) under the same promoter. The constructs 
were linearised and electroporated into mouse embryonic stem (ES) cells. A number of 
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'green' clones were selected and verified to contain the targeting construct by 
polymerase chain reaction (Mullis et al., 1986). They were further shown to express 
Ga2 I Ga2 Q205L and EGFP by immunohistochemistry and western blot analysis. 
When these 'verified' clones were injected into blastocysts and implanted into 
pseudopregnant female mice, less than ten 'green' chimaera were born despite a total of 
twenty injections over a one year period (It is of note that the same ES cells transfected 
with other knockout or transgenic constructs routinely produced germline chimaera over 
the same time period, indicating that the ES cell line used was fully competent). Of the 
'green' chimaera that were produced, most perished within 3 weeks of age and appeared 
larger in size compared to 'non-green' littermates. The few that survived for longer 
than three weeks were infertile. 
Since the over-expression of Ga2 in all tissues under the human elongation factor 1 a 
promoter appears to result in early developmental lethality, I attempted to circumvent 
this problem by collaborating with Dr Kyoko Koishi (University of Otago, New 
Zealand) to generate a 'conditional' transgenic mouse, which would express Ga2 only 
in neurons after the animals have been fed with the tetracycline analog, doxycycline 
(Kistner et al., 1996). This mouse is currently still being produced. When this mouse is 
finally made, my laboratory intends to cross the Ga2 over-expressing transgenic mouse 
with the Ga2 knockout mouse. This would result in a Ga2 knockout mouse that would 
make Ga2 only after it has been fed with doxycycline. The mouse would be very useful 
for certain behavioural experiments as it would allow the same mouse to serve as its 
own control. 
7.5 General Conclusion 
In Chapter 3, I have shown that G2 plays an important role in mediating the supraspinal 
analgesic and lethality effects of morphine after tolerance development. The greater 
morphine tolerance that developed in the Ga2 knockout animals was not due to 
pharmacokinetic or behavioural mechanisms. I have also demonstrated a gene dose 
dependent reduction in naloxone precipitated jumping in the Ga2 knockout mouse. My 
data provides strong support for a dissociation between the different signs of physical 
dependence, indicating that morphine withdrawal is not a unitary phenomenon. It is 
therefore very important when measuring the degree of physical dependence, to 
consider a range of different withdrawal signs. In addition, the dissociation between 
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morphine tolerance and naloxone precipitated jumping suggests that different G2 
signalling pathways are involved in mediating the effects of the loss of Ga2 on 
morphine tolerance and physical dependence. Clinically, it may be possible to 
selectively affect these separate pathways to prevent the development of morphine 
tolerance and physical dependence in human patients. 
In Chapter 4, I have shown that Gz is involved in the regulation of morphine stimulated 
locomotor responses. The locomotor activating effects of psychostimulants are often 
related to their rewarding effects (Wise, 1987). G2 may therefore play a role 1n 
determining the vulnerability of drug users to become dependent on addictive drugs. 
In Chapter 5, I have provided evidence that G2 can couple to D2-like receptors in vivo. 
Since disturbances in dopaminergic networks are implicated in a number of debilitating 
human conditions and diseases, including Parkinson's disease, schizophrenia, and drug 
addiction, G2 might serve as a potential drug target when subtle fine tuning of 
dopaminergic functions are required. 
In Chapter 6, I have shown that morphine induced hypothermia, a major undesirable 
side effect of morphine during its surgical use, is significantly attenuated in mice 
lacking Ga2 , and therefore suggests a potential site for therapeutic clinical intervention. 
However, the mechanism underlying this phenomenon is currently restricted to this 
mouse strain and whether the inactivation of Ga2 mediated signal transduction 
pathways can prevent morphine hypothermia in other mouse strains and humans would 
need to be further explored. 
Finally, this thesis has furnished valuable insights about the organization of cellular 
signalling in intact cells. These insights provide a succinct explanation for many of the 
discrepant findings on G protein coupling in the litterature, depending whether the 
studies were performed using broken membrane preparations or in transfected cell lines. 
By providing a theoretical framework, these insights lay the foundation for future 
discoveries about the functions of G2 and other signalling molecules in vivo. 
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